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The Royal College of Physicians (RCP) exists to improve the care of individual
patients, and the health of the population. As tobacco smoking generates more
illness and premature death than any other avoidable cause, preventing smoking
has been a high priority for the RCP since the health harm of smoking was first
recognised over 60 years ago. In the more than 50 years since our first report,
Smoking and health, in 1962, we have argued consistently for more and better
policies and services to prevent people from taking up smoking, and help
existing smokers to quit.
Smoking is far less prevalent today than it was in 1962, but remains common,
particularly among more disadvantaged individuals in our society. There are still
almost nine million smokers in the UK, half of whom will die prematurely unless
they quit. The evidence in this report demonstrates sustained progress over
recent decades in preventing young people from becoming smokers, but also
shows that much more must be done to increase the number of existing smokers
who succeed in stopping smoking.
In 2007 the RCP published a report, Harm reduction in nicotine addiction,
which argued for the application of harm-reduction strategies to tobacco
dependence. We suggested that making effective, affordable, socially acceptable,
low-hazard nicotine products available to smokers as a market alternative to
tobacco could generate significant health gains, by allowing smokers to stop
smoking tobacco, without having to stop using the nicotine to which they are
addicted. Our report was published just as the prototypes of a new consumer
alternative to tobacco, the electronic cigarette (e-cigarette), were first appearing
on the UK market.
The rapid growth in use of e-cigarettes by smokers since 2007 demonstrates that
many smokers want reduced-harm products, and it is also clear that many
smokers have succeeded in quitting simply by substituting electronic for tobacco
cigarettes. However, e-cigarettes have also proved to be highly controversial,
attracting much criticism as well as support within medicine and public health,
and indeed in wider society.
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This report therefore aims to provide a fresh update on the use of harm
reduction in tobacco smoking, in relation to all non-tobacco nicotine products
but particularly e-cigarettes. It concludes that, for all the potential risks involved,
harm reduction has huge potential to prevent death and disability from tobacco
use, and to hasten our progress to a tobacco-free society. With careful
management and proportionate regulation, harm reduction provides an
opportunity to improve the lives of millions of people. It is an opportunity that,
with care, we should take.
Professor Jane Dacre
President, Royal College of Physicians
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Introduction1
Harm reduction is a strategy used in medicine and social policy to minimise harm
to individuals and/or wider society from hazardous behaviours or practices that
cannot be completely avoided or prevented. Examples include providing clean
needles and syringes to intravenous drug users to reduce the risk of infection,
promoting condom use by sex workers, drink-driving laws, protective clothing in
sport, and motor vehicle safety measures and emission controls. Sometimes by
appearing to condone or perpetuate hazardous behaviours that could in theory be
prevented, harm-reduction approaches can be controversial, particularly in
medicine. To their proponents, however, they represent pragmatic solutions to a
range of otherwise intractable causes of avoidable death and disability.
Tobacco smoking is addictive and lethal. Half of all lifelong smokers in the UK
die as a direct consequence of their smoking,1 and smokers lose an average of
about 3 months of life expectancy for every year smoked after the age of 35; in
sustained smokers this amounts to a total loss of around 10 years of life.1,2
Tobacco smoking harms others, through passive exposure of both adults and
children to exhaled and sidestream smoke,3,4 while smoking in pregnancy
impairs fetal growth and development, in some cases to the point of fetal death.5
Smoking causes fires and litter, reduces economic productivity and social
engagement, and exacerbates poverty.6 Together these effects make smoking
responsible for more loss of quality and quantity of life in the UK than any other
avoidable cause.7 As smoking is strongly related to social disadvantage, the
burden of ill health caused by smoking falls particularly on the most
disadvantaged individuals, making smoking the largest cause of social
inequalities in health in the UK.8
Smoking is completely preventable, yet, more than half a century after the health
harm of smoking first became widely known, almost 1 billion people worldwide
still smoke.9 They do so primarily because they are addicted to the nicotine in
tobacco smoke10 and, as this addiction can be extremely difficult to overcome,
many will continue to smoke until they die.10 Conventional tobacco control
policies, embodied in the World Health Organization’s (WHO’s) Framework
Convention on Tobacco Control (FCTC)11 and MPOWER policy framework
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(Monitor tobacco use and prevention policies, Protect people from tobacco
smoke, Offer help to quit tobacco use, Warn about the dangers of tobacco,
Enforce bans on tobacco advertising, promotion and sponsorship, and Raise
taxes on tobacco)12 aim to prevent the uptake of smoking and to help as many
existing smokers to quit as possible. These approaches have contributed to a 50%
reduction in UK smoking prevalence in the past 35 years,13 as well as increasing
global success in smoking prevention.9,14 However, although smoking prevalence
in the UK is now down to 18%,15 this figure translates into around 8.7 million
current smokers16,17 sustaining significant harm from smoking. Harm reduction
provides an additional strategy to protect this group, and their counterparts in
other countries, from the burden of disability and early death that will continue
to accumulate until and unless they stop smoking.
In 2007 the RCP published a report promoting the principle of harm reduction in
nicotine addiction,18 arguing that, as most of the harm caused by smoking arises
not from nicotine but from other components of tobacco smoke, the health and
life expectancy of today’s smokers could be radically improved by encouraging as
many as possible to switch to a smoke-free source of nicotine. While recognising
the primacy of complete cessation of all tobacco and nicotine use as the ultimate
goal to prevent harm from smoking, the report argued that promoting widespread
substitution of cigarettes and other tobacco combustion products would, for
smokers who made the change, achieve much the same thing.18 Harm reduction,
as a complement to conventional tobacco control policies, could therefore offer a
means to prevent millions of deaths among tobacco smokers in the UK alone.18
This argument was accepted and integrated into national tobacco control
strategies published by the then Labour and subsequent coalition governments in
2010 and 2011,19,20 through the extension of the licence for nicotine replacement
therapy (NRT) to include harm reduction by the Medicines and Healthcare
products Regulatory Agency in 2010,21 and in guidance issued by the National
Institute for Health and Care Excellence in 2013.22
At the time of the 2007 report, the product categories available as potential
smoking substitutes comprised smokeless tobacco, the least hazardous forms of
which were then and still are illegal in the UK,18 and conventional NRT, which,
although effective as a smoking cessation therapy, has proved to have limited
appeal to many smokers.18 E-cigarettes, which appeared in the UK at around the
time the 2007 report was published, have transformed this market, becoming the
most popular choice of product for smokers hoping to quit or cut down on their
smoking23,24 (see Chapter 5). In the UK and many other countries, however, 
e-cigarettes have proved highly controversial, attracting both widespread concern
and disapproval, and strong support, from individuals and organisations both
within and outside medicine. Policies on e-cigarettes vary widely between
countries with some, such as the UK, currently allowing their sale as consumer
products whereas others, eg Australia, prohibit the product25 (see Chapter 10).
2 © Royal College of Physicians 2016
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Harm reduction, and in particular the role of e-cigarettes, has probably split
global and, to some extent, national opinion on tobacco control more than any
other issue. This report therefore aims to provide an update on harm reduction
in the UK, particularly but not exclusively in relation to the role of e-cigarettes.
1.1 The harm of smoking
The harm that smoking causes to individuals and society is extensive and has
been reviewed comprehensively in reports published by the RCP over the past 
15 years,3,4,10,26 by the US surgeon general27–30 and by many other authorities.
The main effects of smoking on health and wellbeing, particularly in the context
of the UK population, are as follows.
1.1.1 Mortality
The most recent detailed analysis of mortality caused by smoking in the UK uses
data from 2010, when tobacco smoking caused an estimated 122,000 deaths in
adults, equivalent to more than one in six of all deaths, in the UK.31 Although due
to a wide range of diseases, 70% of these deaths were from three causes: lung cancer,
chronic obstructive pulmonary disease (COPD) and vascular disease (Fig 1.1).
© Royal College of Physicians 2016 3
Fig 1.1 Deaths attributable to smoking by disease in men and women, UK,
2009.31 (Data for figure from Peto et al.31)
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Deaths caused by passive smoking are more difficult to estimate with precision,
but in 2003 over 10,000 adults in the UK were estimated to have died from
lung cancer, cardiovascular disease or COPD caused by passive smoking.32 The
figure today is likely to be lower, as a result of declining smoking prevalence
and legislation making UK public places and workplaces smoke free. Among
children, around 40 cases of sudden infant death syndrome are caused by
smoking in the UK each year,3 whereas passive exposure of the fetus arising
from maternal smoking during pregnancy causes over 5,000 fetal or perinatal
deaths each year.3
1.1.2 Morbidity
Smoking during pregnancy accounts for around 2,000 premature births and
19,000 cases of low birth weight each year, and increases the risk of fetal
anomalies.3 Among children, passive smoking has been estimated to cause
around 165,000 new cases of disease, predominantly middle-ear disease and
respiratory infections in 2008,3 generating over 300,000 primary care
consultations and 9,500 hospital admissions in the UK each year.3 In adults,
combined morbidity and mortality from smoking accounted for the loss of
around 2 million disability-adjusted life years in the UK in 2010.7 In 2014
smoking caused over 450,000, or about 4% of all, admissions to hospitals in
England.16 Most of these admissions were for cancer, or respiratory or vascular
disease.16
1.1.3 NHS and wider societal costs
Smoking costs the NHS more than £2 billion in direct costs, or more than 2% of
the total NHS budget, every year.6,13 Costs of inpatient and primary care caused
by passive smoking in children in 2007 exceeded £20 million. The total cost of
smoking to society, including healthcare, social care, lost productivity, litter and
fires, was conservatively estimated in 2015 to be around £14 billion per year.13
1.1.4 Smoking and deprivation
Smoking prevalence is strongly and directly related to all measures of
deprivation. Smoking prevalence among those in higher managerial and
professional occupations in the UK is now close to 12%,16 whereas among those
in routine and manual occupations the figure is over 28%.16 Among unemployed
people, almost 40% smoke,33 as do around 40% of people with longstanding
mental health problems26 and more than 70% of people who are homeless or
imprisoned.26
4 © Royal College of Physicians 2016
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1.1.5 Normalisation effects
Smoking harms the health of others through behavioural effects, independent of
tobacco exposure. It was estimated that, in the UK in 2011, over 200,000 11- to
15-year-olds started smoking34 and, although smoking rates have since fallen, it
is still the case that, every day, hundreds of children become smokers. These new
smokers are more likely to come from households that include a smoker35 or to
have been exposed to smoking behaviour in the media36 or in their wider social
environment.36 These effects tend to perpetuate addiction to smoking among
successive generations of families and social groups, and hence also the
consequent inequality in quantity and quality of life in disadvantaged groups.
1.2 Principles of tobacco harm reduction
Tobacco smoke contains thousands of constituents that determine the flavour
and other characteristics of the smoke; but, crucially, they also combine to deliver
nicotine to the lung in an aerosol, with physical properties that allow rapid
absorption into the pulmonary circulation. Although other components of
tobacco smoke may enhance the addictiveness of tobacco smoke, the main driver
of tobacco smoking is addiction to nicotine.10,18 The mechanisms of nicotine
addiction are complex, but it is evident that smokers experience an initial
sensation of reward from exposure to nicotine; after sustained use and
consequent desensitisation to nicotine’s effects, smokers seek nicotine primarily
to relieve the symptoms of nicotine withdrawal.10,18 Regular nicotine use also
confers rewards in some of the stimuli and behaviours associated with nicotine
delivery, such as the sense of smoke in the throat, and the physical acts that are
integral to smoking, such as unwrapping, sharing or handling cigarettes.
Nicotine is not, however, in itself, a highly hazardous drug (see Chapters 4 and
5). It increases heart rate and blood pressure, and has a range of local irritant
effects, but is not a carcinogen.37 Of the three main causes of mortality from
smoking, lung cancer arises primarily from direct exposure of the lungs to
carcinogens in tobacco smoke, COPD from the irritant and proinflammatory
effects of smoke, and cardiovascular disease from the effects of smoke on
vascular coagulation and blood vessel walls. None is caused primarily by
nicotine. For practical purposes, as argued by Mike Russell in the 1970s, ‘smokers
smoke for nicotine but are killed by tar’.38 Although the nature and extent of any
long-term health hazard from inhaling nicotine remain uncertain, because there
is no experience of such use other than from cigarettes, it is inherently unlikely
that nicotine inhalation itself contributes significantly to the mortality or
morbidity caused by smoking. The main culprit is smoke and, if nicotine could
be delivered effectively and acceptably to smokers without smoke, most if not all
of the harm of smoking could probably be avoided.
© Royal College of Physicians 2016 5
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It is also clear that many smokers would prefer not to have to smoke to get
nicotine, provided that they can access the drug in doses and formulations that
they find satisfying and acceptable. The availability and use of an oral tobacco
product known as snus in Sweden, documented in more detail in our 2007
report (and revisited in Chapter 7), demonstrates proof of the concept that a
substantial proportion of smokers will, given the availability of a socially
acceptable and affordable consumer alternative offering a lower hazard to
health, switch from smoked tobacco to the alternative product.18 Particularly
among men, the availability of snus as a substitute for smoking has helped to
reduce the prevalence of smoking in Sweden,39 which is now by far the lowest in
Europe.40 The magnitude of the contribution made by the availability of snus
over and above conventional tobacco control measures is difficult to quantify,
but a recent study of the effect of withdrawal of snus from the market in Finland
in 1995, when both Finland and Sweden joined the EU, but only Sweden was
allowed to continue its use, estimates that over the following 10 years the
availability of snus reduced smoking prevalence in Sweden by an additional 
3.7 percentage points.41 Trends in snus use in Norway are similar to, and
perhaps stronger than, those in Sweden, and there the use of snus is strongly
associated with quitting smoking.42
1.3 Role of harm reduction in tobacco control policy
In 1962, the RCP’s Smoking and health report promoted a range of smoking
prevention measures, including a list of policies that, under the heading ‘Possible
action by the government’, probably represented the first published
comprehensive tobacco control strategy.43 The core components – preventing
tobacco advertising, increasing prices, making public places smoke free,
providing treatment for smokers, educating the public and restricting young
people’s access to cigarettes – remain at the centre of modern tobacco control
strategy as promoted by the WHO44 and the FCTC.11
These policies are effective and, when countries and states adopt them
comprehensively, the prevalence of smoking falls,45 slowly. Australia, Canada and
the UK have implemented increasingly extensive ranges of tobacco control
policies over recent decades and, in these countries, over the past 10 years or so,
prevalence has fallen respectively by around 0.6, 0.75 and 0.7 percentage points
per year.23,46,47 Adult smoking prevalence is now below 20% in all of these
countries, but, even if these rates of decline can be sustained, it will take more
than two decades before rates start to approach zero. Meanwhile, substantial
numbers of people in these countries continue to smoke: nearly 9 million in the
UK, 4.6 million in Canada and 3 million in Australia remain exposed to the
harm of smoking. Tobacco control policies may have a greater effect when
introduced together for the first time in a high-prevalence setting: in Uruguay,
6 © Royal College of Physicians 2016
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for example, a comprehensive package of tobacco control measures was
introduced in 2005, when adult smoking prevalence was around 34%, and led to
a reduction in smoking prevalence of around 1.1 percentage points per year for
the next 6 years.48 However, even if this rate of decline can be sustained, it will
take three decades to eradicate smoking, during which most current smokers will
continue to be harmed or killed by their addiction. It is therefore important to
complement this approach with strategies to reduce or prevent harm in those
who will otherwise continue to smoke.
To date, harm-reduction strategies have tended to focus on reducing emissions
and absorption of toxins from conventional cigarettes, eg through the use of
filters and attempts to limit tar yields, although the latter proved to be more of a
marketing device for the tobacco industry than a genuine reduction in harm
potential. More radical strategies, such as promoting alternative sources of
nicotine as a sustained substitute for smoking, have until recently been pursued
only in the context of therapies for individual smokers attempting to quit. The
potential for more widespread nicotine product substitution at a population
level, with the primary objective of changing the source of nicotine used by
smokers rather than ending all nicotine use, has not to date been widely adopted
as a public health policy. The evidence from Sweden suggests that the harm
reduction could add a further 0.4 percentage points per year to the rate of
decline in smoking prevalence,41 and hence make a substantial contribution to
public health.
1.4 Developments since the publication of the 2007 RCP report
and the need for this update
When the RCP published its last report on harm reduction in 2007, options for
alternative nicotine products for use in a population-level harm-reduction
strategy were limited to smokeless tobacco, the supply of which in the UK is
subject to severe constraints under the terms of legislation passed in 1992,49 and
medicinal NRT products, which many smokers find unsatisfactory as a long-term
substitute for smoking.18 However, the nicotine harm-reduction landscape has
since been transformed by the emergence of e-cigarettes which, as documented
later in this report, have demonstrated a popularity among smokers akin to that
of snus in Sweden. The emergence of e-cigarettes has also provoked substantial
controversy among those involved in tobacco control, wider public health policy
and practice, and the general population, and a spectrum of regulatory responses
in different countries that range from free market access to outright prohibition.
This report has been produced to review developments relevant to tobacco harm
reduction since the publication of the 2007 RCP report Harm reduction in
nicotine addiction,18 to look in particular at the effect that this new product
category has had on smoking and nicotine use in the UK, and to make further
© Royal College of Physicians 2016 7
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recommendations as to how the potential for this approach to prevent death and
disability from tobacco use might be realised, within an appropriate and
proportionate regulatory framework.
1.5 Summary
> Tobacco smoking is addictive, and causes an extensive range of harm to
health and wellbeing in individuals and wider society.
> Tobacco smoking contributes more to social inequalities in health, and to
overall death and disability, than any other avoidable cause.
> Smoking is preventable, and smoking prevalence falls progressively when
countries implement a comprehensive range of tobacco control policies.
> The rate of decline is slow, however, with millions of smokers in the UK
alone continuing to be exposed to the immediate and long-term hazards of
smoking.
> Harm reduction aims to reduce or prevent harm in those smokers who do
not respond to conventional tobacco control approaches by quitting
smoking.
> Harm reduction works by providing smokers with the nicotine to which
they are addicted without the tobacco smoke that is responsible for almost
all of the harm caused by smoking.
> E-cigarettes are a new product class that has proved popular with smokers
and offers a viable harm-reduction option.
> E-cigarettes have proved highly controversial and have provoked widely
different regulatory responses in different countries.
> It is therefore important to look carefully at the role that these and other
novel nicotine products might play in helping to prevent death and disability
caused by smoking, and to consider how regulation should be applied
proportionately to maximise this benefit.
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2.1 Recent trends and current prevalence of smoking in the UK
Reliable national data on the prevalence of smoking among adults in Britain were
collected from 1972 to 2011 in the General Household Survey,1 and since that
date in the Opinions and Lifestyle Survey1 and the Integrated Household Survey.2
Data from these sources demonstrate that, over the more than four decades for
which survey data are available, smoking prevalence fell from 51% of men and
41% of women in 1972,1 to 21% of men and 16% of women in 20142 (Fig 2.1).
Applying age- and gender-specific smoking rates to the 2013 population estimates
of the Office for National Statistics (ONS),3 there are approximately 8.7 million
adult smokers in the UK, of whom 4.8 million are men and 3.9 million women.
12 © Royal College of Physicians 2016
Fig 2.1 Smoking prevalence in men and women in Britain, 1972–20131 and
2014.2 (Adapted with permission from the Office for National Statistics1,2
under Open Government Licence.)
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Smoking has always been more common among men than women, and is also
related to age and socio-economic status. Especially over the past two decades,
smoking tends to be most common among young adults, and least so among
older people, but is following a predominantly downward trend in all age groups
(Fig 2.2).
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Fig 2.2 Smoking among men and women in Britain, by age 1974–2013.1
(Adapted with permission from the Office for National Statistics1 under
Open Government Licence.)
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Cross-sectional prevalence data by age demonstrate that smoking is currently
most common among young adults, and particularly among men aged 25–34
(Fig 2.3). Age-group data also demonstrate marked falls in smoking prevalence
14 © Royal College of Physicians 2016
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Fig 2.3 Prevalence of smoking by age group and gender in Britain, 2014.2
(Adapted with permission from the Office for National Statistics2 under
Open Government Licence.)
Fig 2.4 Smoking in Britain by age group, 20041 and 2014.2 (Adapted with
permission from the Office for National Statistics1,2 under Open
Government Licence.)
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over the decade from 2004 to 2014 in all age groups, but particularly in younger
adults (Fig 2.4).
Smoking among children is also falling, even more markedly than among young
adults. Figure 2.5 shows that the proportion of children aged 11–15 in England
who report that they currently smoke at least one cigarette a week has fallen by
around two-thirds since the 1990s, to figures of 4% and 3%, respectively, in girls
and boys.4 Over the past 10 years the prevalence of smoking in all people aged
11–15 has fallen from 9% to 3%, with smoking among the youngest participants
(those aged 11 and 12) falling to almost zero4 (Fig 2.6). Similarly substantial
declines in smoking prevalence among young people have also occurred in
Scotland.5
2.2 Smoking and disadvantage
Smoking is strongly associated with socio-economic disadvantage, however
defined or measured. Figure 2.7 shows prevalence trends over time in Britain
according to occupational socio-economic status, and demonstrates a falling
prevalence in all groups since 2001, but also prevalence that is twice as high, and
falling more slowly, among those in routine and manual occupations relative to
the managerial and professional group.
© Royal College of Physicians 2016 15
Fig 2.5 Prevalence of regular smoking among children aged 11–15 in
England 1982–2014.4 (Adapted with permission from the Health and Social
Care Information Centre4 under Open Government Licence.)
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A more detailed breakdown of smoking by occupation, from the Integrated
Household Survey, demonstrates a clear and direct relationship between smoking
16 © Royal College of Physicians 2016
Fig 2.6 Smoking by age: children aged 11–15 in England, 2004 and 2014.4
(Adapted with permission from the Health and Social Care Information
Centre4 under Open Government Licence.)
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Fig 2.7 Prevalence of smoking by occupational socio-economic status,
Britain 2001–131 and 2014.2 (Adapted with permission from the Office for
National Statistics1,2 under Open Government Licence.)
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prevalence and occupational social group, being highest in the least skilled
occupations (Fig 2.8).
In 2013, smoking in Britain was almost twice as prevalent among unemployed
people (35%) as among those in employment (19%), and in those with
incomes below £20,000 per year (23%) than those with incomes greater than
£40,000 (11%).1 Smoking is about twice as prevalent among those with a long-
standing mental health condition than in those without (Fig 2.9), and similar
among those with schizophrenia or other psychosis in 20106 to those in the
general population in the 1970s.1 Among other severely deprived groups, such
as those who are homeless, imprisoned, or dependent on other drugs or other
substances, most smoke.6 The strong relationship between smoking and
deprivation means that passive exposure to tobacco smoke, particularly in
children, tends to be much higher among children living in relatively deprived
households.7
Socio-economically disadvantaged people not only are more likely to be smokers,
but also tend to be more heavily dependent on smoking. Levels of cotinine, a
metabolite of nicotine (see Chapter 4) and a marker of nicotine dependence, are
consistently higher among relatively disadvantaged smokers across all age
groups8 (Fig 2.10).
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Fig 2.8 Smoking by occupation in Britain 2014.2 (Adapted with permission
from the Office for National Statistics2 under Open Government Licence.)
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Fig 2.9 Smoking prevalence among people with a long-standing mental
health problem, and in the general population, UK 1993–2013. (Updated for
this report from the RCP.6)
Fig 2.10 Saliva cotinine levels in smokers in relation to age and deprivation
(data from 1998 to 2003).8 (Adapted with permission from Action on
Smoking and Health.8)
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2.3 Trends in the uptake and progression of smoking in the UK
2.3.1 Smoking uptake
Most smokers in the UK start smoking during their teenage or early adult years. In
Britain in 2011, the most recent year for which data are accessible, 68% of male and
65% of female current smokers, respectively, reported that they started smoking
before age 18, and 95% and 93%, respectively, before age 25.9 Children in lower
socio-economic status households tend to start smoking at an earlier age: 43% of
smokers in 2011 who grew up in households in which the main wage earner was
employed in a manual or routine occupation took up smoking before age 16,
compared with 31% of those from professional and managerial households.9
Uptake after age 25 is rare in men and women, and in all socio-economic groups.9
Smoking status in young people tends to be less dichotomous than in adults,
because much early use is occasional and experimental, with a relatively low
likelihood of leading to sustained smoking. Comparison of smoking behaviour
between children and adults is also complicated by the different survey questions
used to define smoking in national surveys in these groups. Thus, by the age of 15 in
2014, 35% of children in England had tried smoking at least once, 5% had smoked
occasionally but less than once per week and 8% were smoking regularly, which in
this survey is defined as smoking at least once a week.4 From age 16, the question
used to define regular smoking changes to ‘Do you smoke cigarettes at all
nowadays?’,10 and by this definition 17% of those aged 16–19 in 2014 were regular
smokers.2 Among those aged 20–24, smoking prevalence was 25% (see Fig 2.4).
However, these are cross-sectional data, so the prevalence of smoking in those
aged 20–24 in 2014 will not necessarily apply to younger cohorts when they
reach that age. As Figs 2.6 and 2.7 demonstrate, uptake of smoking among
children and young people is falling rapidly, indicating that children born since
the early 1990s may be substantially less likely than their predecessors to take up
smoking, at least in their teens; and, unless these cohorts take up smoking in
their 20s to a much greater degree than has typically been the case in the past, it
appears that today’s children and young people in the UK are much less likely
than their predecessors to become smokers. The marked decline in smoking
prevalence among 11- to 15-year-olds began in 2006 (see Fig 2.6) and is likely to
be attributable primarily to the major tobacco control interventions of the
decade: the phased removal of tobacco advertising in the UK from 2002 and
smoke-free legislation, which was in place across the UK by the end of 2007.
2.3.2 Quitting
The proportion of people who have smoked regularly in the past but do not
smoke now increases progressively with age. Taking data for 2011,9 around 2% of
© Royal College of Physicians 2016 19
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men and 4% of women aged 16–19 describe themselves as ex-smokers, whereas,
of those aged 60 and over, the respective proportions are 45% and 30%. Although
the latter figures are likely to be biased upwards by the higher mortality in
continuing smokers, this bias will be less marked among those aged 50–59. In this
age group in 2011, 27% of men and 24% of women were ex-smokers, whereas
20% and 18%, respectively, were still smoking.9 These data therefore indicate that
over half of those who had ever been regular smokers quit before they reached the
age of 60, but that over 40% continue to smoke beyond that age.
2.3.3 Uptake and quitting within birth cohorts
Cross-sectional data on current smoking prevalence and past quitting are not
representative of trends within cohorts of UK individuals born at different times.
Figure 2.11 shows General Household/General Lifestyle Survey data from 1972 to
2011, provided by the UK Data Service, analysed to estimate smoking prevalence
within 5-year birth cohorts over the duration for which data are available. Figure
2.11 demonstrates that, in more recent birth cohorts, smoking prevalence tends
to be highest at around 25 years of age, but also that the peak within-cohort
Fig 2.11 Smoking prevalence in Britain from 1972 to 2011, by 5-year birth
cohort in people born since 1920.
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prevalence has fallen progressively in successive cohorts from almost 50% in
those born between 1951 and 1955, to under 30% in those born since 1986. Peak
prevalence levels in earlier cohorts are not known, but the steady downward
trend in prevalence in all of them indicates that they were probably substantially
higher. After age 24 the prevalence of smoking declines in all cohorts, and this
decline is likely to be attributable primarily to quitting smoking during mid-
adult life, and also to earlier mortality among smokers in older age groups. The
rate of this decline in smoking prevalence within recent cohorts is of the order of
1 percentage point per year, which, if sustained, indicates that, by the time today’s
20- to 24-year-olds reach the age of 50, their smoking prevalence is likely to have
fallen from around 30% (see Fig 2.4) to about 5%.
2.4 Current and expected future mortality and morbidity from
smoking
Mortality from smoking tends to lag behind smoking prevalence by several
decades, and reached a peak of around 151,000 deaths per year in the UK in the
mid-1980s (Fig 2.12).11 This total has since declined progressively to 103,000 in
2009.11 Data for England since 2009 suggest that this trend has continued, with
an estimated 78,200 people,12 equivalent to about 93,000 in the UK, killed by
smoking in 2014.12 The decline has to date been due predominantly to a
relatively marked fall in cardiovascular mortality (Fig 2.13), although modest
© Royal College of Physicians 2016 21
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Fig 2.12 Deaths from smoking, total and by gender, UK 1950–2009.11 (Data
for figure from Peto et al.11)
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declines in all causes of premature mortality among smokers are expected over
the coming decades.
Generating estimates of morbidity from smoking is a more complex process
and direct data are not available. However, figures on hospital admissions
attributable to smoking provide a proxy for morbidity, and demonstrate a
sustained rise over the past decade, from 1.38 million in 2003–4 to 1.63 
million in 2013–14.12
2.5 Summary
> Smoking prevalence has been falling for several decades in the UK, in all age
groups, in both men and women.
> Smoking prevalence has fallen particularly markedly since 2007 among
children and young people.
> Smoking remains much more prevalent among socio-economically
disadvantaged individuals and those with mental health problems.
> Uptake of smoking appears to be falling progressively, whereas quit rates
appear to be remaining relatively constant across successive cohorts.
> Smoking remains most prevalent among disadvantaged individuals, and
addiction to nicotine tends to be higher in more disadvantaged smokers.
22 © Royal College of Physicians 2016
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Fig 2.13 Deaths from smoking in England, by cause, 2003–13.12 (Adapted
with permission from the Health and Social Care Information Centre12
under Open Government Licence.)
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> This means that the approximately 8.7 million smokers in the UK today
include a high proportion of the most disadvantaged individuals in society,
who as a result of higher levels of addiction are likely to find it particularly
difficult to quit smoking.
> Smoking is likely to be rare among today’s young people as they approach
older age, but continuing efforts to reduce child uptake of smoking are 
vital.
> However, smoking continues to cause significant mortality and morbidity, in
part as a consequence of higher smoking rates in past decades.
> Helping disadvantaged smokers to quit or else reduce the harm caused by
smoking is therefore a key priority to prevent current and future death and
disability.
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3.1 Background
In 1962, when most men and almost half of all women in the UK were regular
smokers, the RCP’s report, Smoking and health, identified tobacco smoking as the
primary cause of the twentieth-century global epidemic of lung cancer and
proposed a range of policies to reduce smoking prevalence.1 Progress with
implementation of these policies remained slow, however, until the first
comprehensive UK tobacco control policy document, Smoking kills, was
published in 1998.2 Smoking kills recognised the devastating effect of tobacco
smoking on UK public health, and committed to reduce smoking in children and
young people, help adults to stop smoking, prioritise reducing the prevalence of
smoking in manual occupational groups as a means of decreasing health
inequalities, and offer particular help to pregnant smokers. Drawing heavily on
the policy recommendations of Smoking and health, Smoking kills defined a
package of tobacco control policies including the following:
> a ban on tobacco advertising and sponsorship
> tobacco tax rises
> enforcement of underage sales laws
> reducing point-of-sale tobacco advertising
> introducing smoking cessation services
> facilitating access to smoking cessation medication
> voluntary measures to reduce passive smoke exposure in public places and
workplaces.
Shortly after Smoking kills was published, powers for key policy areas, including
health, were devolved to the newly established Scottish Parliament, Welsh
Assembly and Northern Ireland Assembly, although some powers relevant to
tobacco, such as fiscal policy (via the Treasury), remained within the remit of the
Westminster government. However, Smoking kills had set the scene for tobacco
policy changes throughout the UK and, in the years that followed, the main
policies it recommended were implemented throughout England and the
devolved nations. These new measures included comprehensive smoke-free
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legislation, which was implemented in Scotland in 2006 and throughout the rest
of the UK by the end of 2007. Each of the UK nations has since produced their
own tobacco control strategies, with some variation in emphasis and the timing
of how policies were introduced. The core strategies are, however, broadly similar
and articulated in the most recent tobacco control plan for England, which was
published in March 2011.3 This plan committed to:
> implementing legislation to end tobacco displays in shops
> considering and consulting on plain packaging of tobacco products
> continuing to defend tobacco legislation against legal challenges by the
tobacco industry
> continuing to follow a policy of using tax to maintain the high price of
tobacco products
> promoting effective local enforcement of tobacco legislation
> encourage more smokers to quit by using the most effective forms of
support, through local stop smoking services
> publish a 3-year marketing strategy for tobacco control.
Progress has been made on all these objectives, particularly in ending point-of-
sale tobacco displays and passing legislation mandating standardised packaging
for tobacco products. The plan also proposed adopting a harm-reduction
strategy based on helping tobacco users who cannot or are unwilling to quit
smoking to substitute alternative safer sources of nicotine for tobacco,3 to be
supported by guidance from the National Institute for Health and Care
Excellence (NICE), which was in development at the time but published in 
due course in 2013,4 and undertook to encourage the development of new,
affordable and acceptable nicotine products.3 The UK government elected in
2015 has committed to a new tobacco strategy, although a publication date has
not been set.
In addition to national and devolved government actions, tobacco control policy
in the UK is significantly influenced by international treaties and initiatives. UK
tobacco policy is shaped by the World Health Organization (WHO) Framework
Convention on Tobacco Control (FCTC), a global health treaty5 ratified by most
of the world’s countries, including the UK, that defines a comprehensive range of
tobacco control policies and practices that all political parties undertake to
implement. At the European level, European Union (EU) single market rules
have also been a driver of significant policy initiatives across all EU member
states in recent years, including legislation banning tobacco advertising
(2003/33/EC)6 and mandating health warnings on tobacco packs (2001/37/EC,
known as the Tobacco Products Directive, or TPD).7,8 A revision of the TPD
(2014/40/EU), which comes into force in 2016, will impose a minimum pack size
of 20 cigarettes (and 50 g hand-rolling tobacco), require combined pictorial and
text health warnings to cover 65% of the front and back of the pack, and end
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cigarette flavouring.8 The new TPD will also set out product standards and
regulations on the sale of e-cigarettes (see Chapter 9). UK tobacco control policy
thus continues to be shaped by both national initiatives and international
agreements and legislation. The combination of these processes has led to the UK
becoming the European leader in tobacco control policy implementation.9
3.2 Tobacco control policy effectiveness and implementation in
the UK
3.2.1 Increasing the price of tobacco products
Fiscal measures, including tobacco taxation, are a key element of tobacco control.
In the UK, tobacco tax increased in the mid- to late 1990s, through an escalator
of 3% above inflation from 1993 to 1997 and 5% above inflation from 1997 to
2000. From 2001 to 2008 taxes rose in line with inflation, until, in 2009, a tax
escalator was reintroduced, which is currently set at 2% above inflation, a
commitment that runs until the end of the current parliament in 2020. Overall,
between 1980 and 2012 the affordability of tobacco declined by 28%,10 although,
relative to the 1960s’ prices, tobacco was approximately 50% more affordable in
2006 than when Smoking and health was published in 1962, and remains more
affordable today.11 The price of the most popular price category cigarettes, a
metric that initially reflected the price of the most popular brand or brands on
the market, but now typically represents the prices of the more expensive
(premium-brand) cigarettes, has increased consistently over the last three
decades (Fig 3.1), with the result that the UK now has some of the highest
premium-brand prices in Europe. However, the price of cigarettes in the ultra-
low price category favoured by younger and more disadvantaged smokers has
remained virtually static in recent years, thus undermining the effects of tobacco
tax rises.12,13
The World Bank suggests that price increases through higher taxation are the
single most effective and cost-effective tobacco control measure. Its estimates
from the late 1990s suggested that a price increase of 10% typically decreases
adult consumption by around 4% in developed countries.14,15 A 1996 study in
the UK produced an estimate consistent with the World Bank figure, with a price
increase of 10% reducing consumption by 5% and with evidence that lower
socio-economic groups were more responsive than those in higher socio-
economic groups to changes in the price of cigarettes.16 These figures were
disputed in a recent paper by HM Revenue and Customs (HMRC), which
estimated that the price elasticity of demand for cigarettes increased in the
period from 1982 to 2009,17 suggesting that a 10% increase in price now reduces
consumption by 10%. However, this study included duty-paid manufactured
cigarettes only, and did not take into account other types of tobacco, such as
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hand-rolling tobacco, to which many smokers downtrade when prices for
manufactured cigarettes rise.18
Evidence from a wide range of settings consistently demonstrates the
effectiveness of price increases as a tobacco control measure. From 1990 to 2005,
France tripled inflation-adjusted cigarette prices by raising taxes 5% or more
every year in excess of inflation and, during the same period, cigarette
consumption halved and smoking prevalence fell by a quarter.19 Comparable
price increases in South Africa achieved similar reductions in consumption.19
However, the available evidence relates predominantly to the effects of relatively
small, incremental price rises over time; the effects of sudden large price rises are
less well defined.20 Data from France indicate that a single large increase in
tobacco taxation in 2003, which caused the price of a packet of premium-brand
cigarettes to rise in real terms by almost 20%, resulted in a 13.5% decline in
sales.21 This implies that sudden large price increases may be more effective than
repeated smaller rises.
There is also consistent international evidence that raising taxes to increase the
price of tobacco reduces smoking among young people, who as a group are more
responsive than adults to price increases.22–24 The US surgeon general’s report on
preventing youth smoking concluded that increases in cigarette prices reduce
28 © Royal College of Physicians 2016
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Fig 3.1 Price and affordability of tobacco, 1980–2012.10 (Adapted from the
Health and Social Care Information Centre10 under Open Government
Licence.)
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initiation, prevalence and intensity of smoking among both children and young
adults.23 Evidence from developed countries indicates that a 10% increase in
price reduces youth consumption by between 5 and 12%.24 There is also
evidence from high-income countries that low socio-economic status (SES)
groups are more responsive to price increases, indicating that tobacco price
increases have a key role to play in reducing inequalities in health caused by
tobacco use.25 Two systematic reviews have recently assessed the equity impact of
tobacco control in high-income countries, in terms of differential impact on SES
groups, in both young people and adults.26,27 The reviews found that the clearest
and most consistent evidence of a positive equity impact (ie reduced inequalities
in smoking) for all types of tobacco control in adults, and to a lesser extent in
young people (as there are fewer studies on this), related to price increases.
Although UK tobacco prices increased throughout the 1990s, the effects of
increasing taxation during this period were undermined by, among other things,
a rapid increase in the market share for illicit cigarettes, which rose from 3% in
1996–7 to 21% by 2000–1.28,29 This meant that smokers were switching to cheap,
illicit cigarettes rather than quitting in response to price rises. This and a relative
absence of other tobacco control measures during this period resulted in little
change in UK smoking prevalence, despite year-on-year price rises. From 2000,
however, a comprehensive anti-smuggling strategy reduced the supply of illicit
cigarettes from 21% in 2000–1 to 9% in 2012–13. This included, from 2006,
legislation imposing substantial fines on manufacturers who failed to prevent
their products from being smuggled into the UK.28 Since then, however, tax
increases have been undermined by new developments in tobacco industry
pricing strategy, with the creation of a range of ultra-low-price cigarettes and the
practice of ‘overshifting’ tax on to more profitable premium brands, leaving
ultra-low brand prices relatively unchanged.12 The consequence of this strategy is
that many smokers who might otherwise quit smoking or else reduce their
consumption in response to price rises now ‘downtrade’ to lower-price brands, or
indeed switch to hand-rolling tobacco.
3.2.2 Restrictions on smoking in public places, workplaces and cars
The health effects of passive smoke exposure are well documented30 and, to protect
workers and the public from these effects, bans or restrictions on smoking in
public places and workplaces are a key component of tobacco control policy. In the
UK, smoke-free legislation was introduced first in Scotland in March 2006, in
Wales and Northern Ireland in April 2007, and in England in July 2007.
There is now extensive international and UK evidence that smoke-free laws are
effective in reducing passive exposure to smoke. Before the 2007 smoke-free
legislation, the highest levels of occupational passive exposure to smoke in the
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UK occurred in serving staff in bars and pubs.31 A study of bar workers in
England, Scotland and Wales showed that their exposure was reduced on average
by between 84% and 93% after introduction of the legislation.32 Children are
particularly vulnerable to the effects of tobacco smoke, and research in Scotland,
Wales and Northern Ireland found that passive exposure of children to smoke
declined after the introduction of the legislation in these countries.33 Between
1998 and 2012 in England, passive smoke exposure among children declined by
79%, and the most rapid decline occurred in the period immediately before
smoke-free legislation came into force, thus coinciding with national mass media
campaigns highlighting the dangers of passive smoke exposure.34 Smoke-free
legislation in the UK has also had positive effects on child and adult health, with
substantial reductions in preterm deaths, childhood admissions to hospital with
asthma and adult admissions for myocardial infarction.35–38
Smoke-free legislation also acts as an incentive to smokers to quit smoking. The
Smoking Toolkit Study found that, at the time of the legislation in England, the
number of smokers trying to quit smoking increased significantly, with
approximately 300,000 additional quit attempts made.39 Scottish data suggest
that quit attempts increased in the 3 months leading up to Scotland’s smoke-free
legislation,40 after which there was a temporary fall in prevalence in addition to
the secular reducing trend.40 A further study has suggested that, although smoke-
free legislation was not associated with additional reductions in smoking
prevalence, existing decreasing trends continued in the 18 months following
implementation of the ban.41
Two systematic reviews have recently assessed the equity impact of smoke-free
policy in high-income countries on young people and adults.26,27 A youth review
found that, of the six studies that had looked at the equity impact of
comprehensive smoke-free legislation, two had a neutral effect and four were
negative in terms of second-hand smoke (SHS) exposure.26 Declines in SHS
exposure occurred predominantly among children who had low SHS exposure
before smoke-free legislation, and who were from more affluent families. Thus,
the substantial SES gradients in children’s SHS exposure levels remained
unchanged. Welsh data showed that, although there was a significant decline
among high-SES children perceiving adult smoking as the norm, there was no
change among children from low-SES households.42 Thus, SES disparities in
children’s perceptions of adult smoking as normative increased, which is of
concern because social norms are important influences on smoking uptake. An
adult equity systematic review found that comprehensive national smoke-free
legislation was much more likely to have a neutral or positive equity impact than
voluntary partial policies.27
Following the success of smoke-free legislation in the UK, there are continuing
efforts to extend smoke-free policies to other settings. Some cities are considering
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extending smoke-free laws to outdoor public places including parks or other
open spaces. Since October 2015 it has been illegal for drivers in England and
Wales to smoke in private cars in the presence of children, and Scotland and
Northern Ireland are in the process of introducing similar legislation. Recent UK
research suggests that around one-fifth to one-third of 11- to 15-year-olds are
exposed to SHS in cars sometimes or often, and that this is concentrated among
those from more deprived backgrounds.43,44 Around three-quarters of
adolescents reported disliking being exposed to SHS in cars. Around one-third of
8- to 15-year-olds who reported ever being exposed to SHS in cars felt too
embarrassed or frightened to ask someone smoking in a car when they were
present to stop. Most children, adults and adult smokers in the UK support a ban
on smoking in cars where children are present.45
3.2.3 Mass media campaigns
Tobacco control mass media campaigns (MMCs) use television, radio,
newspapers and other media channels to reach large numbers of smokers and
encourage them to quit smoking, reduce harm to self or others from tobacco use,
and prevent young people from taking up smoking. Large-scale MMCs have been
a key component of UK tobacco control strategy since the early 2000s, and there
is strong evidence that tobacco control MMCs can increase adult smoking
cessation and reduce youth uptake.46–53 Campaigns in England have varied in
informational content; approximately half of the adverts between 2004 and 2010
warned of the negative consequences of smoking, whereas half contained
information on how to quit smoking.54 In April 2010, the government ceased
spending on national public health MMCs in England. A tobacco control MMC
was reintroduced in England in September 2011, but at a much lower rate of
funding.55 Mass media are also used to promote the ‘Stoptober’ campaign, which
has run every year since 2012 and encourages smokers to quit for the month of
October. Examples are shown in Fig 3.2.
The magnitude of the independent effect of MMCs on smoking behaviour is
difficult to establish when, as is usually the case, they are used together with
other tobacco control policies.51–53 However, several recent studies have assessed
the impact of MMCs on a range of measures of quitting behaviour in England
(and, to a lesser extent, Wales), including quit-line calls, hits on the national
Smokefree website, and measures of cigarette consumption and smoking
prevalence.56–60 Over the period from 2002 to 2009, when adult smoking
prevalence in Britain fell from 26% to 21%,61 an estimated 13.5% of this decline
was attributable to the effect of MMCs.58 A further study showed that positive
emotive campaigns – predominantly those promoting the use of NHS Stop
Smoking Services – and negative emotive campaigns – generally those containing
negative health effects messages – played a statistically indistinguishable role in
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triggering this effect.60 More recently, the annual English Stoptober campaign,
which aims to create a positive quitting trigger around a specific call to action –
stopping for 28 days – and which uses a combination of traditional and new
Fig 3.2 Examples of imagery from recent UK smoking mass media
campaigns (MMCs). (a) Toxic cycle MMC: launched in December 2013, and
aimed at reminding smokers of the physical damage caused by tobacco use,
while also offering support to help them quit by urging them to go online to
get information about stopping smoking, and order a free support pack
(Quit Kit), Smokefree app, text and emails, and information on how to
contact local NHS Stop Smoking Services.62 (b) Stoptober: launched in 2012;
runs annually. Uses traditional and new media to set people the challenge
of staying smoke free for 28 days starting on 1 October. The call to action is
reinforced by the positive message that smokers achieving this goal are at
least five times more likely to become permanent ex-smokers.63,64
(Reprinted with permission from Public Health England: https://campaign
resources.phe.gov.uk/resources/campaigns/6-stoptober/resources.)
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media, was estimated to have generated an additional 350,000 quit attempts and
9,000 permanent quitters in October 2012.63
Research from Australia has suggested that the level of exposure to MMCs
required to obtain a detectable reduction in smoking prevalence is the equivalent
of four exposures per person per month (390 gross rating points, known as
GRPs).47 Between 2004 and the spring of 2010, campaign exposure in England
exceeded this threshold in around 40% of months; in other months, exposure
was lower, with no campaign at all during 1 in every 5 months.54 A recent study
found that, below 400 GRPs per month, there was little impact of campaigns on
quit-line calls in England, and that the effect increased significantly above the
400 GRP threshold,59 suggesting that efforts should be made to maintain
exposure above this level.
The US surgeon general’s report on prevention of smoking in youth concluded
that MMCs can be one of the most effective strategies in changing social norms
and preventing youth smoking.23 The surgeon general concluded that the
characteristics of effective campaigns included evoking strong negative emotions
(eg health effects, deceptiveness of the tobacco industry), an appealing format,
clear messages, intensity and adequate repetition (at least four advertising
exposures per month over a 4-month period). There was strong evidence that
MMCs aimed at adults also decreased smoking among young people.
Two recent systematic reviews have looked at the equity impact of MMCs on
youth and adults. The youth equity review found only one study that had
assessed the equity impact of MMCs on young people by SES.26 This was an
evaluation of the US Truth campaign, which had mixed equity effects depending
on the outcome measure used.65 The adult review found 30 studies that had
looked at the equity impact of MMCs.27 These studies included a diverse range
of approaches and messages, including some aimed at increasing quit
motivations and/or attempts, and some aimed at increasing calls to quit-lines or
uptake of free nicotine replacement therapy (NRT). The equity impact of these
campaigns was inconsistent. This is perhaps not surprising given the diversity of
messages, media formats and levels of exposure. There was some evidence that
certain types of message, such as those with a higher emotional narrative, are
more effective with low-SES smokers. A previous review also found that the
impact of campaigns can vary by SES depending on the type of message, media
format and mechanisms of engagement.66,67
3.2.4 Health warnings
Health warnings on tobacco packages are a means of communicating the risks of
tobacco use to smokers. Text warnings became a legal requirement in the UK in
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1971, and since 2008 graphic pictorial warnings covering 40% of the back of the
pack, and text warnings covering 30% of the front of the pack, have been
required (Fig 3.3). The new EU TPD will see a further increase in the
prominence of health warnings, with picture and text warnings covering at least
65% of the front and back of tobacco packaging by May 2016.
Studies from a wide range of countries indicate high levels of awareness of pack
health warnings among both smokers and non-smokers.69,70 Large text warnings
have been shown to be linked to increased knowledge about the health risks of
smoking71 and increased motivation to quit.72–77 In the UK, a study of text-only
warnings found that they were noticed by over half of smokers,78,79 and that
those noticing warning labels were more likely to know about the health risks of
smoking.78 Pictorial warnings are likely to be most effective because they are
more likely to be noticed, improve memory for the health message, and are
associated with stronger beliefs about the risks of smoking and increased
motivation to quit.69
Determining whether exposure to health warnings is causally related to changes
in smoking behaviour has been difficult, owing to the challenges of disentangling
their effect from those of other interventions.69–80 Research has suggested that
pictorial health warnings increase the likelihood of a quit attempt.81 Further
studies, in which UK data were analysed together with data from Australia, the
USA and Canada, concluded that forgoing cigarettes as a result of noticing
warnings and cognitive reactions to warnings is a predictor of quit attempts,82
and that health warnings can help to prevent relapse.83 Some studies have
investigated the effect of health warnings on smoking prevalence,81–84 with some
suggesting positive effects,81 although other factors may also have contributed.69
The US surgeon general’s report on prevention of smoking in youth concluded
that small text-only health warning labels have limited impact on youth and
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Fig 3.3 Examples of UK text and graphic health warnings.68 (Adapted from
Department of Health68 under Open Government Licence; Crown copyright.)
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young adults, but that larger text or pictorial warnings that elicit strong emotional
reactions are significantly more effective at discouraging tobacco use.23
Systematic reviews of the equity impact of tobacco control policies found no
studies that had assessed the equity impact of health warnings in young people,26
and five studies of the effect of health warning labels in adults.27 EU text-only
health warnings and the addition of a quit-line number to new pictorial health
warnings were found to have had a greater impact on low-SES groups, and the
rest were equity neutral.
3.2.5 Comprehensive bans on the advertising and promotion of all
tobacco products, logos and brand names
Prohibiting advertising and promotion of tobacco products is a key element of
tobacco control. Television advertising for tobacco products was banned in the
UK in 1965 under the Television Act 1964, almost 25 years earlier than an EU
directive that prohibited television advertising across the EU in 1989 (Television
without Frontiers Directive (89/552/EEC)).85 This directive was replaced by the
Audiovisual Media Services Directive (2007/65/EC) adopted in December 2007.86
Subsequently, the UK Tobacco Advertising and Promotion Act 2002 (TAPA)
banned print media and billboard advertising from February 2003, tobacco
direct marketing from May 2003 and sponsorship within the UK in July 2003.
Advertising bans have been shown to reduce smoking uptake in children by
lessening its social desirability, and also to reduce tobacco consumption in adults.
The introduction of comprehensive advertising bans in Norway, Finland and
France resulted in significant reductions in tobacco sales in the period following
the introduction of the legislation.87 The US surgeon general’s report on
prevention of smoking among youth concluded that there is a causal relationship
between tobacco advertising and promotion, and the initiation and progression
of smoking in young people.23 It also concluded that comprehensive cigarette
advertising bans reduce youth smoking. The World Bank has estimated that
comprehensive advertising bans can reduce consumption by around 7%.88
A recent systematic review found four studies that had assessed the equity impact
of restrictions and bans on advertising and promotion, all of which had a neutral
equity effect.27 A similar review on the equity impact on young people found
four US studies indicating that, when there is no enforced control of advertising,
promotion or marketing of tobacco, there is the potential for increased inequality
in youth smoking.26
The main exclusions from TAPA, and hence the key remaining forms of
promotion, were displays of tobacco packs at the point of sale in shops, and the
Effectiveness of current and future tobacco control policy 3
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pack itself. Legislation ending both of these exclusions has now been passed in
the UK. Point-of-sale displays were removed from large retailers such as
supermarkets in England, Northern Ireland and Wales from April, October and
December 2012, respectively, and April 2013 in Scotland. Point-of-sale displays in
smaller shops were prohibited across the UK from April 2015 (Fig 3.4). Studies of
the removal of point-of-sale displays in Iceland and Ireland suggest that the
policy is supported by the public and that there are signs that prohibition helps
to denormalise smoking.89 A recent systematic review of the impact of point-of-
sale promotion on youth smoking found that there was a positive association
between exposure and smoking-related outcomes, including smoking and
smoking susceptibility.90 The review also found that point-of-sale bans may
contribute to a shift in youth perceptions about peer smoking prevalence, but
found no evidence of short-term population-level impacts on smoking.
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Fig 3.4 Examples of tobacco point-of-sale displays in small retailers in
England, before and after prohibition.
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Legislation to introduce standardised tobacco packaging in the UK was approved
in March 2015, and from May 2016 imposes a standard plain dark-green/brown
design and a large graphic health warning on all tobacco packaging, and limits
branding to a name and descriptor in a specified and standard plain font (Fig
3.5). A systematic review published in 2012 found that plain packs were rated as
less attractive than branded equivalent packs, or unattractive, by young people.91
An independent review into standardised packaging published in 2014 concluded
that the measure is likely to lead to a modest but important reduction in
smoking, including among children.92 Public support for the measure is also
reported to be high: in January 2015, a YouGov survey conducted for Cancer
Research UK found that 72% of those polled supported standardised
packaging.93
In 2012, Australia became the first country to introduce standardised packaging,
and early evaluations suggest that the removal of branding from packaging has
reduced the ability of the tobacco industry to use the pack to communicate to
Effectiveness of current and future tobacco control policy 3
Fig 3.5 Examples of current and proposed standardised cigarette packs.
(Reprinted with permission from Cancer Research UK and Action on
Smoking and Health.)
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young people and adults, and made products less appealing.94–96 There is also
evidence that standardised packaging has increased both thoughts about quitting
and quit attempts in adult smokers, and reduced smoking prevalence.97,98
Concerns that standardised packaging would lead to reductions in the price of
cigarettes and increases in illicit tobacco consumption appear not to have been
borne out.99,100
With point-of-sale and standardised packaging legislation complementing
TAPA, there are few remaining means by which smoking can be promoted in the
UK. However, tobacco and related imagery remains prevalent in the media,
including films, television programmes, magazines and social media. Although
paid-for product placement is illegal under the terms of TAPA, smoking
imagery remains common in popular films, computer games and on prime-time
UK television.101,102 Evidence suggests that there is a clear association between
exposure to such imagery in the media and young people starting smoking.103
Smoking in the media thus remains a major driver of smoking uptake among
children and young people, and needs to be addressed.
3.2.6 Restricting young people’s access to tobacco products
Measures to reduce young people’s access to tobacco have been recommended as
a means of reducing uptake of smoking. Evidence arising mostly from the USA
indicates that reducing youth access to tobacco by implementation of the
minimum age-of-sale laws reduces smoking prevalence among young people,
although this is highly dependent on levels of enforcement and access to
alternative non-retail sources of cigarettes.104,105 European evidence indicates
that access to cigarette-vending machines was significantly associated with
regular smoking by young people.106
Across the UK, the minimum age at which young people are permitted to purchase
tobacco was raised from 16 to 18 in 2007, and legislation prohibiting vending
machines was implemented between 2011 and 2013.107 The increase in minimum
purchase age in England was associated with a significant reduction in regular
smoking among 11- to 15-year-olds107 and a decline in smoking prevalence among
16- to 17-year-olds.108 The percentage difference in current smoking pre- and
post-legislation was significantly greater among those under 18 than in older age
groups. However, the effect of the legislation is undermined by substitution of
other means of access, particularly proxy purchasing by adults.109,110 Scotland
banned such sales in 2010 and England from 2015, although the Scottish
legislation appears not to have been successful in reducing proxy sales.111
A recent systematic review of the equity impact of tobacco control policies found
only five studies that have assessed the equity impact of such measures on
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youth.26 Two were equity positive (greater impact on low-SES youth), two
neutral (no difference by SES) and one negative (greater impact on high-SES
youth). Thus, no overall conclusion can be drawn about their equity impact.
However, stronger (ie comprehensive and enforced) US state-level, age-of-sale
laws were associated with lower smoking initiation and a reduction in low-SES
adolescent girls moving on to regular smoking. In England, raising the age of sale
from 16 to 18 was associated with a significant reduction in regular smoking
among those aged 11–15 years, with no difference by SES (measured by eligibility
for free school meals).112 However, although the percentage of high-SES pupils
who found it difficult to buy cigarettes from a shop increased, this was not the
case for low-SES pupils.
3.2.7 Treatments to help dependent smokers stop, including increasing
access to medications
Evidence-based smoking cessation treatments typically comprise behavioural
interventions, delivered as brief advice from healthcare professionals, telephone
quit-lines, more intensive one-to-one or group counselling, and
pharmacotherapies, including NRT, bupropion and varenicline.113 The UK was
one of the first countries to make these services easily available to all smokers as
a tobacco control policy. In England and Wales, NHS Stop Smoking Services
(NHS SSSs), free at the point of use, were launched in areas of high deprivation
defined as Health Action Zones (HAZs) in 1998–9, and extended to the rest of
England and Wales in 2000–1. The number of people using NHS SSSs grew year
on year, rising to over 800,000 in 2011–12, although they have fallen each year
since then to a total of 450,582 in 2014–15.114
These services, which use evidence-based guidelines115 and strongly
recommend the use of pharmacotherapy, have been shown to be effective over
a number of years. A national evaluation conducted in the early years after
their establishment found that 53% of attendees confirmed abstinence at 
4 weeks, with 15% still abstinent at 1 year.116 This study has recently been
updated, and 1-year abstinence rates are now lower, at 8%;117 however, some of
this change may be attributable to the growth of less intensive and hence less
effective forms of support, such as one-to-one interventions in pharmacies
rather than individual or group behavioural support delivered by smoking
cessation specialists.117 In the UK, cessation support is also available to
smokers through stop smoking helplines and websites where smokers can speak
to or converse online with a trained expert adviser. In a recent trial using the
NHS Stop Smoking helpline, approximately 20% of smokers who agreed to set
a quit date were abstinent at 6 months.118 The number of calls to the NHS
quit-line is small, however, averaging 20,000 per month between 2005 and
2010.60
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Pharmacological therapies such as NRT, bupropion and varenicline are highly
effective when delivered with behavioural support (see Chapter 5), and initiatives
to increase access to these treatments by smokers should improve the success of
quit attempts. Making cessation therapies available on reimbursable prescriptions
and NRT products available on general sale, which occurred in the UK between
1999 and 2002, resulted in a rapid increase in the proportion of quit attempts
supported by medication from 28% to 61%.119 However, a great deal more could
be done to extend delivery of stop smoking interventions, particularly by making
intervention a component of all NHS care delivery, including secondary care.120
Smoking cessation services tend to be more effective in adults than in young
smokers. The US surgeon general’s report on prevention of smoking in youth
concluded that several cessation programmes for youth are efficacious in the
short term but that, in contrast to adults, there is little evidence of the efficacy of
pharmacotherapies in youth cessation.23 Data from the NHS SSSs indicate that
relatively few under-18-year-olds access these services, and that those who do
have lower quit rates than other age groups.121 A recent systematic review found
only two studies that had assessed the equity impact on youth of cessation
services.26 Participants in both studies were mobile phone owners in their late
teens / early 20s, who were motivated to quit and received text messaging
support. Only one study demonstrated a long-term effect on quitting and this
was significant only in low-SES intervention participants.
The contribution of NHS SSSs to the reduction in smoking prevalence over
recent years has been estimated at between 0.1 and 0.3% above the background
quit rate per year.122,123 Although the impact on prevalence of policies and
initiatives to improve access to treatment is modest, these interventions have
been successful in reaching smokers in the most disadvantaged areas,123 who
tend to be more addicted and have the most difficulty stopping.124 A recent
systematic review of cessation studies concluded that untargeted smoking
cessation interventions across Europe are, on balance, likely to have increased
inequalities in smoking. However, the same review found that the comprehensive
UK stop smoking services, which are targeted at low-SES smokers, have reduced
inequalities in the harm caused by smoking, because higher reach among low-
SES smokers compensates for lower quit rates.27
3.3 Cumulative impact of conventional tobacco control policies
and future challenges
Although evidence of the impact of individual interventions on smoking
prevalence is limited by the difficulty of separating out the independent effects
on smoking prevalence of individual components from a wider package of
measures, the multi-component approach adopted in the UK appears to be
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effective, for both adults and young people. The effectiveness of comprehensive
packages of tobacco control policies has been further demonstrated in a recent
study of the association between MPOWER policies – a list of measures
developed by the WHO that are intended to assist in the implementation of
interventions required by the FCTC (Monitor tobacco use and prevention
policies, Protect people from tobacco smoke, Offer help to quit tobacco use,
Warn about the dangers of tobacco, Enforce bans on tobacco advertising,
promotion and sponsorship, and Raise taxes on tobacco) – and changes in
prevalence, by scoring countries according to their implementation of MPOWER
measures. The study showed that countries with higher MPOWER composite
scores experienced greater decreases in current tobacco smoking between the
years 2006 and 2009, and therefore underlines the need to implement the widest
possible range of policies.125 The study also assessed the effect of changes in each
MPOWER measure on changes in current tobacco smoking, and confirmed
existing evidence that price increases are the most effective tobacco control
measure.
Figure 3.6 demonstrates the declines that have occurred in smoking prevalence
among adults and young people in Britain since Smoking kills was published in
1998, in relation to the timeline of policies introduced. The reduction of adult
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smoking by around one-third, and by almost twice that proportion among
young people, represents a substantial success for tobacco control policy.
However, these figures also demonstrate that, despite this progress, smoking
remains a significant public health problem in the UK, with around one in five
adults still smoking regularly.61,128 These smokers, who are increasingly
predominantly from the more deprived SES groups in UK society,61 have by
definition proved resistant to policies applied to date, and also by definition are
in desperate need of measures to help them stop smoking.
The Scottish Government has recently set a target for Scotland to become ‘tobacco
free’, defined as a smoking prevalence below 5%, by 2034. Figure 3.7 demonstrates
how challenging it will be to meet this objective given current trends in smoking
prevalence, particularly among low-SES groups, and it will be equally challenging
in the rest of the UK. If such an ambition is to be realised, new tobacco control
approaches that can bring about substantial declines in smoking among the most
deprived individuals in society are urgently needed.
3.4 Developing a more effective tobacco control policy
approach
There are many ways in which existing UK tobacco control policies could be
improved and complemented to achieve faster declines in smoking
42 © Royal College of Physicians 2016
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prevalence.129,130 In addition to policy measures already in place, greater
investment in innovative MMCs, reversing declines in the uptake of SSSs and
wider integration of smoking cessation interventions into NHS service delivery,
extending smoke-free polices to a wider range of public places, preventing
smoking promotion through media imagery and other loopholes in advertising
and promotion legislation, and tighter measures to prevent youth access would
all make contributions to this end.
However, the most effective policy measure is price. Repeated substantial
increases in tobacco price, and removal of the price differentials for premium
cigarettes, budget cigarettes and hand-rolling tobacco, would have a
substantial impact, particularly among low-SES groups. The effect of taxes
can be further enhanced if some of the revenue generated is used to support
comprehensive tobacco control strategies. However, the negative effect of
price rises on the incomes of those who continue to smoke, as well as the
need to do more in general to provide smokers with alternative means to stop
smoking, demands additional alternative approaches. Making non-tobacco
nicotine products available to smokers, as envisaged in the Tobacco Control
Plan for England3 and advocated in this report, could not only reduce the
prevalence of smoking but also offset the negative effect of increased tax on
continuing smokers by providing a more affordable and acceptable alternative
product.
3.5 Summary
> Increasing the price of cigarettes reduces smoking prevalence, particularly
among young and relatively disadvantaged smokers.
> Price increases may be more effective if introduced in single large rather
than multiple small increments.
> The effect of price increases is undermined by the availability of illicit
tobacco, and the option for smokers to downtrade to ultra-low-price
cigarettes and hand-rolling tobacco.
> Smoke-free legislation has reduced passive exposure of children and adults
to smoke, and may also have generated some further reduction in smoking
prevalence.
> MMCs reduce smoking in all age groups and are an important factor in
enhancing the effectiveness of other interventions, but are effective only if
sufficiently well funded.
> Graphic health warnings on packs discourage smoking uptake, and
encourage and sustain quit attempts.
> Removal of tobacco advertising is particularly effective in reducing smoking
uptake, and both point-of-sale display prohibition and standardised
packaging of tobacco products further reduce exposure to tobacco branding.
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> Smoking imagery in the media, both branded and unbranded, remains a
strong promotional driver of smoking, particularly among young people.
> Raising the minimum age of sale, and prohibiting vending machine sales,
reduces smoking among young people.
> Providing cessation support to smokers helps them to quit smoking and, if
widely available, increases the rate at which smoking prevalence declines.
> Smokers from low-SES groups are particularly likely to respond to price
increases and graphic health warnings.
> Existing tobacco control policy could be enhanced by: further reducing the
affordability of tobacco, particularly of budget cigarettes and hand-rolling
tobacco; investing in MMCs; preventing smoking imagery in the media,
including social media; and extending smoke-free policies to outdoor areas.
> NHS SSSs need to be expanded, and appropriately funded to be integrated
and actively promoted in clinical care pathways.
> However, even with all such measures in place, millions of people in the UK
will continue to smoke for the foreseeable future. Alternative approaches,
particularly for young and disadvantaged smokers, are urgently needed.
> Promoting the use of alternative, acceptable and more affordable nicotine
products as a harm-reduction strategy has the potential to complement
existing tobacco control policy, and in particular to offset the potentially
regressive nature of tobacco tax rises.
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4.1 Nicotine chemistry and absorption
Nicotine is a naturally occurring alkaloid present in the leaves of the tobacco
plant, and is the major psychoactive compound and mediator of addiction to
tobacco use.1 Nicotine absorption across cell membranes is highly pH
dependent, because only non-ionised nicotine can cross biological membranes
and be absorbed into the bloodstream.2 Nicotine is a weak base with a pKa of
approximately 8,2 so, in the relatively acidic medium of cigarette smoke with a
pH typically ranging from 6.0 to 7.8, more than half of the nicotine in tobacco
smoke is protonated3 and cannot be absorbed. Manipulating the pH of tobacco
smoke to make it more alkaline thus increases nicotine absorption.4
The average nicotine content of commercially available manufactured cigarettes
is around 10 mg, but, as a result of loss in sidestream smoke, retention in the
cigarette stub and delivery of nicotine in ionised form, only about 1 mg is
absorbed from each cigarette smoked.5 When tobacco smoke is inhaled, nicotine
passes through the alveolar membranes of the lung into the pulmonary venous
circulation. It is then carried into the heart, and then directly into the arterial
system, reaching the brain within 10–20 s. The rate of increase in arterial
nicotine concentration achieved by inhaling nicotine is thus faster even than that
achieved by intravenous administration, with peak arterial concentrations
occurring at around 20 and 30 s, respectively.6 After smoking a single cigarette,
arterial nicotine concentrations differ according to the type of cigarette and the
way in which it is smoked. Thus, one study reported arterial levels of only about
20 ng/mL,6 but some smokers can achieve arterial nicotine concentrations of
about 60 ng/mL with just a few puffs7 and arterial concentrations of 100 ng/mL
have been reported after smoking a single cigarette.8 The arterial blood nicotine
levels achieved by inhaling nicotine are much higher than in the venous
circulation8 (Fig 4.1). As the rate at which an addictive drug reaches the brain
influences its addictive potential,9 the fast absorption and delivery of nicotine
after inhaling tobacco smoke underpin the rapid behavioural reinforcement of
smoking.10
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In contrast, when nicotine is swallowed, it is absorbed from the gastrointestinal
tract into blood that flows into the portal veins and hence to the liver, where it
undergoes substantial first-pass metabolism. Oral nicotine therefore generates
very low and similar systemic venous and arterial blood levels. Conventional
nicotine replacement therapy (NRT) products avoid this first-pass metabolism by
delivering nicotine via the skin, mouth or nose, blood from which drains directly
into the systemic venous system. NRT thus generates higher arterial nicotine
levels than those achieved by gastrointestinal absorption, but levels in arterial
blood are similar to those in venous blood and much lower than those achieved
by inhalation. There are also marked differences in venous plasma concentrations
of nicotine achieved, depending on the form and dose of NRT used11 (Fig 4.2).
The variation in time to reach maximal nicotine plasma concentration is due, in
part, to differences in administration duration as well as absorption time that
occur with each route of delivery.11
The relatively slow delivery of nicotine to the brain achieved by NRT is much less
reinforcing, and hence much less likely to generate dependence, than cigarette
smoking.12 However, forms of NRT that deliver nicotine relatively quickly, such
as the nasal spray, are thought to be more likely to generate dependence than
others. Overall, however, the addictive potential of cigarettes is much higher than
that of NRT or other non-inhaled nicotine products.13 Clinically, very few users
of NRT become dependent on it.
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Fig 4.1 Arterial and venous plasma nicotine levels after smoking a
cigarette. (Adapted and reprinted from Le Houezec8 with the permission of
the International Union Against Tuberculosis and Lung Disease. Copyright
© The Union.)
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4.2 Nicotine metabolism
Around 70–80% of absorbed nicotine is metabolised to cotinine,14 and around
90% of this metabolism is via the hepatic cytochrome P450 (CYP) 2A6
enzyme.15 The majority of cotinine is then further metabolised to 3′-
hydroxycotinine in a reaction mediated exclusively by CYP2A6.16 Both nicotine
and its metabolites are excreted in urine. As most nicotine clearance occurs via
metabolic (ie non-renal) means, variability in nicotine metabolism is likely to
cause substantial variation in the rate of nicotine clearance between
individuals.17,18 The ratio 3′-hydroxycotinine:cotinine is known as the nicotine
metabolite ratio (NMR), which serves as a phenotypic indicator of CYP2A6
enzymatic activity. As CYP2A6 represents the major route of nicotine clearance,
the NMR is also strongly correlated with the rate of nicotine clearance.18
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Fig 4.2 Venous plasma nicotine concentrations achieved over 1 h by a
single cigarette and by single doses of various forms of nicotine
replacement therapy (NRT – nicotine nasal spray (NNS), 2 and 4 mg gum,
and nicotine patch). Inset: nicotine levels after a 16- and 24-h course of
nicotine patch treatment over a 24-h period. (Reproduced from: Schneider
NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical
pharmacokinetics and comparison with other nicotine treatments. Clinical
Pharmacokinetics 2001;40:661–84.8 With permission from Springer.)
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Variation in the CYP2A6 gene, which has an impact on the functionality of the
CYP2A6 enzyme, is common and associated with alterations in the rate of nicotine
clearance, together with a variety of smoking behaviours.19 Slower nicotine
metabolism, as inferred from CYP2A6 genotypes or as measured directly by the
NMR, is associated with lower cigarette consumption,20,21 lower nicotine
dependence,22 lower smoking-related reward22 and lower risk of being a current
smoker.20 Slower nicotine metabolism is also associated with an increased
likelihood of unaided cessation (ie cessation without behavioural or
pharmacological support)23,24 and cessation in clinical trials, in which slow
metabolisers are typically more likely to achieve abstinence on both placebo25,26
and NRT.27,28 A separate study that used an alternative CYP2A6 phenotype
measure also found associations between slow nicotine metabolism and higher
abstinence rates.29 The prevalence of slower nicotine metabolism differs according
to ethnicity, predominantly owing to interethnic variability in patterns of CYP2A6
allele expression. The frequency of CYP2A6 alleles conferring reduced or loss of
CYP2A6 activity is generally higher in African and East Asian populations than in
European populations, as reflected by a higher prevalence of reduced nicotine
metabolism in populations of African and East Asian descent (approximately
40–50%) versus European descent (approximately 10–25%).30–32
In addition to CYP2A6-mediated nicotine inactivation, nicotine can be
inactivated through N-glucuronidation and N′-oxidation, through metabolism
by uridine diphosphate (UDP) glucuronosyltransferase (UGT) 2B10 and flavin-
containing monooxygenase (FMO) 3, respectively. The resulting minor nicotine
metabolites, nicotine N-glucuronide and nicotine N′-oxide, account for up to 5%
and 7% of a nicotine dose that can be recovered from urine, respectively.2 In
individuals with no functional CYP2A6 activity, FMO3- and UGT-mediated
nicotine metabolism may be more important for nicotine clearance;33 however,
reduced FMO3 function did not substantially affect nicotine metabolism in
individuals with reduced CYP2A6 activity.32 UGT2B10 can also metabolise
cotinine to cotinine N-glucuronide, comprising 12–17% of a nicotine dose
recovered from urine.14 A second UGT enzyme, UGT2B17, metabolises 3′-
hydroxycotinine to 3′-hydroxycotinine O-glucuronide, and accounts for about
9% of a nicotine dose recovered from urine.2
Several of these minor enzymes involved in the nicotine and cotinine metabolic
pathway (FMO3, UGT2B10 and UGT2B17) are highly polymorphic, with some
genetic variants leading to altered activity of these enzymes. Variation in FMO3 is
associated with minor alterations in nicotine metabolism, but appears to be of
insufficient magnitude to alter cigarette consumption or total tobacco dose in
light smokers of African-American ancestry.32 In heavy smokers of European
ancestry, variation in FMO3 has little effect on consumption, unless restricted to
those with faster CYP2A6 activity (a difference of about three cigarettes a day).34
The influence of UGT genetic variation, tested to date on variation in nicotine
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metabolism, is also relatively modest and does not appear to alter smoking
behaviours substantially.35,36 Although UGT2B17 genetic variation is associated
with altered 3′-hydroxycotinine metabolism,36 variation in genes for UGTs that
alters cotinine and 3′-hydroxycotinine metabolism is unlikely to affect smoking
behaviours because cotinine and 3′-hydroxycotinine are essentially inactive
metabolites of nicotine.
4.3 Systemic and central nervous system effects
4.3.1 Nicotinic acetylcholine receptors
Nicotine exerts its pharmacological effects through binding to nicotinic
acetylcholine receptors (nAChRs). These receptors are universally expressed in cells
throughout the body,37 including the central and peripheral nervous systems,
where they play a key role in mediating nicotine dependence and addiction. The
nAChRs are ligand-gated ion channels composed of five transmembrane subunit
proteins arranged around a central pore. Neuronal nAChRs consist of α (α2–α10)
and β (β2–β4) subunits,
38 each of which is encoded by a single gene (denoted with
a ‘CHRN’ prefix), and may be homomeric or heteromeric in terms of subunit
composition. Different combinations of subunits result in receptors differing in
pharmacological and physiological profiles.39,40 Individual subtypes differ, eg in
their affinity for nicotine, and sensitivity to upregulation and desensitisation after
nicotine exposure.40
Each nAChR subtype has a distinct distribution profile within the brain, which can
be determined through assessment of subunit mRNA using techniques such as in
situ hybridisation, and through imaging techniques such as positron emission
tomography (PET) and single-photon emission computed tomography (SPECT),
using subtype-selective radioligands.40 The differential expression of specific
subunits, with distinct biological functions in brain regions mediating specific
behaviours, allows nicotine to exert a broad range of effects.41 The α4β2 receptor
is the most commonly expressed subtype in the human brain, and historically
has been implicated through animal models as critical to the experience of
nicotine’s reinforcing effects (eg Picciotto et al42). In recent years, however, the
importance of the less studied α3- and α5-receptor subunits in mediating
nicotine dependence has been recognised. The α5-receptor subunit appears to
play a key role in determining aversive responses to high doses of nicotine.43
4.3.2 Systemic and central nervous system effects
Nicotine, at relatively low doses, is a stimulant. It increases heart rate, and has
been reported to have beneficial effects on cognition and performance,
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improving attention, memory and fine motor skills.44 Tolerance to nicotine can
develop rapidly (within a few days of use), and cessation of use then results in
the experience of withdrawal symptoms, both somatic and affective, such as
anxiety, restlessness, inability to concentrate, irritability and change in appetite.45
Chronic exposure to nicotine results in a number of neuroadaptions,46 including
desensitisation of nAChRs and upregulation in their expression,47 both of which
are linked to nicotine tolerance and withdrawal.
4.3.3 Mechanisms of effect
Nicotine exerts its complex effects (including arousal, mood modulation and
pleasure) via several neurotransmitter pathways. Once bound to neuronal nAChRs,
nicotine facilitates the release of dopamine, serotonin and a host of other
neurotransmitters including g-aminobutyric acid (GABA), glutamate,
noradrenaline, acetylcholine and endorphins.47 The mesolimbic dopamine pathway
has, perhaps, been the most widely studied in relation to nicotine dependence.46
Dopamine release in the nucleus accumbens, resulting from nicotinic stimulation of
dopaminergic neurons in the ventral tegmental area, is crucial to the processing of
rewarding and reinforcing the effects of nicotine. Indeed, dopamine release in the
nucleus accumbens appears to be critical in the experience of the rewarding effects
of many drugs of abuse. Continued pairing of the rewarding/reinforcing effects of
nicotine with specific sensory and environmental stimuli (which could include, for
example, the smell of tobacco smoke or the sight of a pack of cigarettes – smoking-
related behaviours) results in these stimuli also acquiring reinforcing properties.
These cues (conditioned reinforcers) have been linked to the maintenance of
smoking, smoking-related cravings and relapse.47
4.4 Toxicity and potential hazards
4.4.1 Toxicity of nicotine
Although nicotine is a toxic compound, overdosing on nicotine products used as
directed is almost impossible, given the individual ability to titrate dose and the
short half-life of nicotine (see Development of addiction below – Section 4.5).
However, ingestion of high doses (purposeful or accidental) can be fatal.
Historically, the lethal dose of nicotine for a human adult has consistently been
stated to be about 60 mg,48 corresponding to an oral median lethal dose (LD50)
of approximately 0.8 mg/kg. However, this figure has recently been disputed in
the light of reports of non-fatal suicide attempts or accidents involving nicotine
ingestion, leading to an estimate that the lower dose limit for fatal outcomes is
likely to be 500–1,000 mg ingested nicotine, equivalent to an oral LD50 of
6.5–13 mg/kg.48
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4.4.2 Potential hazards of short- and long-term nicotine use
At commonly used dose levels, short-term nicotine use does not result in
clinically significant harm. The safety of NRT products, which have typically
been used for days or weeks in the context of an attempt to quit smoking, is well
established49 (see Chapter 5 for further detail), with no evidence of any increase
in the risk of heart attack, stroke or death.50,51
Evidence about long-term nicotine or NRT use is relatively scarce, and concerns
have been raised that long-term NRT use may increase cancer risk, in part owing
to endogenous formation of carcinogens such as N′-nitrosonornicotine
(NNN).52 However, studies carried out in experimental animals largely indicate
that nicotine alone is not carcinogenic.53 In vitro and in vivo studies in animals
do, however, suggest that nicotine can have tumour-promoting effects through
activation of intracellular signalling pathways. Such effects include cell
proliferation, enhanced angiogenesis and decreased apoptosis.37,49 However, it is
important to note that many studies in this area have used nicotine at higher
doses than those achieved in heavy smokers.54 In vitro research suggests that
nicotine can have a negative impact on the function of some cells within the
cardiovascular system,55 and adverse effects on glucose metabolism.56 However,
robust evidence on the safety of long-term nicotine use in humans from the
5-year Lung Health Study, in which participants were actively encouraged to use
NRT for several months and many continued to consume NRT for a much
longer period, demonstrates no association between sustained NRT use and the
occurrence of cancer (lung, gastrointestinal or any cancer) or cardiovascular
disease.57,58 In addition, a recent clinical trial comparing 8, 24 and 52 weeks of
NRT treatment found that treatment duration was not associated with any
adverse effects, further supporting the safety of long-term NRT use.59
Although there is little evidence on the safety of using nicotine for periods longer
than 5 years, and no data on the safety of long-term use of nicotine by inhalation
other than when delivered by tobacco smoke, it is widely accepted that any long-
term hazards of nicotine are likely to be of minimal consequence in relation to
those associated with continued tobacco use. Notably, and in recognition of this
fact, the UK Medicines and Healthcare products Regulatory Agency (MHRA)
recently approved an extension to the indication of NRT to include ‘harm
reduction’,60 defined as ‘for use as a substitute or partial substitute for smoking
tobacco, both for those making an attempt to quit and those not currently
intending to make a quit attempt, without any restriction on its duration of use’.61
Guidelines on harm-reduction approaches to smoking from the National
Institute for Health and Care Excellence (NICE) further state that ‘it is safer to
use licensed nicotine-containing products than to smoke’ and ‘there is reason to
believe that lifetime use of licensed nicotine-containing products will be
considerably less harmful than smoking’.62
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Research from animal studies suggests that fetal exposure to nicotine may lead to
adverse postnatal health consequences63 and that cognitive function and
development are adversely affected by nicotine exposure during both the fetal and
the adolescent periods.64 The relevance of these findings to human brain
development remains uncertain, however. There is evidence that smoking in
adolescence is associated with cognitive and attentional impairments in later life, and
possibly an increased risk of mental health problems,65 but it is difficult to exclude
the effects of confounders of this association in the observational studies available.66
4.5 Development of addiction
Nicotine is the primary addictive component in cigarettes and other tobacco
products. It establishes and maintains addiction, thereby sustaining use, through
a range of complex actions on brain neurochemistry, which have been reviewed
in detail elsewhere.67,68 However, the addictiveness of any nicotine-containing
product depends on several factors beyond merely the presence of nicotine.
These factors primarily include the rate at which nicotine is absorbed and
delivered to the brain, and the dose of nicotine delivered. Other factors, such as
the speed at which the drug is metabolised and how soon withdrawal symptoms
occur, play a role. This is particularly relevant to nicotine, given its short half-life
(about 2 h), but this is a feature of the drug more than the product delivering the
drug. A nicotine-containing product will therefore be more or less addictive
depending on the dose and rate at which the nicotine is delivered. Essentially, a
product that delivers a high dose rapidly will have a greater liability for addiction
than one that delivers a low dose slowly. In this section, we describe the
importance of these factors.
4.5.1 Dose effects on addiction potential
Dose is an important factor in the development of nicotine dependence. Animal
models clearly demonstrate an inverted-U relationship between nicotine dose
and self-administration, although there is interindividual variability in the shape
of this curve, some of which is under a genetic influence.43 Therefore, increasing
the dose is associated with increased self-administration up to a point, after
which higher doses become increasingly aversive and ultimately toxic. One
advantage of the short half-life of nicotine is, however, that it enables consumers
to self-titrate their achieved dose. The dose (ie plasma concentration) of nicotine
achieved via use of different nicotine-containing products varies considerably
(see Fig 4.1 – the total dose achieved is reflected by the area under the curve for
each product). Figure 4.1 also illustrates the considerable variability in speed of
delivery across these products which, as discussed above, also contributes to
addiction liability.
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4.5.2 Rate of nicotine clearance
Nicotine is metabolised principally in the liver, with a half-life for elimination
of approximately 2 h (although, as discussed above, this varies considerably
between individuals). As a result of this short half-life, plasma nicotine
concentrations drop rapidly after nicotine administration, leading to
withdrawal symptoms, prompting further nicotine administration in regular
users, eg in a typical heavy, dependent smoker, nicotine levels increase rapidly
after smoking a cigarette (by about 5–30 ng/mL), then drop before increasing
again after smoking the next cigarette. Over the course of a day, plasma
nicotine concentrations rise gradually to a steady state of between about 10 and
50 ng/mL.8 The combination of a short half-life and regular administration via
frequent smoking (eg hourly) results in a distinctive pattern of nicotine
concentrations, as represented in Fig 4.3. Critically, overnight abstinence leads
to the almost-complete elimination of nicotine from the body, leading to
marked withdrawal on waking, and the need to consume nicotine in order to
reverse these symptoms.
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Fig 4.3 Simulated plasma nicotine concentrations obtained after smoking a
cigarette every hour for 16 h. (Adapted and reprinted from Le Houezec8 with
the permission of the International Union Against Tuberculosis and Lung
Disease. Copyright © The Union.)
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4.6 Smoke constituents influencing the addictive potential of
cigarette smoke
The addictive potency of cigarettes (and indeed other tobacco products) is
influenced by not only their nicotine content but also other aspects of product
design, including substances added to the cigarette to enhance nicotine delivery
and absorption. Monoamine oxidase (MAO) inhibitors in tobacco smoke
increase the levels of amines in the brain, such as dopamine and serotonin, and
may subsequently potentiate the reinforcing effects of nicotine.69 Indeed, animal
studies have demonstrated that MAO inhibitors facilitate nicotine self-
administration and enhance its motivational properties.70,71 These findings may
also contribute to the strong reinforcing properties of nicotine from cigarettes.
Sugars and polysaccharides are commonly added to tobacco products72 to
increase the formation of aldehydes, including formaldehyde and acetaldehyde,
in tobacco smoke. Acetaldehyde itself has addictive potential,73 as demonstrated
through self-administration experiments in animals,74 but it also enhances the
addictive potential of nicotine. The interaction between these compounds also
generates a rewarding effect that exceeds the additive effects of either component
in rodent studies.
Menthol and other flavourings (including cloves and liquorice) increase the
palatability of cigarette smoke and, in the case of menthol and cloves, facilitate
deeper inhalation and therefore a higher nicotine dose (owing to their
cooling/local anaesthetic effects). These are widely added at levels below those
used in what are conventionally considered to be ‘flavoured’ cigarettes. Flavours
may also become conditioned reinforcers in themselves, as a consequence of their
repeated pairing with nicotine.75 In addition, menthol inhibits metabolism of
nicotine to cotinine, purportedly through inhibition of CYP2A6 enzyme
activity,76 thus increasing the effect of nicotine. Cocoa and chocolate, which
contain theobromine, are also common additives in tobacco. Theobromine is a
bronchodilator, and thus has been proposed to enhance nicotine absorption in
the lungs. However, the theobromine content of cigarettes was deemed too low to
exert bronchodilatation in a recent review.77 Levulinic acid is an additive with a
sweet caramel taste, but it also alters the pH and so reduces the ‘harshness’ of
inhaled smoke.78 This, similarly to menthol, facilitates a higher nicotine dose.
Alkaline additives such as ammonia compounds are among the most common
additives used in cigarette manufacture.79 These substances are added to
cigarettes (and other tobacco products) to manipulate the pH. As discussed
above, increasing the pH increases the proportion of non-ionised, or freebase,
nicotine, which is more physiologically active than the ionised form, crossing
biological membranes more readily. Tobacco industry scientists have extensively
investigated the potential of pH manipulation to optimise nicotine delivery (see
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Hurt and Robinson79). Curing methods used in the production of tobacco can
also influence the pH of tobacco smoke. In particular, air-cured tobacco, as used
in cigars, generates nicotine at a relatively high pH, facilitating absorption from
oral and upper airway mucosa. Cigarette tobacco is largely flue cured, resulting in
nicotine at a lower pH and lower upper airway absorption, hence requiring
inhalation into the much larger surface area of the lung alveoli to achieve
significant absorption.
4.7 Impact of cigarette design characteristics on nicotine
delivery
A number of physical characteristics of cigarettes have been engineered to
influence nicotine delivery, including cigarette dimensions, filtration, ventilation,
paper porosity and tobacco shred size.79 Ventilation, for example, serves to
manipulate nicotine, tar and carbon monoxide levels through dilution of tobacco
smoke, and is achieved through the introduction of holes in both the filter and
the paper wrap.77 Ventilation technology was used in the production of ‘light’ or
‘low-tar’ cigarettes, which were promoted by the tobacco industry as healthier
alternatives to full-strength cigarettes. However, these descriptions have been
shown to be misleading and for this reason have been banned in the UK.
Although smoking machine assessments give readings indicating that these
cigarettes yield lower doses of nicotine, studies in humans have shown that
smokers compensate by altering their smoking topography (ie the way in which
people smoke their cigarettes). Thus, smokers use deeper inhalation, increased
number of puffs per cigarette, etc when smoking these cigarettes, in order to
achieve the same dose of nicotine attained when smoking stronger brands.80
This results in equivalent levels of exposure to the harmful constituents of
tobacco smoke.81
Smoking topography also affects nicotine delivery. Smokers can make changes to
their blood nicotine levels by altering depth and frequency of inhalation and
volume of smoke inhaled. A 20-a-day smoker can halve the number of cigarettes
that they smoke, but sustain the same plasma nicotine levels by taking larger and
deeper puffs. It is this compensatory behaviour that leads to a lack of association
between machine-determined nicotine levels in cigarettes and the nicotine dose
and quantity of toxic smoke inhaled by a smoker (see below). This may be why
reductions in the amount individuals smoke, although making it easier for them
to go on to quit, have a relatively limited impact on health outcomes compared
with quitting altogether. There are also sex differences in smoking topography
(women typically take smaller puffs than men) and ethnicity (African-American
individuals typically smoke more of their cigarette than people of European
descent).2 Mood may also affect the way in which people smoke, with positive
effect being associated with a greater increase in blood nicotine levels.82
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4.8 Lessons from cigarette design for harm-reduction product
development
Nicotine is the primary addictive component sustaining tobacco use, but is not
the cause of the vast majority of harm associated with tobacco use. Therefore, a
product that delivers nicotine in the absence of other constituents of tobacco will
be associated with dramatically less harm. The safety of NRT demonstrates this
and, although long-term use is relatively uncommon, there is sufficient evidence
to conclude that any harm from long-term nicotine use will still be negligible
compared with the harm of tobacco use. However, nicotine-containing products
such as NRT, although very low in harm, are also substantially less satisfying to
smokers than, for example, cigarettes, as evidenced by their modest efficacy as
smoking cessation products. As discussed above, this is due to the favourable
nicotine delivery characteristics and unique range of behavioural reinforcers
associated with cigarette smoking. The ideal harm-reduction device should
therefore deliver nicotine in a manner as similar as possible to cigarettes, while at
the same time maximising palatability and nicotine delivery to approximate the
experience of cigarette smoking more closely.
4.8.1 Targeting the determinants of addictiveness
The principal determinants of the addictiveness of a nicotine-containing product
are the dose that it delivers, and the speed with which the dose is delivered. Given
that most cigarette smokers are dependent (at least to some degree) on nicotine,
targeting these determinants is a critical requirement of any harm-reduction
product. The use of additives in tobacco products and the design of the cigarette
are both engineered to enhance nicotine delivery from the cigarette, by
modifying both the palatability of the cigarette smoke (and therefore the ease
with which it can be inhaled, facilitating rapid delivery and self-titration) and the
bioavailability of the nicotine contained within it. Other factors, such as the taste
and smell of cigarette smoke, and the behavioural action of smoking, can
themselves become conditioned reinforcers over time and, although secondary to
the effects of nicotine, are important drivers of continued smoking .
4.8.2 E-cigarettes and harm reduction
E-cigarettes meet many of the criteria for an ideal tobacco harm-reduction
product. Although nicotine delivery from e-cigarettes depends on a number of
factors, including level of user experience and device characteristics,83 they can in
principle deliver a high dose of nicotine, in the absence of the vast majority of the
harmful constituents of tobacco smoke (or at least at negligible levels), in a way
that enables accurate self-titration (see Chapter 5). They also provide some of the
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cues associated with cigarette smoking, such as taste and throat rasp, as well as
behavioural actions such as hand-to-mouth movement. At present therefore,
although little is known of the kinetics of nicotine uptake from e-cigarettes into
arterial blood, e-cigarettes offer a substitute to smoking that is more likely, on
theoretical grounds, to prove satisfying and acceptable to smokers than NRT.
4.9 Summary
> Nicotine is the primary addictive component of tobacco smoke.
> When inhaled into the lungs, nicotine from tobacco smoke is absorbed and
delivered to the brain much more quickly, and in higher doses, than can be
achieved by other routes of absorption.
> This rapid delivery of repeated high doses of nicotine to the brain is thought
to underpin the addictive nature of cigarettes.
> Nicotine is metabolised quickly, causing blood levels to fall rapidly after
dosing. People who metabolise nicotine more slowly, and therefore maintain
more constant blood levels, tend to be less heavily addicted.
> Nicotine is a stimulant that improves concentration and fine motor skills.
However, once tolerance is acquired, unpleasant withdrawal symptoms occur
when nicotine blood levels fall.
> Sustained use of nicotine is reinforced by some of the co-stimuli of smoking,
such as the taste and sensation of tobacco in the throat, and the smells and
behaviours associated with smoking.
> The tobacco industry has manipulated other constituents and additives in
tobacco to enhance the addictiveness of nicotine in smoke.
> NRT products may not be effective in some smokers because they replicate
few of the delivery, sensory or behavioural characteristics of cigarettes.
> E-cigarettes have the capacity to replace more of the characteristics of
tobacco cigarettes than conventional NRT, and therefore have potential as
effective smoking substitutes.
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5.1 Introduction
For many years, the range of non-tobacco nicotine products available in the UK
has been dominated by nicotine replacement therapy (NRT) products, developed
and licensed as medicines to aid smoking cessation. The range of NRT products
available has grown to include transdermal patches, chewing gum, lozenges, nasal
spray, oral pouch, oral spray, oral strips and the ‘inhalator’, a device that provides
a nicotine vapour for oral absorption. In recent years the licences for these
products have been extended in several countries, including the UK, to include
use to assist smoking reduction and temporary abstinence.
There is strong evidence from randomised controlled clinical trials that NRT can
be an effective smoking cessation therapy. A Cochrane review carried out in late
2012 identified 150 such trials, and concluded that all commercially available
forms of NRT increase the likelihood of successful cessation among smokers
making a quit attempt.1 NRT products also have a very good safety record.2 The
products differ in the speed of nicotine delivery and the degree of behavioural
replacement for smoking that they provide, but are fairly similar in the amount
of nicotine that their strongest formulation delivers. Some require specific
techniques for correct use (eg chewing gum and nasal spray), whereas others (eg
the transdermal patch) are very simple to use. None, however, reproduces the
rapid delivery of high doses of nicotine achieved by inhaling tobacco smoke, and
few smokers find them enjoyable or satisfying.
NRT products have traditionally been produced and marketed by the
pharmaceutical industry, but in recent years tobacco companies have also begun
to acquire or develop products manufactured to standards similar to those of
NRT products. Examples of these ‘clean’, non-tobacco nicotine products include
Zonnic nicotine gum, marketed by Niconovum, part of Reynolds American Inc,
and Verve nicotine-containing discs marketed by NuMark, part of Philip Morris.
In the past 5 years, however, the non-tobacco nicotine market has been
transformed by the emergence of e-cigarettes, which are now the most widely
used form of non-tobacco nicotine. Unlike NRT, they have been marketed as
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consumer products rather than therapeutic goods, and also, unlike most forms of
NRT, they retain several important features of smoking other than nicotine
delivery, including similar hand-to-mouth movements, behavioural rituals, an
inhaled sensory stimulus and a range of flavours. These characteristics make 
e-cigarettes attractive to a wide range of smokers, including many who do not or
would not use NRT; hence, they provide a potentially viable, lower-hazard
market competitor to tobacco cigarettes. As consumer products, they are subject
to varying degrees of regulation in different countries, and are evolving quickly
as the technology improves. Most e-cigarettes are marketed by independent
companies importing products from China, but some production is now based
in the UK. Several leading brands have now been bought by tobacco companies
(see Chapter 8).
The non-tobacco nicotine market in the UK and many other countries is thus in
a state of rapid change, with use of e-cigarettes already eclipsing that of
pharmaceutical NRT (see Chapter 7), and an increasingly wide range of new
products that deliver nicotine at or close to medicinal standards, some of them
marketed by the tobacco industry, becoming available. Indeed the status quo of
the nicotine market, whereby medicines have to date been made exclusively by
pharmaceutical companies, has recently been challenged by the award of
medicines licences to two new products: a nicotine-metered dose inhaler (Voke),
and an e-cigarette (E-Voke), both of which are being brought to market by
Nicoventures, a subsidiary of British American Tobacco.
This chapter provides a summary of currently available non-tobacco nicotine
products, their pharmacokinetic profile, safety, addiction potential and trends in
their use. Where blood or plasma nicotine levels are given, they relate to those in
venous blood (see Chapter 4) unless stated otherwise.
5.2 NRT products
5.2.1 Transdermal nicotine
5.2.1.1 Doses and pharmacokinetics
Commercially available transdermal nicotine patches provide nicotine at a
controlled rate for absorption through the skin into the systemic venous
circulation. Products vary in dose from around 7 to 25 mg per patch, and deliver
nicotine for either 16 or 24 h. High-dose examples include patches that deliver
25 mg over 16 h, or 21 mg over 24 h; lower doses, which are intended for
weaning some weeks after smoking cessation, deliver (for example) 15 or 10 mg
over 16 h, or 14 or 7 mg over 24 h. The rationale behind the 24-h patch is that it
delivers nicotine during sleep and thus provides some protection against urges to
smoke immediately after waking. The occasional drawback of 24-h delivery,
70 © Royal College of Physicians 2016
HRR Chapter 5:Layout 1  05/04/2016  12:03  Page 70
Non-tobacco nicotine products 5
which is avoided by 16-h formulations, is that nicotine can cause vivid dreams or
otherwise disturbed sleep.
The rate of absorption of nicotine from transdermal patches is slow, although
there are some differences in pharmacokinetic profile between available products.
In general, after application of the patch there is a delay of up to 2 h before
plasma nicotine levels start to rise. High-dose products can generate maximum
venous plasma concentrations of 16–18 ng/mL at around 6–12 h.3,4 Plasma
nicotine levels at 24 h are about 11 ng/mL with the 24-h patch, and 3 ng/mL with
the 16-h patch.3 During use a small reservoir of nicotine accumulates in the skin
under the patch, which means that nicotine continues to be absorbed into the
blood for an hour or so after the patch has been removed.
5.2.1.2 Safety profile
The nicotine patch has a good safety profile, even when more than one high-dose
patch is applied simultaneously.5 In addition to the generic nicotine effects
outlined briefly in Chapter 4, which apply to all the products described in this
section, the most common side effects of the nicotine patch are insomnia,
abnormal dreams, and skin irritation at the application site. There were early case
reports of cardiovascular adverse effects, but more robust reviews suggest that
these were not caused by NRT.6
5.2.1.3 Addiction potential
The addiction potential of nicotine products is generally related to the speed of
nicotine delivery, with faster delivery systems more likely to be used long term.7,8
As transdermal patches deliver nicotine very slowly, long-term dependence is not
expected to be a problem, and empirical evidence confirms that this is indeed the
case.7,9
5.2.2 Oral and nasal nicotine
5.2.2.1 Doses and pharmacokinetics
Oral and nasal NRT products deliver nicotine more rapidly than nicotine
patches, typically achieving peak plasma nicotine concentrations within 30–60
min. However, this kinetic profile is due in part to the sustained-release
formulations used in many oral products, and faster absorption is possible.
Formulations that spray nicotine solutions directly on to the mouth or nasal
linings are among the most quickly absorbed NRT products, achieving peak
levels within about 10 min of dosing. Nicotine absorption is influenced by the
pH of the oral lining, being faster in relatively alkaline conditions. As with all oral
or nasal products, nicotine that is swallowed undergoes extensive first-pass
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metabolism (see Chapter 4) and makes no appreciable contribution to levels of
nicotine in the blood.
Nicotine gum
Nicotine gum is available in two strengths, 2 mg and 4 mg, with the higher dose
recommended for more dependent smokers. The nicotine contained within the
gum is released on chewing and absorbed through the tissues lining the mouth.
After chewing a single 2-mg piece of gum, peak plasma concentrations of
3–5 ng/mL are observed within 30–60 min,10,11 and chewing a 2-mg piece of
gum every hour results in plasma nicotine concentrations of between 12 and
16 ng/mL. The maximum concentration (Cmax) for a single dose of 4-mg gum is
around 10 ng/mL, and regular dosing can generate plasma nicotine
concentrations of between 27 and 32 ng/mL.11
Nicotine oral disc
A recently developed nicotine oral disc has similar characteristics to the gum. It is
a non-dissolving polymer disc containing 1.5 mg tobacco-derived nicotine,
which is released when it is chewed. Chewing for 15 min results in an increase in
plasma nicotine concentration of around 2 ng/mL.12
Nicotine oral pouch
The nicotine in this product is in a powder, contained in a small pouch designed
to be held in the mouth. A single 4-mg pouch, if held against the inner lining of
the cheek for 30 min, produces a peak plasma concentration of approximately
10 ng/mL.13
Nicotine lozenges and sublingual tablets
Products in this NRT category differ in how quickly they dissolve in the mouth,
and in their dose and pharmacokinetic profile. A single 1-mg lozenge creates a
peak plasma concentration of around 2 ng/mL,10 a 2-mg lozenge between 4 and
5 ng/mL and a 4-mg lozenge about 10 ng/mL, all within about 60 min. A study
of a 2.5-mg nicotine lozenge showed that single use resulted in a maximum
plasma concentration of 10.8 ng/mL in 30 min.14 Regular use of lozenges (eg one
every 1–1.5 h) results in plasma nicotine concentrations of between 10 and 
15 ng/mL for the 1- and 2-mg lozenges10,11 and 20 and 26 ng/mL for the 4-mg
lozenge.11 The pharmacokinetic profile of the 2-mg sublingual tablet is similar to
that of the 2-mg lozenge.15
Nicotine oral film
This product contains 2.5 mg nicotine in a thin film, designed to be applied to
the roof of the mouth, where it dissolves in less than 5 min. Use of a single strip
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produces a peak plasma nicotine concentration, similar to the 2-mg lozenge and
gum, of between 4 and 5 ng/mL.
Nicotine inhalator
The nicotine inhalator consists of a plastic tube holding a replaceable
cartridge containing either 10 or 15 mg nicotine. When the user inhales
through the device, nicotine vapour is generated, which deposits on and is
absorbed through the lining of the mouth. Although used by inhalation, this
product does not achieve appreciable pulmonary delivery or absorption, and
the pharmacokinetic profile is similar to that of other oral NRT products.
After 20 min intensive use, around 2 mg nicotine is released from the device,
resulting in peak plasma concentrations of up to 8 ng/mL and, if this use is
repeated hourly for 10 h, levels of around 20–25 ng/mL are achieved.16 Most
users do not, however, use the device with this level of intensity, so lower
plasma levels, similar to those achieved by 2-mg gum, are more typical.
Nicotine release from this device decreases with ambient temperature17 so, 
in cold conditions (<15°C), users should be advised to keep the inhalator
warm.
Nicotine nasal and mouth sprays
The nasal spray delivers nicotine solution to the nasal mucosa and, after a single
1-mg dose (two sprays containing 0.5 mg nicotine), a peak plasma nicotine
concentration of about 5–6 ng/mL is observed within 10–15 min.18 Taking an
hourly dose results in a steady-state plasma concentration of about 10 ng/mL.
Although one of the fastest-acting NRT products, the nasal spray is also one of
the most aversive to use initially.
The nicotine mouth spray also delivers nicotine quickly. Each spray delivers 1 mg
nicotine and results in a peak plasma concentration of around 3–4 ng/mL within
10 min.19 A 2-mg dose gives a plasma concentration of around 5–6 ng/mL.
Another mouth spray formulation has shown higher maximum plasma
concentration (10 ng/mL) with a 2-mg dose, but with a slightly longer time 
(15 min) to reach this.14
5.2.2.2 Safety profile
Similar to the nicotine patch, oral and nasal nicotine products have a good safety
profile. The most commonly reported adverse effects are related to mouth and
throat irritation, and hiccups. The nasal spray is a local irritant to the nasal
lining.20
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5.2.2.3 Addiction potential
Some 5% of smokers who use oral nicotine products to stop smoking will
continue to use them for a year or longer.9 With the nicotine nasal spray, this
figure is closer to 10%,9 which probably reflects the faster nicotine delivery of
this product. Long-term users are usually people who were highly dependent on
nicotine from their cigarettes and who would be relatively unlikely to maintain
long-term abstinence from smoking without such help.21 There are no
documented cases of non-smokers becoming dependent on NRT.
5.2.3 Dual use of NRT and smoked tobacco products
NRT appears to be safe and well tolerated when used together with smoking.22,23
Randomised placebo-controlled trials of dual use indicate that the occurrence of
expected symptoms of nicotine overdose, such as nausea and palpitations, is
uncommon.24,25 A meta-analysis of NRT use before quitting found no increase
in adverse events in patch users compared with those on placebo.26 No reported
concerns over the use of NRT while smoking have arisen from post-marketing
surveillance. Smokers who also use NRT (known as ‘dual users’) are
approximately twice as likely in the following months to make a quit attempt,
and to quit smoking, than those who do not.27,28
5.3 E-cigarettes
E-cigarettes provide nicotine for inhalation in a vapour generated by heating a
solution containing water, nicotine, propylene glycol, vegetable glycerine and
typically also some flavouring. E-cigarettes were developed and first marketed in
China in around 2003, and appeared on the market in the UK about 4 years
later. The quality of early devices was variable, as was the consistency of the
nicotine solutions (e-liquid) that they contained29 and their ability to deliver
nicotine, which, in some cases at least, was poor.30 Newer studies have
demonstrated some improvements in quality, at least in relation to declared
nicotine content.31,32
The many brands and models of e-cigarettes available can be grouped into three
broad categories of different appearance (Fig 5.1). The original or first-
generation e-cigarettes were designed to be of similar size and appearance to a
conventional cigarette, and hence are sometimes known as ‘cigalikes’. These
devices typically comprise two components: a battery and a ‘cartomiser’, a
section of the device that contains nicotine solution and a vaporiser. Although
some cartomisers are refillable, most are disposable, ie designed for single use
and replacement when empty. Second-generation e-cigarettes are larger,
74 © Royal College of Physicians 2016
HRR Chapter 5:Layout 1  05/04/2016  12:03  Page 74
Non-tobacco nicotine products 5
© Royal College of Physicians 2016 75
Fig 5.1 The three generations of e-cigarettes: (a) first generation; (b) second
generation; and (c) third generation. (Images provided by Anna Phillips.)
a
b
c
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typically the size of a large fountain pen, and incorporate a more powerful
battery linked to a permanent vaporiser, and a tank system that users can refill
with nicotine solution. Third-generation devices are typically larger still, with a
still more powerful battery, usually with two heating elements (coils), and allow
users to vary power and sometimes also the draw resistance of the device.
Third-generation devices are also designed to allow modifications and
substitution of individual components according to preference. Second- and
third-generation devices generally deliver nicotine more effectively than first-
generation devices (see below). The nicotine, propylene glycol, glycerine and
flavouring contents of e-liquids also vary substantially, particularly in relation
to nicotine content (with some being nicotine free), and in the ratio propylene
glycol:glycerine.
5.3.1 Pharmacokinetics
Nicotine delivery from e-cigarettes is influenced by the concentration of nicotine
and other constituents of the e-liquid, and the puffing (‘vaping’) technique used,
and has generally increased with successive generations of the technology.33 The
earliest first-generation devices delivered little or no nicotine, eg two early
products containing a 16 mg/mL nicotine solution; when tested in smokers who
had not previously used e-cigarettes, it was found that the devices delivered
either very little nicotine, achieving a maximum blood level of 1.3 ng/mL at 
20 min,34 or none at all.35 However, with improved technology and more
experienced users, nicotine delivery is improved, eg whereas one study found
that, among naive users, 5 min free use of an e-cigarette containing 24 mg/mL
nicotine produced a peak plasma concentration of 4.6 ng/mL within 5 min, after
4 weeks’ practice the same users were achieving levels of 5.7 ng/mL.36 A study of
a more advanced first-generation e-cigarette containing 18 mg/mL nicotine, and
using a longer puffing (vaping) regimen (10 puffs 30 s apart on six occasions
every 30 min), resulted in a maximum plasma nicotine concentration of
7.4 ng/mL at 2.5 h after the first puffing bout.37 In experienced users, using the
same 10 puffs in a 5-min regimen, plasma nicotine levels can rise by around
8–16 ng/mL within 5 min of the first puff.38,39
Use of higher nicotine concentrations in the e-liquid increases nicotine delivery,
as does the inclusion of propylene glycol. In a study that examined nicotine
delivery from a first-generation e-cigarette containing either 16 or 24 mg/mL
nicotine, in either 75% glycerine or a 50% glycerine:20% propylene glycol 
e-liquid, peak plasma nicotine concentrations after 30 min of controlled puffing
were highest (18 ng/mL) with the 24 mg/mL nicotine in the mixed
glycerine:propylene glycol formulation, and lowest (10 ng/mL) with the
16 mg/mL nicotine in 75% glycerine solution40 (Fig 5.2). The propylene
glycol:glycerine mix formulation delivered more nicotine at either dose than the
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75% glycerine solution. This higher delivery is thought to result from the lower
boiling point of propylene glycol (187.6°C) than of glycerine (290°C).
Nicotine delivery is generally better from second- and third-generation devices,
eg in a direct comparison with first-generation devices using a prescribed 
5-min puffing regimen, second-generation e-cigarettes produced significantly
higher rises in plasma nicotine concentration (by 4 ng/mL vs 2 ng/mL) at 
5 min41 (Fig 5.3), and with repeated use these devices can sustain venous blood
levels comparable with those expected in smokers.42 In a study examining the
nicotine delivered by a third-generation device, experienced vapers were able to
achieve a greater rise in blood nicotine levels than naive users under the same
prescribed 5-min puffing regimen (5.8 ng/mL vs 2.7 ng/mL at 5 min),43
although the speed of nicotine delivery remains much slower than from
cigarettes.
Levels of the nicotine metabolite cotinine, which reflect nicotine intake over
the past 3–4 days,44 are similar in experienced e-cigarette users to those
observed in smokers,45–47 indicating that e-cigarettes are capable of delivering
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Fig 5.2 Venous blood nicotine levels from low and high nicotine
concentrations, glycerine or propylene glycol:glycerine mix solutions, and
from a conventional cigarette.40 (Reproduced from: Sherwin Yan X, D’Ruiz C.
Effects of using electronic cigarettes on nicotine delivery and cardiovascular
function in comparison with regular cigarettes. Regulatory Toxicology and
Pharmacology 2015;71:24–34.40 With permission from Elsevier.)
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total doses of nicotine similar to those from cigarettes. However, because, at the
time of writing, available data relate only to venous blood levels, the extent to
which e-cigarettes deliver nicotine for absorption into the pulmonary
circulation, and hence reproduce the high arterial levels achieved by cigarettes,
remains uncertain.
5.3.2 Safety profile
E-cigarettes are generally well tolerated. Similar to oral NRT products, reported
short-term adverse effects relate predominantly to mouth and throat irritation,
and tend to be self-limiting.29,48,49 As with all new products, however, long-
term or rare adverse effects will remain uncertain until e-cigarettes have been
in widespread use for several decades. Discussion of the potential long-term
adverse effects of e-cigarette use is therefore limited to consideration of the
likely effects of sustained inhalation of the known constituents of e-cigarette
vapour.
Analysis of vapour generated by e-cigarettes has identified a number of
potentially harmful constituents delivered alongside the nicotine and other 
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Fig 5.3 Nicotine absorption from first- and new-generation e- cigarettes.41
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e-liquid components. These include volatile organic compounds, carbonyls,
aldehydes, tobacco-specific nitrosamines (TSNAs) and metal particles, but all at
much lower levels than in cigarette smoke.50–64 Levels of formaldehyde and other
aldehydes can be relatively high when vaporisation occurs at high
temperatures,65,66 although in practice this overheating generates an aversive
taste known as a ‘dry puff ’, which vapers avoid.66,67 Recent reviews of the health
effects of toxins inhaled during normal use of e-cigarettes have expressed
concerns over potential adverse effects based on the presence of these
contaminants,68–70 but not their levels, which are generally the more important
determinant of toxicity. In normal conditions of use, toxin levels in inhaled 
e-cigarette vapour are probably well below prescribed threshold limit values for
occupational exposure,71 in which case significant long-term harm is unlikely.
Some harm from sustained exposure to low levels of toxins over many years may
yet emerge, but the magnitude of these risks relative to those of sustained
tobacco smoking is likely to be small. However, consideration of the potential
harm of long-term e-cigarette use should serve as a guide to evidence-based
product development, regulation and monitoring.
5.3.3 Areas of potential concern over hazards arising from vapour
exposure
Areas of potential concern over the long-term effects of e-cigarette use include
the effects of vapour constituents depositing in the mouth, upper airway and
lungs, and systemic effects of vapour components absorbed as a result of
swallowing or inhalation. The vapour constituents to be considered consist of
those that should be present in e-liquids, and hence also the vapour, including:
nicotine, propylene glycol, glycerine and flavours; those arising from impurities
and contaminants in the e-liquid, which vary between batches and suppliers;72
and toxins, particles and other components created by the vaporisation process.
The long-term adverse effects of nicotine are likely to be minimal73 (see also
Chapters 4 and 7), although it is acknowledged that the effects of sustained
inhalation of nicotine, in isolation from tobacco smoke and as opposed to
absorption by another route, have not been studied. There are, however, no
grounds to suspect that inhaled nicotine will have an appreciably different risk
profile from nicotine delivered via other routes of absorption. The following
discussion therefore relates to the effects of other constituents of e-cigarette
vapour.
Inhaled vapours deposit first, and often substantially, in the mouth and upper
airway. Much of this deposition is then swallowed, absorbed from the
gastrointestinal tract and excreted, mostly in urine, either unchanged or after
metabolism. This process of deposition, absorption and excretion of TSNAs and
other carcinogens in tobacco smoke probably accounts for the increased risks of
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cancer of the oropharynx, stomach, bladder and other organs involved in the
absorption and excretion process in smokers. The presence of carcinogens in 
e-cigarette vapour therefore increases the risk of similar outcomes but, in view of
the very low levels of exposure generated by e-cigarette vapour, the magnitude of
any increase in risk, in either relative or absolute terms, is likely to be low.
After passing through the mouth and upper airway into the lungs, larger particles
and droplets in inhaled vapours deposit substantially throughout the
intrapulmonary airways, to be either absorbed and excreted as above, or
expectorated.74 Vapour components <5 µm in diameter reach the alveoli, where
they either deposit and are then absorbed or cleared through phagocytosis or
other processes, or are exhaled.74 In tobacco smoking, the deposition of
carcinogens carried in tobacco smoke results in an increased risk of lung cancer,
whereas oxidants and other toxins and irritants in smoke cause direct and
inflammation-induced damage to lung tissues, which leads to chronic bronchitis
and emphysema (chronic obstructive pulmonary disease (COPD))64 and to
pulmonary fibrosis.75,76 Smoke components absorbed from the lung, including
particles and carbon monoxide, contribute to the increased risk of cardiovascular
disease in smokers64 and, together with local effects, to an increased risk of
infection.77 Although e-cigarette vapour contains a far less extensive range of
toxins, and those present are typically at much lower levels, than in tobacco
smoke, it is appropriate to consider potential hazards of e-cigarettes in relation to
this spectrum of harm.
5.3.3.1 Generic effects of vapour
Data on the effects of e-cigarette vapour on the airways are limited to studies of
short-term exposure. Use of an e-cigarette in healthy individuals for 5 min has
been shown to reduce exhaled nitric oxide (NO) and increase airway resistance,78
consistent with an irritant effect on the airways resulting in mucosal oedema,
smooth muscle contraction or increased production of lung secretions in
response to the vapour. Another study reported a reduction in exhaled NO after
inhaling vapour from an e-cigarette, with or without nicotine, of an order of
magnitude similar to that provoked by conventional cigarette smoke.79 However,
short-term e-cigarette use has been found to have no effect on spirometric
markers of lung function,80 and another study found no difference in reported
adverse events over 12 weeks’ use of an e-cigarette with or without nicotine, or
conventional NRT.81 It is therefore far from clear whether these short-term
airway effects will translate into long-term airway damage. Furthermore, as
smoking cessation is associated with a reduction in respiratory symptoms in
people with respiratory disease,82,83 many smokers who switch to an e-cigarette
are likely to experience improvements in respiratory symptoms. This is
illustrated in a study that followed a small cohort of patients with asthma, in
whom improvements in symptoms and respiratory function were observed after
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switching from smoking to vaping.84 These observations therefore provide
reassurance about short-term use of e-cigarettes in relation to adverse respiratory
effects. One survey from Hong Kong has reported a higher prevalence of
respiratory symptoms among Chinese adolescents who were ex- or never-
smokers, and reported any use of an e-cigarette in the preceding month.85
However, e-cigarettes were used by only 1.1% of the total sample and 0.1% of
never-smokers and, as use of e-cigarettes was not quantified, there is no evidence
that those reporting symptoms were using the product regularly.
E-cigarette vapour has been reported to influence resistance to infection, and to
delay recovery from influenza infection, in an animal model,86 although the
validity of these findings and relevance to the effects in humans are far from
clear. At the time of writing we are not aware of any published evidence on
cardiovascular effects of e-cigarette use other than those attributable to
nicotine.40 It is known, however, that the vapour does not deliver appreciable
amounts of carbon monoxide,87,88 which represents a significant advantage
relative to tobacco smoke. A study of carcinogen excretion in participants’ urine
after use of e-cigarettes or tobacco cigarettes found significantly lower levels of
TSNAs, benzene and polyaromatic hydrocarbons with e-cigarettes,89
demonstrating systemic absorption of these carcinogens and hence some 
degree of potential cancer risk, although clearly much less than that associated
with smoking.
5.3.3.2 Propylene glycol and glycerine
Propylene glycol is an active ingredient of the solutions used to generate the
synthetic smoke widely used in the performing arts and nightclubs, and in this
context is generally considered to be safe.90 In animal studies, a month of
exposure to propylene glycol vapour produced no apparent tissue toxicity of the
lung, liver or kidney in beagles or rats,91 although 90 days’ nasal inhalation in
rats was associated with an increase in the number of goblet cells and mucin
production in the nasal mucosa at levels of exposure >1.0 mg/L.92 An early study
examined long-term exposure to propylene glycol vapour over 12–18 months in
rats and monkeys, and identified no lung or other adverse effects.93 However,
acute exposure to propylene glycol has been shown to induce airway irritation
and cough in humans, together with minor airflow obstruction.61 One study also
found an association between levels of propylene glycol exposure in the home,
and asthma and rhinitis in children.94
Evidence on the adverse effects of inhaled glycerine is limited to a single case
report of lipoid pneumonia with onset of symptoms associated with
commencing e-cigarette use. The pneumonia was attributed to glycerine-based
oils in the e-liquid,95 although commentators pointed out that glycerine is an
alcohol and not a lipid.96 There have been no further reported cases of this
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outcome. Studies of repeated inhalation in rats found no evidence of damage to
the lungs.97,98
5.3.3.3 Flavours
Although the flavours used in the e-cigarette liquid are generally those
considered safe when ingested orally, some are irritant to the airways and the
safety of most flavours after heating and inhalation is unknown.99 Diacetyl is an
example of a flavour used in popcorn, and some other foods, that is safe for oral
consumption but which, when heated and inhaled in large doses over long
periods of time, can cause irreversible bronchiolitis.100 Vapour produced from 
e-liquids containing flavours has been demonstrated to be more cytotoxic than
unflavoured vapour101 and, although both are far less so than tobacco smoke,
this exposure may increase airway inflammation.102 In vitro experimental studies
have also reported increased susceptibility of airway cells to viral infection after
direct contact with e-liquid103 and evidence of cytotoxicity from cinnamon
flavours, although the relevance of direct effects of contact with e-liquid, as
opposed to vapour, is unclear.50 Although no study so far shows any clear
hazards of flavours in e-cigarette vapour, those derived from flavours seem the
most likely to pose appreciable health risks from long-term use.
5.3.3.4 Components generated by vaporisation
Heating propylene glycol or glycerine can cause decomposition to low-
molecular-mass carbonyl compounds including formaldehyde and acetaldehyde,
which can be carcinogenic in large doses.104 A study investigating the effect of
varying the heating element voltage in e-cigarettes found that, at low voltage,
levels of these compounds were up to 800-fold lower than in tobacco smoke, but
that, at higher voltage (4.8 V), the levels were similar.56 In a study involving a
third-generation – or variable-voltage – e-cigarette, negligible levels of
formaldehyde were generated at lower (normal) power settings, but, when used
at maximum power with 3- or 4-s puffs, levels 5–15 times higher than those
found in cigarette smoke were observed.65 However, in a study simulating this
‘dry puff ’ use, generating high levels of formaldehyde (up to 355 µg),
acetaldehyde (up to 206 µg) and acrolein (up to 210 µg), experienced vapers were
easily able to detect dry puffs and none could tolerate them.66 Under normal
conditions of use, the levels were negligible.66
Two studies have examined urinary levels of aldehydes in vapers. One was a
cross-sectional study that demonstrated considerably lower levels of urinary
acrolein and crotonaldehyde in vapers than in smokers.89 The other was a cohort
study that examined the change in urinary acrolein level when smokers switched
to vaping. Significant decreases in acrolein concentrations were observed in
smokers who switched completely to e-cigarettes as well as in those who were
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both smoking and vaping, showing that ‘dual use’ of tobacco cigarettes and 
e-cigarettes leads to a reduction in smoke intake.88
In addition to the vaporised liquid, e-cigarette devices include metals, ceramics
and rubber, all of which may become aerosolised in the process of vapour
generation,62,105,106 eg copper particles of respirable size (0.450–2.02 µm) have
been demonstrated in e-cigarette vapour at a level six times that seen in
conventional cigarette smoke;57 levels of nickel and silver that are also higher
than those in tobacco smoke have been noted.60 Whether these exposures
comprise a significant health hazard remains uncertain. Potential toxicity of
metal and other fine particles include carcinogenicity, cardiovascular disease
and diseases such as COPD and interstitial lung disease, which are
characterised by sensitisation, chronic inflammation or tissue remodelling.107
Inhalation of small particles, over both the short and the long term, also
increases the risk of cardiovascular events.108 However, this is probably not a
major concern because levels of exposure are well below recognised safety
thresholds,109 and could be reduced still further by improving manufacturing
processes and standards.
5.3.3.5 Hypersensitivity reactions
Hypersensitivity pneumonitis has been described in response to a range of
inhaled organic materials. Allergy to nickel, which can be present in very small
amounts in e-cigarette vapour, is a relatively common problem in clinical
practice,110 although there has been no reported case of this problem in 
e-cigarette users. A case of eosinophilic pneumonia has been reported in a
smoker who tried an e-cigarette,111 but again this has not been replicated and
hence is of uncertain relevance.
5.3.3.6 Relevance to potential long-term harms
The above observations indicate that e-cigarettes deliver a much smaller range of
toxins at much lower concentrations than cigarettes, and therefore indicate that
harm from e-cigarette use is likely to be far less than that from smoking. They
also demonstrate a possibility that some harm from long-term e-cigarette use
cannot be dismissed. From first principles, we would expect repeated and
sustained inhalation of the generally low concentrations of particulates, oxidants,
carcinogens and other constituents to pose some risks to health, particularly in
relation to COPD and lung cancer. However, the absolute magnitude of any risk
attributable to e-cigarette use is likely to be very small in absolute terms, and
hence substantially smaller than that arising from tobacco smoking. A recent
evidence review concluded that e-cigarette vapour can contain some of the toxins
present in tobacco smoke, but at much lower levels, and that the long-term
health effects of e-cigarette use, although unknown, are likely to be much less, if
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at all, harmful to users or bystanders than cigarette smoke.29 An analysis based
on expert opinion quantified the likely harm to health and society of 
e-cigarettes at about 5% of the burden caused by tobacco smoking,112 and a
recent report by Public Health England supported this conclusion.113
With appropriate product standards to minimise toxin and contaminant
exposure in e-cigarette vapour, it should be possible to reduce risks of physical
health still further. It is also possible, although unlikely, that other, unexpected
harm from inhaling e-cigarette vapour over the longer term might yet emerge.
Although it is not possible to quantify the long-term health risks associated with
e-cigarettes precisely, the available data suggest that they are unlikely to exceed
5% of those associated with smoked tobacco products, and may well be
substantially lower than this figure.
5.3.3.7 Effects of passive exposure to e-cigarette vapour
Users of e-cigarettes exhale the vapour, which may therefore be inhaled by
others, leading to passive exposure to nicotine.114 There is, so far, no direct
evidence that such passive exposure is likely to cause significant harm, although
one study has reported levels of polycyclic aromatic hydrocarbons that were
outside defined safe-exposure limits.106 It is clear that passive exposure will vary
according to fluid, device and the manner in which it is used.52 Nicotine from
exhaled vapour can be deposited on surfaces,115 but at such low levels that there
is no plausible mechanism by which such deposits could enter the body at doses
that would cause physical harm.
5.3.4 Addiction potential
Speed of nicotine delivery seems to be important for smokers’ satisfaction and
addiction potential. As outlined in Chapter 4, as a consequence of pulmonary
absorption, cigarettes deliver nicotine to the brain very quickly. Although there
are no available data on arterial nicotine levels after e-cigarette use, its venous
delivery kinetics appear similar to those of products delivering to the mouth or
upper airway, suggesting that pulmonary absorption from currently available 
e-cigarettes is low. In addition to this, the addictiveness of cigarettes is probably
also related to other chemicals in tobacco smoke that enhance nicotine’s effects.
These observations tally with other evidence, eg e-cigarette users report that they
feel less dependent on them than on tobacco cigarettes,116 and empirical
evidence from adolescent use suggests that, although adolescents experiment
with e-cigarettes, few – if any – never-smokers who do so become regular 
e-cigarette users.117,118 The addiction potential of currently available e-cigarettes
is therefore likely to be low. NRT and e-cigarettes may satisfy smokers who are
already using nicotine, but they have little appeal for never-smokers. This may
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change in the future, however, if e-cigarette and other nicotine inhalation
technology improves sufficiently to achieve significant pulmonary absorption.
5.3.5 Dual use of e-cigarettes and tobacco cigarettes
Observational population-level evidence indicates that dual users of both
tobacco and e-cigarettes are more likely to make an attempt to stop smoking
than smokers who do not also use e-cigarettes, but it is not yet clear whether they
are more likely to succeed119,120 (see Chapter 6). Some researchers have found a
lower subsequent cessation rate among smokers who tried e-cigarettes but
continued to smoke than among smokers who did not try e-cigarettes, but this
could be explained by self-selection and exclusion of smokers who switched
completely to e-cigarettes. One study found that daily users of the more
advanced models had a higher cessation rate.120 Experience with NRT suggests
that e-cigarette use is likely to increase the proportion of smokers making a quit
attempt, but appropriate evidence on this effect is not yet available. A recent
study has shown that dual users maintain their intake of nicotine, but reduce
their intake of smoke and related toxins significantly.88 Obtaining nicotine from
an alternative source leads to a reduction in smoking.22
5.3.6 Use to inhale other drugs
Refillable e-cigarettes can be used to inhale other materials including cannabis oil
or narcotics. Although such use is outside the scope of this report, use of 
e-cigarettes to deliver cannabis is likely, as is the case for nicotine, to be
substantially less hazardous than conventional inhalation of cannabis smoke
either alone or mixed with tobacco.
5.4 Products in development
At the time of writing there is a range of non-tobacco nicotine products in
development, most of which are variations on the formulations outlined above,
but some of which represent genuinely novel approaches, with the potential to
deliver nicotine by inhalation with significant pulmonary absorption. As this is
the route of absorption that generates the fastest increases in arterial blood levels,
this range of products may prove to be the most effective, and also possibly the
most addictive, smoking substitutes.
A metered-dose inhaler using propellants to deliver small droplets of nicotine to
the respiratory tract has been developed.121 Ten puffs of a 50-µg nicotine/puff
inhaler, inhaled via a spacer, resulted in peak plasma nicotine concentrations of
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12.5 ng/mL within 6 min of finishing the 10 puffs. A 100-µg dose was also tested
and resulted in slightly lower peak nicotine concentrations (9.4 ng/mL), most
probably owing to the greater adverse effect of coughing at the higher dose. Voke
is an inhaler device that is similar in shape and size to a conventional cigarette; it
is charged and recharged with an aerosol containing nicotine, propylene glycol
and a propellant from a small pressurised canister (similar to those used in
asthma inhalers), housed in a pack about the size of a pack of 20 cigarettes.
Inhalation of the entire contents of the device provides 0.45 mg of nicotine to
the user, with nicotine measurable in arterial blood (mean 2.06 ng/mL) within
2 min of the first inhalation, suggesting at least some pulmonary absorption. A
Cmax of 3.7 ng/mL in arterial blood was reached in 7 min. A Cmax in venous
blood of approximately 3 ng/mL was reached within 15–20 min. Hourly use
results in steady-state plasma nicotine levels of between 8 and 10 ng/mL.122 The
product has now been awarded a medicines licence, and hence is likely to be
brought to market, although at the time of writing no date has been set.
Nicotine pyruvate is formed from the combination of nicotine and pyruvic acid.
Its salts are small (similar in size to the particulate matter in cigarette smoke) and
so can be carried deeper into the respiratory tract in the process of inhalation,
and are less harsh than pure nicotine to inhale. An inhaler has been developed
that contains pyruvic acid and nicotine, which are combined when the user
draws air through the device. In participants taking 10 controlled inhalations
over 5 min, plasma nicotine levels rose to 5 ng/mL within 5 min when using a
dose of 20 µg nicotine pyruvate per puff, and to 8.3 ng/mL with a 30-µg dose.123
This technology was purchased by Philip Morris International Inc in 2011,124 but
has not yet been brought to market.
The Aradigm AERx system, which was developed for inhalation of insulin, has also
been tested for nicotine delivery.125 There are limited published data about nicotine
delivery, but those that are available on the company website126 suggest that nicotine
delivery is rapid. The product has not, however, yet been commercialised.
5.5 Summary
> The market in non-tobacco nicotine products in the UK has been
dominated for several decades by NRT.
> NRT is licensed as a medicine to help smokers quit smoking, and there is
strong clinical trial evidence of effectiveness in this role.
> NRT is also licensed for use to help smokers cut down on smoking, and for
temporary abstinence.
> NRT products have an excellent safety profile and present negligible risks to
users.
> However, NRT products do not reproduce the rapid, high-dose delivery of
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tobacco smoke, and reproduce few if any of the behavioural components of
tobacco smoking.
> The dominance of NRT has been challenged in recent years by a growing
range of consumer nicotine products, some of which are made to high
standards of purity but not necessarily licensed as medicines, and by 
e-cigarettes, which are now more widely used than NRT.
> Unlicensed nicotine products made to high standards of purity are also likely
to have very little risk for users.
> Currently available e-cigarettes are manufactured to variable standards, and
many are therefore likely to be more hazardous than NRT.
> Nicotine delivery from e-cigarettes is variable and, with some first-
generation devices, very low.
> However, e-cigarette design is evolving quickly, with newer models delivering
higher doses of nicotine than their predecessors, and hence being more
satisfying for smokers.
> Some of the carcinogens, oxidants and other toxins present in tobacco
smoke have also been detected in e-cigarette vapour, raising the possibility
that long-term use of e-cigarettes may increase the risks of lung cancer,
COPD, cardiovascular and other smoking-related diseases.
> However, the magnitude of such risks is likely to be substantially lower than
those of smoking, and extremely low in absolute terms.
> These potential health risks arise primarily from contaminants and
components generated by the vaporisation process, which should be
amenable to reduction through technological and purity improvements.
> New nicotine products in development are likely to extend the range of
choices available to smokers further, increasing purity and safety, and, in
those achieving greater pulmonary absorption, addictiveness.
> Although it is not possible to precisely quantify the long-term health risks
associated with e-cigarettes, the available data suggest that they are unlikely
to exceed 5% of those associated with smoked tobacco products, and may
well be substantially lower than this figure.
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6.1 Introduction
Quitting smoking is the most effective means by which smokers can avoid the
premature death and disability caused by smoking. This chapter describes
current patterns of smoking cessation in the UK, to provide context in which to
consider the position and role of harm-reduction policies. As in Chapter 5, data
are again drawn from the Smoking Toolkit Study (STS: www.smokinginengland.
info),1 the only national survey within the UK that provides detailed data on
smoking cessation behaviour in a representative general population sample.
Although limited to smokers in England, STS data are likely to be broadly
representative of trends across the UK. This chapter uses STS and other data to
explore recent trends in quitting behaviour, and the association between 
e-cigarette use and smoking prevalence, and to consider approaches to increasing
the number of quit attempts made. It also describes patterns of use of 
e-cigarettes among young people
6.2 Quit attempts and quit success
STS data indicate that the proportion of smokers making at least one quit
attempt each year has fallen over the past 8 years, from 43% in 2007 to 32% in
the first 9 months of 2015 (Fig 6.1). This overall trend was reversed in 2012 and
2013, when 34% and 39% made quit attempts, but has since fallen again.
These attempts were slightly more likely to occur in women and younger adults
and, in 2014 and 2015, among those in non-manual occupations (Fig 6.2).
The proportion of these attempts that are successful in the short term, which can
be identified as survey responses from individuals reporting that they have made
a quit attempt in the past year and are now not smoking, is around 16%, a slight
increase since 2011 (Fig 6.3). There were no marked differences in the proportion
of successful attempts in relation to age or gender, but success was more likely
among those in higher occupational groups (Fig 6.4).
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Fig 6.1 Proportion of people who have smoked in the past year who made
at least one serious quit attempt in that year1 (data from 42,386 people
who smoked in the past 12 months; 2015 figures based on January to
September data). (Adapted from the Smoking Toolkit Study1 with
permission.)
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Fig 6.2 Proportions of people who have smoked in the past year making at
least one serious quit attempt in that year, by gender, age and occupational
group (data details as per Fig 6.1).1 (Adapted from the Smoking Toolkit
Study1 with permission.)
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Fig 6.3 Proportion of people who have tried to stop in the past year and are
currently not smoking1 (data from 15,720 people who tried to stop smoking
in the past 12 months; 2015 figures based on January to September data).
(Adapted from the Smoking Toolkit Study1 with permission.)
Fig 6.4 Proportion of people who have tried to stop in the past year and are
currently not smoking by occupational social group (data details as per Fig
6.3).1 (Adapted from the Smoking Toolkit Study1 with permission.)
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6.3 Methods used to quit
The methods chosen by smokers in England to help them to quit, reported in the
STS study between 2007 and 2015, are represented in Fig 6.5. Until 2013, the
most commonly used aid to cessation was nicotine replacement therapy (NRT)
bought over the counter, but NRT has been displaced as the most popular choice
by a rapid increase in the use of e-cigarettes in England since 2012 (see also
Chapter 5). The proportion of smokers who use no aid to cessation has fallen
progressively over recent years, but remains above 40%.
Evidence from randomised trials2 and English population data3–6 indicate that
there are three main categories of quit attempt in terms of aids used; these are
grouped below in relation to their relative likelihood of success.
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Fig 6.5 Percentage of smokers using different aids to cessation in at least
one quit attempt in the past year1 (data from 15,720 people who tried to
stop smoking in the past year; 2015 figures based on January to September
data; respondents may use more than one method per quit attempt). NRT
OTC = nicotine replacement therapy bought from a shop; NRT Rx = nicotine
replacement therapy obtained on prescription; Varen = varenicline
(Champix) prescribed therapy; Bupr = bupropion (Zyban) prescribed therapy;
E-cig = e-cigarette; Behav’l support = one-to-one sessions with an adviser or
group support; None = none of the aforementioned. Use of other methods
such as telephone quit-lines is very low. (Adapted from the Smoking Toolkit
Study1 with permission.)
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6.3.1 Lowest likelihood of success
The approaches to quitting associated with the lowest likelihood of success are
those that are unaided, including use of over-the-counter NRT and use of
NRT without professional support. STS data suggest that there is little or no
difference in the likelihood of quitting using either of these methods.5,6 This
observation contrasts with randomised trial evidence that NRT can increase
the likelihood of cessation,7 and suggests that trial procedures, and perhaps in
particular an element of professional instruction and follow-up, may be
crucial to NRT effectiveness. This, in turn, indicates that providing even
minimal behavioural support to purchasers of NRT could improve the
likelihood of successful quitting. As one in five smokers who tried to quit
smoking in 2015 did so using NRT purchased from a shop or pharmacy, the
low effectiveness of this approach represents a considerable lost opportunity
to promote cessation.
6.3.2 Intermediate likelihood of success
Quit attempts among STS participants are around 50% more likely to succeed
if they involve NRT, varenicline or bupropion obtained on prescription (and
hence involving at least some contact with a health professional), or an 
e-cigarette bought from a shop.3–6 These methods are typically used by more
heavily addicted smokers who would otherwise be expected to have a lower
chance of success than those using the methods of lowest effectiveness.8 The
fact that NRT obtained on prescription yields higher success rates than over-
the-counter NRT suggests that, again, with this product, some form of clinical
supervision or involvement is required for NRT to have an effect. This may be
because without supervision smokers use NRT incorrectly, eg by using too
little, or use the therapy for too short a time. However, this in turn raises the
question of why use of e-cigarettes, which in the limited clinical trials available
to date appear to be of similar efficacy to NRT,9 appears to be effective even
without this supervision. There are, however, a number of possible
explanations, as follows.
6.3.2.1 Nicotine delivery kinetics
Although early-generation e-cigarettes delivered relatively little nicotine,
experienced e-cigarette users, particularly when using a later-generation product,
can achieve venous blood levels similar to those obtained from smoking10 (see
Chapter 5). Although this is also possible with NRT, it generally requires very
frequent dosing with a short-acting product used in combination with a nicotine
transdermal patch,11 and few consumers of NRT are likely to be aware of the
need to follow this kind of dosing regimen. It is therefore possible that users
100 © Royal College of Physicians 2016
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adopting e-cigarettes without direction on optimal use are more likely to achieve
satisfactory nicotine substitution than those choosing NRT.
6.3.2.2 Duration of use
There is a tendency for e-cigarettes to be used for longer than NRT. Although
some smokers who use NRT to stop smoking continue to use NRT for months or
even years after quitting, they are in a minority; most discontinue the product
within a few weeks. In contrast, many users of e-cigarettes continue using the
product both before and after quitting smoking, and for a longer period after
quitting than most NRT users.12–15
6.3.2.3 Sensory replacement
Unlike NRT, e-cigarettes replicate many of the sensory characteristics of
smoking. As outlined in Chapter 4, nicotine addiction is sustained not only by
the rewarding characteristics of nicotine itself, but also by reward given to the
stimuli and behaviours associated with nicotine delivery.16 As sensory
replacement can reduce tobacco withdrawal symptoms,17 the sensation of vapour
in the back of the throat, the plume of exhaled vapour, the hand-to-mouth
action, and various other sensory and behavioural similarities with cigarettes
may help to make e-cigarettes a closer sensory substitute for tobacco smoking
than NRT products.
6.3.2.4 Cultural acceptability
Particularly among smokers, e-cigarettes are a socially and culturally accepted
direct substitute for smoking. E-cigarette users can still share smoking breaks
with and be accepted by other smokers, thus sustaining a social identity as a
smoker, but can also tap into the enthusiasm, knowledge sharing and social
support for e-cigarette use generated via online user groups and vaping websites.
Also, unlike NRT, e-cigarettes are not medicalised, and use does not imply
rejection of smoking or a commitment to quitting.
6.3.2.5 Confounding
People who choose to purchase e-cigarettes may differ from those who choose
NRT in relation to factors that also influence the likelihood of successful
quitting. Although STS analysis suggests that differences in characteristics known
to predict smoking cessation outcome, including nicotine dependence, age, social
grade and recent history of quit attempts, do not account for the difference in
quit rates between those using e-cigarettes and those using NRT,3–6 it is still
possible that unmeasured confounding variables could account for the apparent
advantage of e-cigarettes.
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Clarifying whether and why over-the-counter e-cigarettes appear to be more
effective than NRT purchased in the same way clearly requires further research,
comparing e-cigarettes and other cessation pharmacotherapy in head-to-head
pragmatic trials, and exploring the importance of sensory replacement and other
characteristics of the products involved.
6.3.3 Highest likelihood of success
STS data indicate that the greatest improvement in quit rates comes from use of
NRT, varenicline or bupropion together with multi-session, face-to-face specialist
behavioural support from a qualified stop smoking adviser. This method tends to be
used by the most heavily addicted smokers, who would therefore be expected to
have the lowest success rates of the three categories8 but, after adjustment for
characteristics associated with likelihood of cessation,5,6,18 this approach appears to
increase success rates by between two- and threefold.6 As NHS Stop Smoking
Services (SSSs) have only recently started to support quit attempts using 
e-cigarettes, the available data on success rates are limited, but early experience
estimates quit rates to be at least as high as among those using other medication.
In the year to March 2015 in England, only 2,221 SSS users made a quit attempt
using an unlicensed nicotine product (ie an e-cigarette), from a total of 445,979
setting a quit date.19 The average quit rate in all smokers using SSSs was around
51%, and among e-cigarette users it was 66%;19 although factors other than the
product itself are likely to be involved in this difference, the finding is certainly
consistent with high efficacy as a cessation therapy.
6.3.4 Trends in uptake of different quitting methods over time
Figure 6.6 shows the proportions of quit attempts using these three groups of
quitting methods among smokers in England from 2009 to 2015. It
demonstrates that use of specialist services is rare among smokers and that,
although most of those making a quit attempt still use the least effective
methods to do so, the proportion using methods of intermediate effectiveness
is increasing, largely as a consequence of increased use of e-cigarettes.
Through use of estimates of relative effectiveness based on Cochrane reviews
of trials of medication and behavioural support,20–23 supplemented by the
data from smokers in England described above, the growth in use of
intermediate effectiveness methods between 2012 and 2015 from 18% to 40%
is likely to have generated many thousands of additional successful quit
attempts by 2015; the figure for 2014 is likely to be around 19,000.24 However,
these trends also demonstrate that much more needs to be done to increase
the number of smokers attempting to quit, and to increase the proportions
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using the more effective approaches. The data available from NHS SSSs
indicate that there is no reason to believe that the integration of e-cigarettes
into treatment support would reduce quit rates.
6.4 What motivates smokers to try to quit and what are the
obstacles?
Smokers make a quit attempt when the desire to quit and confidence in
success reach an action threshold. Environmental factors can trigger a quit
attempt by either momentarily raising motivation above this threshold or
reducing the level of the threshold.25 In this context, the environment includes
social norms about the desirability of smoking, as well as triggers such as
health campaigns or advice on smoking from health professionals.
Survey data suggest that, in Britain, motivation to quit is driven primarily by
health concerns and the financial cost of smoking, whereas factors such as
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Fig 6.6 Percentages of those attempting to quit smoking in the past year
by method used in most recent quit attempt1 (data from 15,723 people
who tried to stop smoking in the past year; 2015 figures based on January
to September data). Specialist support = specialist SSS involving
behavioural support plus medication/NRT. Meds = NRT or medication on
prescription (Rx) or e-cigarette bought over the counter. No aid or NRT
OTC = no aid or NRT bought from a shop. (Adapted from the Smoking
Toolkit Study1 with permission.)
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concern about the effect of smoking on one’s family, not liking being addicted
to smoking and feeling stigmatised are present but less frequently cited.26,27
The most important environmental trigger identified from smokers’ reports is
health professional advice.26 Mass media campaigns can also play an
important role,28 although this does not appear to be explicitly recognised by
smokers.26 The introduction of a comprehensive ban on smoking in indoor
public areas appears to have had a short-term, but not a sustained long-term,
effect on quitting.29
The main personal barriers to making an attempt to quit smoking appear to
be enjoyment of smoking, having a positive smoker identity and low
confidence in success.27,30 Motivation may also be reduced by smoking 
among other people who are important to the smoker, such as a partner or
friends, colleagues and wider family, although evidence for this influence is
less strong.27
6.5 Why do more smokers not try to quit and how could the
numbers be increased?
The figures outlined in this chapter thus far relate to the approximately one
in three smokers who make a quit attempt each year. Although is it essential
to ensure that as many of those as possible succeed in quitting, it is at least as
important to increase quit attempts among the remaining majority of
smokers who do not make a quit attempt in any given year. Measures are
therefore required to increase the proportion of smokers making any attempt
to quit smoking, as well as to increase the likelihood of success among those
who try.
Chapter 3 outlined the population measures that can influence both quitting and
uptake of smoking, and identified price rises and media campaigns as among the
most effective. As studies of smokers also identify that the main drivers of
motivation to quit are concerns about the health consequences of smoking and
the cost of smoking,26,27 the evidence is consistent in indicating that the most
effective approaches to increase quit attempt numbers in the UK are likely to
comprise price rises and media campaigns using health messages. However,
advice from a health professional is also identified by smokers as a key trigger for
quit attempts,26 and it would appear that a great deal more could be done to
increase the delivery of such advice. Figure 6.7 shows the proportion of smokers
in England who report having received advice to stop smoking from their GP in
the past year during 2010–15, and reveals that fewer than 40% of smokers recall
having received advice to quit; of these, only two-thirds recall having received an
offer of help with quitting. Equivalent data from people accessing NHS
secondary care services are not available, but anecdotal evidence suggests that
delivery of smoking cessation advice and support is also low. As over 1 million
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smokers are admitted to hospitals in the UK each year,31 this also represents a
substantial missed opportunity to initiate and support quit attempts.
These findings indicate that guidance from the National Institute for Health and
Care Excellence (NICE), which recommends that health professionals should
offer help to quit at every opportunity,32,33 and support of harm-reduction
initiatives among those unwilling to quit,34 is not being implemented
sufficiently widely. Clinical trial evidence also suggests that, although simple
advice from a physician to quit is effective, offers of support are more effective,
generating quit attempts in around 40% of those receiving the offer.35
Therefore, there is substantial scope for healthcare professionals to increase the
rate of quit attempts by integrating advice and support to quit smoking in all
healthcare consultations.
Since 2004, GPs in the UK have received financial incentives to record smoking
status and provide advice on smoking, which, although unspecified, is generally
interpreted as advice to quit.36 This scheme applied initially only to smokers with
smoking-related conditions and people with serious mental health disorders, but
in 2012 was extended to cover everyone who smokes. Moreover, in 2012, the
contracted requirement was changed from an offer of advice to an offer of
pharmacotherapy and referral for smoking cessation support. Early evidence on
the scheme demonstrated that it led to marked increases in the recording of both
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Fig 6.7 Proportion of people who smoked in the past year who reported
receiving any advice on stopping or offer of help with stopping from their
GP1 (data from 27,000 smokers; 2015 figures based on January to
September data). (Adapted from the Smoking Toolkit Study1 with
permission.)
© Royal College of Physicians 2016 105
HRR Chapter 6:Layout 1  07/04/2016  15:26  Page 105
Tobacco harm reduction
smoking status and delivery of advice, but no increase in the prescription of
pharmacotherapy36 over the background trend.37 A later evaluation of the 2012
change showed a similar result for all smokers, with increased recording by GPs
of smoking status, delivery of advice to quit and referral to smoking cessation
services, but no actual increase in prescription of pharmacotherapy.38 A similar
scheme that rewarded hospitals for ensuring that opportunistic advice on
smoking was given to patients was introduced in 2012, and there is also no
evidence that this initiative has had any effect.39 Reform of these schemes would
therefore appear appropriate.
6.6 How could changes in the availability of nicotine products
influence quitting behaviour?
Evidence from time-series analyses indicates that increasing the availability of
NRT, and introducing new smoking cessation medications to the market,
increases the use of these products by smokers trying to stop smoking, but does
not increase the proportion of smokers attempting to quit.40
Evidence from placebo-controlled trials indicates that use of an NRT product
while continuing to smoke can increase the likelihood of a quit attempt (see
Chapter 5), and that this effect is due to the nicotine in the products rather
than being a placebo response.41 Population-level data confirm that smokers
who use an NRT product while smoking are more likely to try to stop, and
eventually to succeed in quitting.42–45 Although the mechanism for this effect
does not appear to involve increased confidence in quitting,43 it is possible that
nicotine from the NRT product interferes with the maintenance of the
association between smoking and nicotine reward, and hence reduces the
motivation to smoke. It is also possible that encouraging smokers to
experiment with nicotine products, including e-cigarettes, would generate more
quit attempts and hence increase smoking cessation. The limited available
evidence on this indicates that quit attempts are indeed more common among
daily e-cigarette users who continue to smoke, but that successful quitting
using the early-generation ‘cigalike’ devices is less common.46,47 Research into
methods of increasing quit rates among people experimenting with alternative
nicotine sources, perhaps by finding ways to deliver quitting advice and
behavioural support, is therefore needed.
6.7 Summary
> Approximately one in three smokers in the UK currently attempts to quit
each year, but only about one in six of those who try to quit remains
abstinent for more than a few weeks or months.
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> Most smokers who try to quit do so without accessing professional help,
preferring either to use no help or support, or else to use NRT or e-cigarettes
bought over the counter.
> Those who use over-the-counter NRT appear to be no more likely to quit
than those getting no help.
> Smokers who use over-the-counter e-cigarettes or prescribed medications
are more likely to succeed.
> The greatest increase in the chances of stopping successfully occurs with
prescribed medications used together with specialist behavioural support.
> The effectiveness of e-cigarettes used with behavioural support is uncertain,
but early data demonstrate a relatively high quit rate.
> Smokers are motivated to make a quit attempt in particular by cost and
health concerns.
> Price rises, media campaigns and brief advice from health professionals are
therefore likely to increase the numbers of smokers trying to quit.
> Health professional advice and support to quit smoking should be offered as
a routine component of healthcare consultations.
> Smokers who use nicotine products as a means of cutting down on smoking
are more likely to make quit attempts. Promoting wider use of consumer
nicotine products, such as e-cigarettes, could therefore substantially increase
the number of smokers who quit.
> New research is needed to improve the effectiveness of over-the-counter
NRT, and to find ways of providing behavioural support to smokers who
choose e-cigarettes.
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7.1 Sources of data
Although detailed data on the prevalence of smoking in Britain have been
collected for some decades (see Chapter 2), sources of survey data on the use of
nicotine replacement therapy (NRT) or unlicensed nicotine products are
relatively limited. The most detailed source is the Smoking Toolkit Study (STS:
www.smokinginengland.info), a monthly, household, face-to-face survey of
representative samples of the population of England aged 16 and over, in
operation since 2007.1 Data on all smoking and non-tobacco nicotine-containing
products, including e-cigarettes, have been collected since 2007 for smokers, since
2011 for recent ex-smokers (<1 year), and since 2013 for never-smokers and
long-term (>1 year) ex-smokers. Other large national surveys have added
questions on e-cigarettes much more recently, eg in 2014 in the Opinions and
Lifestyle Survey2 and Scottish Health Survey.3 Data on use of e-cigarettes by
children have also begun to be collected only relatively recently in national
surveys in England, Scotland and Wales.4–6 Action on Smoking and Health
(ASH) UK has commissioned annual surveys of e-cigarette use among adults
since 2010 and children since 2013, and these extend beyond simple measures of
prevalence to include reasons for use, and a range of other factors.7,8 The STS is
the only source of data on NRT use. This chapter draws on all these sources to
review trends in use of NRT and e-cigarettes in Britain over recent years. Most of
the data presented are drawn from samples of smokers and recent ex-smokers
participating in the STS.
7.2 Trends in the use of non-tobacco nicotine products among
adults
Before the widespread uptake of e-cigarette use began in around 2011, NRT was
being used by between 15% and 20% of smokers in England (Fig 7.1). However,
use of non-tobacco nicotine products has risen sharply since 2011, primarily as a
result of a marked increase in e-cigarette use, which has more than offset a more
sustained decline in use of licensed NRT. In 2015 about 28% of smokers were
110 © Royal College of Physicians 2016
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using at least one non-tobacco nicotine product, and more than 20% an 
e-cigarette (Fig 7.1).
Among recent (<1 year) ex-smokers, use of non-tobacco nicotine products also
rose between 2012 and 2015, despite a fall in the use of NRT (Fig 7.2). In 2015
more than half of all recent ex-smokers were using a non-tobacco nicotine
product, with more than 40% of these being e-cigarette users.
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Fig 7.1 Prevalence of use of NRT, e-cigarettes or any non-tobacco nicotine
products among current cigarette smokers in England 2007–151 (data from
36,896 cigarette smokers; 2015 figures based on January to September
data). (Adapted from the Smoking Toolkit Study9 with permission.)
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Fig 7.2 Prevalence of use of NRT, e-cigarettes or any non-tobacco nicotine
products among recent ex-smokers in England 2011–141 (data from 2,318
people who stopped smoking in the past year; 2015 figures based on
January to September data). (Adapted from the Smoking Toolkit Study9
with permission.)
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Data for longer-term (>1 year) ex-smokers, which are available since 2013, show
a slightly different pattern, with generally lower levels of prevalence of use and
stable NRT prevalence, whereas e-cigarette use has increased (Fig 7.3).
The explanation for these trends is not certain, but is likely to be mainly due to
continued e-cigarette use among people who have used them to quit smoking,
because the proportion of smokers in England who have stopped smoking but
then take up an e-cigarette within a year of stopping is only about 10%.1 The
ASH survey in 2015 found that the principal reasons given by ex-smokers who
are currently vaping are ‘to help me stop smoking entirely’ (61%) and ‘to help me
keep off tobacco’ (53%). The principal reasons given by current vapers who still
smoke are ‘to help me reduce the amount of tobacco I smoke, but not stop
completely’ (43%) and ‘to help me stop smoking entirely’ (41%).7 Whether some
of these individuals would otherwise have relapsed back to cigarette smoking,
had e-cigarettes not been available, is not clear. Exploration of the explanations
for these trends is an important area for future research.
Among never-smokers, non-tobacco nicotine use is extremely uncommon. In
2015, 0.1% of never-smokers were using NRT and 0.3% an e-cigarette, and these
figures have remained virtually unchanged since 2013 (Fig 7.4).
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Fig 7.3 Prevalence of use of NRT, e-cigarettes or any non-tobacco nicotine
products among long-term ex-cigarette smokers in England 2013–151 (data
from 6,487 long-term ex-smokers; 2015 figures based on January to
September data). (Adapted from the Smoking Toolkit Study9 with
permission.)
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Among current smokers and recent ex-smokers, e-cigarettes tend to be used by a
slightly higher proportion of younger than older smokers (Fig 7.5), but this use
does not differ by socio-economic status (Fig 7.6) or gender.
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Fig 7.4 Prevalence of use of NRT, e-cigarettes or any non-tobacco nicotine
products among never-smokers in England, 2013–151 (data from 24,041
never-smokers; 2015 figures based on January to September data).
(Adapted from the Smoking Toolkit Study9 with permission.)
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Fig 7.5 Age distribution of e-cigarette or NRT users in 2013–151 (data from
11,186 smokers and <1 year ex-smokers; 2015 figures based on January to
September data). (Adapted from the Smoking Toolkit Study9 with
permission.)
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Fig 7.6 Social grade distribution of e-cigarette and NRT users in 2013–151
(from 11,186 smokers and <1 year ex-smokers; 2015 figures based on
January to September data). AB, professional managerial; C1, clerical; C2,
skilled manual; D, semi-skilled manual; E, unskilled manual/unemployed.
(Adapted from the Smoking Toolkit Study9 with permission.)
Fig 7.7 Proportion of adults in Scotland in 2014 who had ever used an 
e-cigarette, by age and sex.3 (Adapted from the Scottish Government3 with
permission under Open Government Licence.)
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The Opinions and Lifestyle Survey estimated that, in the first quarter of 2014, 
e-cigarettes were being used by 11.8% of smokers, 4.8% of ex-smokers and
0.14% of never-smokers.2 Data from Scotland indicate that, in 2014, around 15%
of men and women reported ever having used an e-cigarette, and about 5%
reported current use.3 This current use was entirely restricted to current smokers
(of whom 15% were current e-cigarette users) and ex-smokers (7%). Of never-
smokers, 1% reported ever using an e-cigarette, and none were current users.
‘Ever use’ was much more prevalent among younger people (Fig 7.7).
Annual surveys by ASH demonstrate data consistent with STS findings, with
almost 60% of smokers in Britain ever having tried an e-cigarette, and just under
18% reporting current use in 2015.7 Similar to the STS findings, current use had
remained unchanged between 2014 and 2015 after rapid growth since 2010 
(Fig 7.8).
As in the Scottish data, however, this use of e-cigarettes has occurred almost
entirely among current and ex-smokers; in 2015, the prevalence of current use of
e-cigarettes among never-smokers was 0.2%.7 The most frequently reported
reasons for using e-cigarettes were to quit smoking, to help maintain abstinence
having already quit and, among dual users, to cut down on smoking.7 The ASH
survey in 2015 also explored the type of e-cigarettes that respondents were using,
and demonstrated that most had started use with first-generation disposable or
‘cigalike’ devices, but then migrated to second- and third-generation refillable or
tank designs (Fig 7.9).7
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Fig 7.8 Prevalence of ever use and current use of e-cigarettes among adult
smokers in Britain, 2010–15.7 (Adapted from ASH7 with permission under
Open Government Licence.)
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Over 80% of e-cigarette users surveyed by ASH in 2015 were using flavoured 
e-liquids. Tobacco was the most popular flavour (35% of users), but fruit (25%)
and menthol (19%) were also popular.7
7.3 Trends in the use of non-tobacco nicotine products among
children
Data on the use of non-tobacco nicotine among children are limited to 
e-cigarette use. Annual surveys by ASH of young people in the UK since 2013
demonstrate that awareness of e-cigarettes has grown substantially, such that, in
2015, only 7% of young people reported no knowledge of these products, and
the proportion of young people who had tried e-cigarettes increased over these
three surveys from 5% to 13% (Fig 7.10).8
However, of the 13% of young people who reported in 2015 ever having tried an
e-cigarette, most (80%) had done so only once or twice.8 Only 2.4% of all
participants in the survey had used e-cigarettes once or more a month, and 0.5%
once or more a week. The Scottish SALSUS (Schools Adolescent and Lifestyle
and Substance Use Survey) study5 reported similar findings among 13- and 15-
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Fig 7.9 Types of e-cigarette tried in the past and now.7 (Adapted from ASH7
with permission under Open Government Licence.)
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year-olds in 2013, with 7% and 17%, respectively, reporting ever having tried to
use or used an e-cigarette, and only 1% in each age group using the product
more than ‘once or a few times’. In 2014, the Welsh Health Behaviour in School-
aged Children survey of 11- to 16-year-olds in Wales reported that 12.3% of
participants had ever used an e-cigarette, and 1.5% were using e-cigarettes at
least once a month.6 The 2014 Smoking, Drinking and Drug Use survey of
children aged 11–15 in England found that 22% of participating children had
ever used an e-cigarette, but only 1% reported regular use.4 Regular use of 
e-cigarettes among young people in the UK thus appears to be very rare. As in
adults, it appears that it occurs predominantly among those who are using, or
have used, tobacco cigarettes. In 2013 in the Scottish study, all of those who
reported having used e-cigarettes more than a few times had been, or were still,
smokers (Fig 7.11).5
The 2014 Welsh survey reports very similar findings, with young people aged
11–15 who had ever used an e-cigarette being over 20 times more likely than
never-users to have ever smoked; those using e-cigarettes more than once a
month were more than 100 times more likely to be smoking cigarettes at least
once a week.6 The 2015 ASH survey also reports a strong association between use
of e-cigarettes and tobacco cigarettes (Fig 7.12), with almost all e-cigarette users
either being current smokers, or having tried or been regular smokers in the
past.8 Regular e-cigarette use in the 2014 English Smoking, Drinking and Drug
Use survey was exclusive to children who had at least tried smoking.4
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Fig 7.10 Prevalence of awareness and frequency of use of e-cigarettes
among young people aged 11–18, UK, 2013–15.8 (Adapted from ASH8 with
permission under Open Government Licence.)
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Of those using e-cigarettes in the ASH survey, most used a tank or other refillable
device, and most used e-liquids with fruit (42%), tobacco (23%) or menthol
(13%) flavours.8
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Fig 7.11 Use of e-cigarettes, by smoking status, among 13- and 15-year-olds
in Scotland in 2013.5 (Adapted from NHS National Services Scotland5 with
permission under Open Government Licence.)
Fig 7.12 Young people aged 11–18 who have ever tried an e-cigarette, by
smoking status, UK, 2015.8 (Adapted from ASH8 with permission under
Open Government Licence.)
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7.4 Summary
> Use of e-cigarettes among adults in the UK was rare before 2010, but has
since increased to the point that up to one in five smokers now uses an 
e-cigarette, more than twice as many as use NRT.
> The proportion of smokers using NRT has fallen by about half over this
period, but the proportion using any non-tobacco nicotine product has
increased to just under 30%.
> These trends are similar but more marked among recent ex-smokers, 40%
of whom use an e-cigarette.
> Use of e-cigarettes among adults who have never been regular smokers is
very rare.
> There is a slightly greater likelihood that younger adult smokers will use 
e-cigarettes than NRT; in Scotland, younger men are more likely to use
them.
> Adult regular e-cigarette users tend to use tank or other refillable devices,
rather than first-generation ‘cigalikes’, and tobacco-, fruit- or menthol-
flavoured nicotine.
> The proportion of young people in Britain aged <18 who have ever used an
e-cigarette is increasing, but remains low.
> Most use among young people appears to be single or very occasional
experimentation. Use more than once a month is relatively rare and more
than once a week extremely rare.
> Regular use is almost exclusively limited to young people who are already
either regular or occasional smokers, or have experimented with smoking in
the past.
> Young regular users of e-cigarettes also favour later-generation devices, and
fruit, tobacco or menthol flavours.
> In adults and young people in the UK, therefore, use of e-cigarettes is
limited almost entirely to those who are already using, or have used,
tobacco.
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8.1 The need for harm reduction
Prevention of smoking is vital to public health, and much progress has been
made in reducing the prevalence of smoking in the UK over recent decades (see
Chapter 2). However, the data presented in Chapter 2 also demonstrate that this
success has been achieved primarily by reducing uptake of smoking among
younger people, more than improvements in the rate at which established
smokers quit smoking. It is, however, these established smokers in middle and
older age who will generate most of the population burden of morbidity and
premature mortality caused by smoking over the next two decades.1,2 As
established smokers today are more likely to be socio-economically
disadvantaged or to have mental health problems (see Chapter 2), this burden of
disease will fall disproportionately on these groups who, as a result of higher
levels of addiction to nicotine, also find it particularly difficult to quit smoking.
Increasingly powerful incentives for existing smokers to try to quit smoking, and
strong support to help them succeed, are therefore urgently required. Further
application and extension of the conventional policy options summarised in
Chapter 3 might be expected, at best, to sustain the decline in smoking
prevalence of close to 0.7 percentage point per year achieved over the past
decade in the UK (see Fig 2.1, Chapter 2), the consequence of which will be that
most of the current smokers in the UK, and particularly the most heavily
addicted smokers, will continue to smoke for several decades. The public health
imperative in relation to smoking is, however, to reduce prevalence as much and
as quickly as possible, for example, to achieve the widely agreed objective of a
‘tobacco-free’ society (comprising smoking rates of 5% or less in all socio-
economic groups) by 2035,3 and this requires the addition of new strategies.
Harm reduction offers the potential to add significantly to the current rate of
decline in smoking prevalence among all population groups. The availability of
alternatives to tobacco, as a source of nicotine for the most heavily addicted
smokers, also allows the application of much higher levels of taxation on
tobacco without necessarily exacerbating poverty in those smokers who find
themselves unable to quit in response to increases in tobacco prices. In Sweden,
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the availability of snus has been estimated to have added around 0.4 percentage
point per year to the rate of decline in smoking prevalence.4 E-cigarettes, and
other non-tobacco nicotine products, surely have the potential to achieve at least
the same in the UK.
Harm-reduction approaches, by promoting substitution of tobacco with less
hazardous sources of nicotine, thus represent a potentially powerful
complement to existing prevention policy, particularly among the relatively
highly addicted and typically disadvantaged smokers who are likely to find it
most difficult to quit.5,6 However, pursuing a harm-reduction strategy also
carries risks of unwanted effects in society. This chapter explores some of the
harms caused by tobacco smoking in different periods of life, and the probable
balance of risks and benefits of harm-reduction approaches based on
substitution with NRT or other non-tobacco nicotine products, particularly 
e-cigarettes.
8.2 Potential hazards of harm reduction
Although harm-reduction approaches have the potential to reduce the hazard of
nicotine use among the current smoking population, they also bring potential
hazards to wider public health. For example, a product that is half as damaging
to health as tobacco smoking has the potential to halve the harm caused by
smoking in society, if used exclusively and completely as a substitute for tobacco
by current smokers, and young people who would otherwise have become
smokers. That benefit would be reduced or even reversed, however, if the new
product came to be sufficiently widely used among non-smokers that the
benefits to smokers were eclipsed by harm sustained by non-smokers. The
benefit of harm reduction to smokers would also be offset at population level if
use of harm-reduction products increased the risk of smoking uptake (known
as gateway progression, see below), undermined existing tobacco control
measures by making the act of smoking socially acceptable again
(renormalisation) or discouraged quitting by being used as a partial substitute
for tobacco smoking (‘dual use’), without progression to complete substitution
among smokers who would otherwise have quit. These processes are discussed
in more detail below.
8.2.1 Renormalisation
In relation to tobacco smoking, renormalisation refers to processes that
undermine or reverse a progressively increasing perception in society that
smoking is not a normal or desirable behaviour.5 For much of the 20th century
smoking was part of the fabric of British life, and children grew up perceiving
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smoking to be something that many, if not most, adults did. In recent years,
however, the acceptability of smoking has changed, particularly as a
consequence of prohibition of tobacco advertising, smoking in enclosed public
places and point-of-sale displays, and other measures. Although smoking
remains relatively common, and hence relatively normal, in some communities
or social groups, this is no longer the case in general. Examples of
renormalisation might include: the use of e-cigarettes in areas where smoking is
prohibited, thus creating an impression that smoking is acceptable; advertising
or other imagery that evokes tobacco smoking through e-cigarette use;
behavioural modelling from use of e-cigarettes by parents, siblings, peers,
friends, celebrities or others; or other processes that in some way make smoking
more appealing.6,7
8.2.2 Gateway progression
Gateway progression is a process by which, in relation to tobacco smoking, use
of non-tobacco nicotine is proposed to cause uptake of smoking that would not
otherwise have occurred. Gateway theory has its origins as a descriptive model
for progression from use of soft drugs to use of hard drugs, and a recent review
of evidence from animal models concluded that nicotine exposure may indeed
increase susceptibility to other drug use, independent of other determinants of
common liability.8 In nicotine use, however, the gateway theory has also been
applied as a predictive model proposing that use of non-tobacco nicotine is
likely to cause progression to use of nicotine through tobacco smoking,9 and
therefore that use of e-cigarettes by non-smokers, and particularly by children,
could cause smoking uptake independent of other determinants of smoking
initiation. Similar concerns have in the past been expressed in relation to
nicotine replacement therapy (NRT) and smokeless tobacco.9
8.2.3 Dual use
Dual use refers to the concomitant use of non-tobacco nicotine by smokers who
continue to smoke tobacco. As outlined in Chapter 5, reasons for dual use
include relief of nicotine withdrawal symptoms at times when smoking is not
allowed, or a desire to cut down on smoking without necessarily a commitment
to quit. However, concerns have been expressed that dual use may inadvertently
sustain smoking by making it easier to abstain when smoking is prohibited and
the smoker might otherwise have quit, and that smokers who could otherwise
have quit elect for dual use instead, in the mistaken belief that this generates
significant health gains. There are particular concerns that the tobacco industry
will promote dual use of e-cigarettes as a means of sustaining, rather than
cutting down or quitting, tobacco smoking in their customers10 (see Chapter 9).
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8.3 Harm to health and wellbeing of self and others from
smoking at different stages of life
Smoking directly damages the health of all who smoke (see Chapter 1),
increasing the risk of a wide range of fatal and non-fatal illnesses11 and causing
over 120,000 deaths in the UK in 2010.12 However, the adverse effects of
smoking extend well beyond this direct harm to the individual smoker, and are
not limited to the later period of life when the increased mortality in smokers
becomes more acute. Through the life course of any individual from the point
of conception, maternal smoking (and hence fetal exposure in utero) impairs
fetal growth and development, and increases rates of fetal and neonatal death,
low birth weight, preterm birth and developmental anomalies.13 Passive
maternal smoking during pregnancy increases the risk of stillbirth and
developmental anomalies14,15 and reduces birth weight.16 In childhood, passive
exposure to tobacco smoke causes sudden infant death, respiratory infections,
middle-ear disease and exacerbation of asthma.13 Passive exposure to others’
smoke during adulthood causes transient symptoms such as eye and throat
irritation at all ages, and in later life contributes to higher mortality from lung
cancer, cardiovascular disease and chronic obstructive pulmonary disease
(COPD).17
Harm from smoking is not limited to that arising from inhaling tobacco
smoke. Probably through behavioural modelling and opportunities for
experimentation, children whose parents or other household members smoke
are more likely to take up smoking themselves,18 thus perpetuating smoking
and its consequent harm in successive generations. Smoking rates in the wider
communities and environments that children grow up in also influence
smoking uptake, because children whose peers smoke, and those exposed to
smoking imagery in the media, are more likely to become regular smokers.19
Smoking is a significant drain on family budgets, exacerbating poverty,20
and a drain on wider society, which suffers the opportunity cost of funding
over £3.3 billion in direct healthcare and social care costs in the UK, and over
£10 billion in lost productivity and other societal costs.21 Thus, although
smoking has little direct effect on the personal health of individual smokers
during early adult life,22,23 the risks to others, especially children, are
substantial.
As outlined above, all or almost all of these harms could be prevented or else
much reduced by substitution of smoked tobacco with a less hazardous source
of nicotine. The potential benefits and risks to individual and societal health of
doing so are now considered in relation to the two main options currently
available in the UK: conventional NRT products and unlicensed non-tobacco
nicotine products, including e-cigarettes.
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8.4 Harm reduction with conventional NRT products
8.4.1 Health harms
As use of nicotine alone in the doses used by smokers represents little if any
hazard to the user,24 complete substitution of smoking with conventional NRT
products is, for practical purposes, the equivalent of complete cessation in almost
all areas of harm to the user. NRT products do not emit vapour and so are not a
source of passive exposure for adults or children. Packaging and dose restrictions
render accidental poisoning in children highly unlikely. Questions remain about
the safety of nicotine in pregnancy25 and potential effects on fetal development
and mortality,11 although one recent study has reported a lower occurrence of
developmental abnormality among children whose mothers used NRT in
pregnancy than in those whose mothers did not.26
8.4.2 Renormalisation of and gateway to smoking
Only the Nicorette inhalator bears any resemblance to a cigarette, so users of
most NRT products provide no behavioural modelling that could encourage
primary uptake of, or sustain, tobacco smoking by others. Use of NRT among
never-smokers is rare at all ages and, despite early concerns to the contrary, there
is no reported evidence that use of the inhalator or any other NRT product in
young people has ever acted as a gateway to smoking.
8.4.3 Dual use and gateway from smoking
NRT was developed as a smoking cessation therapy for use after an abrupt and
complete cessation of tobacco smoking. The efficacy of NRT used in this way
is well established.27 More recently, however, NRT has been licensed in the UK
for use together with continued smoking, to relieve withdrawal symptoms
during temporary abstinence from smoking, or to cut down on smoking,28
ie for dual use. Before the advent of e-cigarettes, up to 15% of current
smokers in England used NRT in this way, although the proportion is now
closer to 5% (Fig 8.1).29 Although cutting down on smoking achieves
relatively little in terms of health benefits, use of NRT together with tobacco
smoking does appear to reduce compensatory smoking to a modest extent30
and, among smokers with no intention to quit, to increase, by as much as
twofold, the likelihood of a subsequent quit attempt.31 It also protects those
around the smoker from the harmful effects of passive smoking. For this and
other reasons, dual use of NRT and tobacco smoking is licensed by the
Medicines and Healthcare products Regulatory Agency (MHRA)32 and
recommended by the National Institute for Health and Care Excellence
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(NICE) as a tobacco harm-reduction strategy.3,24 As use of NRT in this way
increases the likelihood of quitting, in these circumstances NRT acts as a
gateway from smoking.
8.4.4 Population health effects of substitution of smoking by NRT
With the possible exception of use during pregnancy, complete substitution of
smoking by NRT achieves much the same in health terms as quitting both
smoking and all nicotine completely. Widespread uptake of NRT by non-smokers
would therefore result in little harm to public health, but is in any case rare.
Gateway progression from NRT to smoking among those who have never
smoked does not, for practical purposes, occur. Dual use results in a modest
reduction in tobacco smoking of little or no significance to health, but promotes
quitting. Promotion of NRT as a reduced harm substitute for smoking is
therefore unequivocally good for health. Economic analysis of the use of NRT in
a harm-reduction strategy, including a range of scenarios in which opting to cut
down rather than quit detracted to different degrees for those who would
otherwise have quit, found that all options were cost-effective in relation to
preventing major disease costs to the NHS,33 and hence were acting in favour of
population health.
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Fig 8.1 Self-reported use of NRT or e-cigarettes to aid cutting down on
smoking, England, 2009–15.29 (Adapted from the Smoking Toolkit Study29
with permission.)
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8.5 Substitution with e-cigarettes
8.5.1 Health harm
As e-cigarettes have been in widespread use in the UK and most other countries
for less than a decade, the health effects of long-term use are as yet unknown. As
outlined in Chapter 5, there is very little evidence that short-term use of 
e-cigarettes causes any appreciable harm to users or to others, but information
on long-term health effects of repeated and sustained inhalation of e-cigarette
vapour is of necessity limited to inference, based on knowledge of the vapour’s
constituents. The oxidant, particulate, carcinogen and other toxin contents
summarised in Chapter 5 would be expected, from first principles, to increase the
risk of lung cancer, COPD, cardiovascular disease and other diseases caused by
smoking, but at much lower levels of risk. For the less common health sequelae
of smoking,11 levels of increased risk are likely to be negligible. The risks
attributable to long-term inhalation of nicotine in isolation from tobacco smoke,
and of the propylene glycol, glycerine and other components unique to 
e-cigarettes, are also uncertain but likely to be low. The health harm to long-term
users of e-cigarettes is therefore likely to be marginally greater than for those who
use conventional NRT.
Harm to others from vapour exposure is negligible (see Chapter 5). The effects of
maternal use on the fetus are unknown but, on the grounds of the very low levels
of toxins in vapour, are probably close to those of NRT. Accidental poisoning in
children from ingestion of e-cigarette solutions, which has been reported and
typically results in nausea and vomiting,34 are preventable through the use of
childproof fasteners.
8.5.2 Renormalisation and gateway to smoking
First-generation e-cigarettes were designed to resemble tobacco cigarettes in
approximate shape and size, and hence their use provides a behavioural model
similar to smoking, which could appeal to young people or smokers trying to quit
smoking, appear to undermine smoke-free policy, and be used by the tobacco
industry to cross-promote smoking imagery and hence tobacco products through
e-cigarette advertising (see Chapter 9). However, even first-generation products are
visually distinct from cigarettes, and exhaled vapour easily distinguishable from
tobacco smoke in terms of appearance, smell and irritancy, making confusion
unlikely between e-cigarettes and tobacco cigarettes in areas covered by smoke-free
legislation.35 Later-generation e-cigarettes have less or no physical resemblance to
tobacco cigarettes. Use of e-cigarettes to generate smoking imagery in
advertisements is prevented under UK advertising codes of practice.36,37
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Data from Wales indicate that children whose parents or peers use e-cigarettes
are more likely to experiment with e-cigarettes themselves,38 and to intend to
smoke in the future, than children without this exposure.38 However, as parental
e-cigarette use occurs almost exclusively among current or former smokers,
children in these households would be expected to have higher smoking
intentions,19 and it is unclear whether this risk is either increased or decreased by
the availability of e-cigarettes as opposed to tobacco cigarettes.
The prevalence data on the use of e-cigarettes by both adults and children
presented in Chapter 7 demonstrate that e-cigarette use in Britain is, to date,
almost entirely restricted to current, past or experimental smokers. As with NRT,
there is no evidence thus far that e-cigarette use has resulted, to any appreciable
extent, in the initiation of smoking in either adults or children; the extremely low
prevalence of use of e-cigarettes among never-smoking adults39 and children40–42
indicates that, even if such gateway progression does occur, it is likely to be
inconsequential in population terms. Although it remains important to monitor
the use of e-cigarettes in young people, to ensure the quick identification of
evidence of any increase in uptake of smoking arising from e-cigarette use, it
appears that, to date, concerns over gateway progression into smoking are
unfounded. The association between e-cigarette and tobacco cigarette use is
therefore more likely to arise from common liability to use of these products, and
to use of e-cigarettes as a gateway from, rather than to, smoking.
8.5.3 Dual use and gateway from smoking
Office for National Statistics data indicate that, in the first quarter of 2014, 11.8%
of smokers, 4.8% of ex-smokers and 0.14% of never-smokers in Britain used 
e-cigarettes; smoking prevalence data from the same source indicate that these
proportions represented approximately 2.2%, 2.6% and 0.08% of the total adult
population, respectively.43 On these figures, therefore, about 45% of e-cigarette
users in Britain are using them together with smoking, which is about twice as
many as do so with NRT.44 As dual use of NRT is recommended as a means of
increasing the likelihood that smokers will attempt to quit smoking,3 and early-
generation e-cigarettes appear to be approximately as effective as NRT as a
cessation aid,45 it follows that the same is likely to apply to e-cigarettes.
Observational data from England confirm that smokers who use e-cigarettes at
least daily are indeed twice as likely to make a quit attempt, or else to reduce
their smoking, than those who do not, although in this study the likelihood of
success among those attempting to quit was not increased by e-cigarette use.46
Independent clinical trials45 and observational data from the Smoking Toolkit
Study47 indicate that e-cigarette use is associated with an increased chance of
quitting successfully, but further longitudinal and trial data would be helpful to
define any such effect more precisely.
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These findings suggest, however, that, among smokers, e-cigarette use is likely to
lead to quit attempts that would not otherwise have happened, and in a proportion
of these to successful cessation. In this circumstance, e-cigarettes act as a gateway
from smoking. However, it is not yet known whether, or by how much, e-cigarettes
are being dually used by smokers who would otherwise have quit completely, and
hence act as a barrier or delay to cessation. It is also not known whether or by how
much a preference to try to quit using e-cigarettes is displacing uptake of the more
effective conventional NHS Stop Smoking Services (SSSs)48 or other services
combining pharmacotherapy with behavioural support, and hence reducing overall
quit numbers, or whether this effect is counteracted by the much broader reach
and uptake of e-cigarettes relative to NHS SSSs.
It seems likely that the chance of successful quitting with e-cigarettes would be
increased if smokers who chose to use them, whether for cutting down or
quitting, could also receive additional behavioural support,49 and perhaps, given
the evidence that the combination of two nicotine products is more effective
than one alone, were encouraged to combine e-cigarette use with a nicotine
transdermal patch.50 Research and development of methods are clearly needed to
engage and support smokers who start to use e-cigarettes, for whatever reason, to
increase the likelihood of successfully quitting .
8.5.4 Population health effects of substitution of smoking with 
e-cigarettes
Thus far, the availability of e-cigarettes appears to have been positive for UK
public health. Uptake has been rapid among adults and limited almost entirely to
smokers, and has contributed to a continued downward trend in UK smoking
prevalence. Use by children who would not otherwise smoke appears to be
minimal. In many ways, therefore, their availability and adoption as a consumer
alternative to smoking share many parallels with the use of snus as a consumer
harm-reduction product in Sweden.51 Although long-term safety remains a
concern, it appears likely that the combined influences of impending regulatory
controls (see Chapter 10) and technological advances will lead to significant
improvements in the probable long-term hazard profile of these products in the
near future. These developments mean that unlicensed e-cigarettes are likely, in
the near future, to approximate to NRT in terms of long-term hazard. The arrival
on the market of licensed products, whether e-cigarettes or other novel designs,
will make that prospect even more of a reality. In that case, e-cigarettes are likely
to share the efficacy of NRT as a harm-reduction option under most
circumstances.33
However, the creation of models of these beneficial effects for products available
today, and also those of potentially adverse influences such as widespread uptake
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by non-smokers, gateway effects into smoking and sustaining dual use rather
than quitting among established smokers, is difficult and inevitably dependent
on assumptions about the probable magnitude of these influences. At the time of
writing, we are aware of only two published attempts to do so. A proof-of-
concept study applying Markov modelling to a cohort of adults aged 18–24 in
the USA developed two models of smoking and e-cigarette use, the more
conservative of which predicted that the prevalence of adult cigarette smoking
within the cohort would increase from 15% at baseline to 21% after 10 years.52
These figures do not therefore appear applicable to the UK, where a 6 percentage
point increase in smoking prevalence after the age of 25 has not happened in
over 40 years (see Fig 2.11). A Monte Carlo analysis approach, modelling various
scenarios of relative uptake by smokers and non-smokers, and at levels of harm
relative to smoking ranging from 1% to 50%, predicted population benefits as
long as use of e-cigarettes is concentrated among those who already smoke, or
would otherwise have become smokers.53 As the true magnitude of e-cigarette
harm is likely to lie at the low end of that modelled range, and experience to date
indicates that use of e-cigarettes is almost entirely confined to smokers, these
predictions support the notion that e-cigarettes, within the context of a
regulatory environment designed to discourage use among youth and never-
smokers, are likely to benefit public health.
8.6 Summary
> Uptake of smoking is falling in the UK, but most current smokers are likely
to continue smoking for many years.
> Most of the morbidity and mortality caused by smoking in the short- and
near-term future will occur in people who are smoking now.
> More effective measures to help existing smokers to quit smoking, as soon as
possible, are therefore urgently needed.
> Harm reduction has the potential to complement conventional tobacco control
policy by offering an alternative means for smokers to stop smoking tobacco.
> Substituting medicinal nicotine (NRT) for tobacco almost completely
prevents any further damage to self or others from nicotine use.
> Although the long-term hazards of e-cigarette use are not yet clearly defined,
e-cigarettes are probably close to NRT in the harm that their use confers on
the user and others.
> The long-term hazard associated with e-cigarette use is likely to fall, as a
result of regulatory and technological developments.
> There is no evidence that either NRT or e-cigarette use has resulted in
renormalisation of smoking.
> None of these products has to date attracted significant use among adult
never-smokers, or demonstrated evidence of significant gateway progression
into smoking among young people.
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> NICE guidance recommends dual use of NRT for harm reduction, largely
because dual users are more likely eventually to quit smoking.
> Evidence on the natural history of smoking among dual users of e-cigarettes
is less well established, but a similar effect is likely.
> Promotion of the use of non-tobacco nicotine, including e-cigarettes, as
widely as possible as a substitute for smoking, in the context of a regulatory
framework designed to discourage use among youth and never-smokers, is
therefore likely to generate significant health gains in the UK.
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E-cigarettes, harm reduction and the 
tobacco industry9
9.1 Introduction
In 2013, the investment bank Goldman Sachs identified e-cigarettes as one of
eight emergent themes in the global economy capable of ‘creative destruction’,
representing a new technology that could offer consumers a significantly superior
proposition and potentially ‘forcing established companies and business models
to either adapt or die’.1 In the same year, The Economist newspaper similarly
asked whether the rise of e-cigarettes represented the tobacco industry’s ‘Kodak
moment’ – ‘its version of the point at which the world’s leading maker of camera
film realised that consumers had gone digital, and it was too late to chase them’.2
The continuing profitability of the tobacco industry, which arises
overwhelmingly from sales of tobacco cigarettes,3–6 suggests that such reports of
the industry’s demise are at best premature. However, these claims do highlight
the substantial degree of uncertainty about the commercial implications of 
e-cigarettes for the future of the tobacco industry and therefore for the strategic
development of tobacco control.
The disruptive effect of e-cigarettes is not confined to the tobacco industry. The
chairman of the pharmaceutical giant GlaxoSmithKline, for example, has
acknowledged that, in response to the declining performance of their nicotine
replacement therapies (NRTs), the company considered manufacturing 
e-cigarettes before concluding that such a step would be ‘just too controversial’.7
Leading tobacco companies have, perhaps predictably, made a different decision,
implementing a rapid programme of investment in and acquisition of vapour
devices. The public health implications of such developments remain uncertain
and contested, and reflect broader debates about the role of harm reduction in
general. At one end of the spectrum, harm-reduction advocates and researchers
see advantages in engaging an industry skilled in marketing nicotine in the
promotion of products that could offer a potential exit strategy from selling
cigarettes: identifying, for example, the ‘need to create a situation in which there
are incentives for tobacco companies to gradually become nicotine companies …
[such] that their long-term profits are going to be in other products than
cigarettes’.8 At the other end of the spectrum are those who see no such prospect,
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claiming, for example, that ‘only the most naive or captured advocates for vaping
could fail to acknowledge that the tobacco industry wants people who vape to
smoke and vape, not vape instead of smoking’.9 This chapter explores the motives
for and potential consequences of the tobacco industry’s engagement in harm
reduction and, in particular, the emerging e-cigarette market.
9.2 The tobacco industry and e-cigarettes
E-cigarettes have emerged as a significant component of the market in nicotine
products with astonishing rapidity, both in the UK and globally. The market
research company Nielsen identified e-cigarettes as the fastest-growing product
in British supermarkets during 2014, with sales across large grocers increasing by
almost 50%.10 A report on the UK market in nicotine vapour devices by the
industry analysts Euromonitor suggested even greater growth, with a category
that was worth only £25 million as recently as 2011 having reached overall sales
of £459 million in 2014. This growth also reflected changing consumer
preferences, with first-generation (‘cigalike’) devices (see Chapter 5) being
displaced in the UK by the rapid expansion of tank systems and of e-liquids,
which experienced value growth of 110% and 145% respectively in 2014.11 This
shift is also strongly evident in other leading western European markets,
although ‘cigalikes’ retain majority shares in both Russia and the USA.12 The UK
e-cigarette market is now estimated to be the world’s second largest, being
exceeded only by the USA,13 whereas global sales of an estimated $US6.5 billion
now dramatically outstrip the declining international market for NRT (US$2.4
billion), and are equivalent in value to cigarette sales in the world’s 20th-largest
cigarette market.12
Having perhaps been taken by surprise by the rise of e-cigarettes, the
transnational tobacco companies have all now committed to major initiatives in
this emergent industry. A key moment was the April 2012 acquisition of the 
e-cigarette brand blu™ by the US-based cigarette manufacturer Lorillard for
$US135 million,14 marking the tobacco industry’s first major foray into the 
e-cigarette market. In December 2012, British American Tobacco (BAT) became
the first leading tobacco company to buy a British e-cigarette manufacturer
through its purchase of CN Creative, the maker of Intellicig.15 This
complemented BAT’s earlier formation of what was billed as a stand-alone start-
up company, Nicoventures, to ‘focus exclusively on the development and
commercialisation of innovative regulatory approved nicotine products’.16 All of
the leading international cigarette manufacturers have now made substantial
acquisitions or launched strategic initiatives in nicotine products, principally in
e-cigarettes. Altria and Philip Morris International (PMI) manage vapour brands
including Mark Ten, Nicolites and the heat-not-burn product iQOS; BAT brands
include Vype, Intellicig and an inhaled nicotine device called Voke; Japan
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Tobacco International have purchased E-Lites and launched Ploom; RJ Reynolds
have developed Vuse and Revo, whereas Imperial Tobacco launched Puritane
through its Fontem Ventures subsidiary and, in July 2014, obtained the blu™
brand that was sold as part of Reynolds’ takeover of Lorillard.11–12,17
These investments have, to date, been weighted heavily towards first-generation
‘cigalikes’, which mimic tobacco cigarettes more closely, but tend to deliver lower
doses of nicotine than, later-generation devices (see Chapter 5), and it has been
suggested that this is a deliberate strategy to avoid promoting products likely to
be effective in aiding cessation.18 Recent developments suggest diversification,
with tobacco companies looking beyond ‘cigalikes’: the Vivid Vapours e-liquid
brand has become increasingly prominent in the UK after its acquisition by PMI,
and the blu™ product range is expanding via its e-liquid portfolio.19 Investments
in heat-not-burn technology (positioned as reducing risks associated with
combustion by electronically heating tobacco rather than burning it6), as well as
in non-tobacco nicotine products (see Chapter 5), further increase the diversity
of tobacco company initiatives in reduced risk products, and PMI’s launch of its
iQOS Heatsticks, under its flagship Marlboro brand in test markets in Japan and
Italy, suggests that this development is of major strategic importance to PMI.20 It
does appear that tobacco industry efforts to build a market for reduced-risk
products are now centred on vapour devices, as epitomised in July 2015 by PMI
announcing the dissolution of its snus joint venture with Swedish Match while
extending its international strategic collaboration with Altria in vaping
products.21
The engagement of the tobacco industry in the reduced-risk product sector is
thus changing rapidly, and in relation to e-cigarette products is likely to continue
to do so, given, among other things, the expected changes in regulatory context,
new patterns of ownership and investment, the currently fragmented market,
absence to date of dominant brands, and continuing technological innovation
and shifting consumer preferences. Such uncertainties notwithstanding, however,
rapid growth in the e-cigarette market is predicted to continue over the next few
years, with Euromonitor suggesting that the global market for vaping products
could reach US$50 billion by 2030. This is clearly a substantial and enticing
prospect from a commercial perspective, although it needs to be interpreted
alongside an expectation that it will remain a fraction of the market in tobacco
products, with cigarettes remaining the dominant product category.22
9.3 E-cigarette marketing
The first television advertisement for an e-cigarette, promoting the then
independently owned E-Lites brand, was broadcast in the UK in January 2013.11
This was followed a year later by advertisements for Vype, an e-cigarette
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marketed by BAT and representing the first overt paid-for television
advertisement by a tobacco company in over two decades,23 and then, later in
2014, by advertisements showing the act of vaping for the VIP e-cigarette
brand.24 Such developments occurred amid considerable ambiguity about how
and whether existing regulatory frameworks applied to reduced-risk nicotine
products. This led to a public consultation by the Committees of Advertising
Practice,25 followed by the issuance of specific guidance25,26 intended to govern
the period until the implementation of more stringent regulation of advertising,
sponsorship and promotion under the 2014 revision of the EU Tobacco Products
Directive 2014/40/EU.
The development of television advertising campaigns forms one strand of an
extensive array of marketing, sponsorship and promotional efforts that have
contributed to the rapid growth of the e-cigarette market. Sports sponsorship
deals, for example, have included Nicolites partnering with Birmingham City
Football Club, whereas E-Lites secured distribution deals and designated vaping
areas in Celtic and Rangers football stadiums in Glasgow, and invoked the strong
association between tobacco and motorsport in announcing its sponsorship of
the British Superbike Championship.27–29 E-Lites secured the first product
placement for e-cigarettes in a music video by the artist Lily Allen. Packaging
innovations have included ‘smart packs’ produced by blu™ e-cigarettes that
vibrate and flash a blue light when within 50 feet of other users, and which can
transmit to Facebook and Twitter profiles, whereas Vapestick has created a retro-
style computer game named Electronic cigarette wars. PMI also offered retailers
free retail display shutter cases heavily branded with its Vivid e-liquid and
Nicolites e-cigarettes, in preparation for the second stage of UK point-of-sale
display legislation, which prohibited point-of-sale display of any tobacco product
from April 2015.30
Such high-profile activity is indicative of the recent rise of e-cigarette promotions
across multiple fields, driven by rapidly escalating expenditure. During 2013,
around £8.4 million was spent in the UK promoting five leading brands (E-Lites,
Vype, SkyCig, NJOY King and Gamucci) across press, television, radio, the internet
and outdoor media, figures that were to be dwarfed in 201431 with BAT’s television
advertising for Vype as part of a £3.6 million marketing campaign and Skycig
announcing investment in a £20 million marketing campaign.27 A similar surge in
marketing spending has occurred in the USA, where a study of advertising
spending across television, print, radio and the internet found that expenditure in
the second quarter of 2013 amounted to $US28 million, some eight times more
than that for the equivalent period in 2012.32
This escalation of marketing expenditure reflects the increased resources
available following the wave of investments in e-cigarettes by the tobacco
industry, with the latter’s engagement in marketing raising distinct concerns.
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Looking at the future development of the market in vapour devices from a
commercial perspective, this represents both opportunity and risk, because
leading tobacco companies ‘have the capital to turn e-liquid brands into
household names but also the reputational impairment to attract draconian
regulation to the category’.19 In this context, discussions about how to regulate
the marketing of e-cigarettes are inevitably coloured by the tobacco industry’s
long-standing global reliance on advertising and marketing to promote and
maintain cigarette consumption, particularly by targeting young people.33,34
Health campaigners have raised concerns about the extent to which some 
e-cigarette advertising has sought to replicate imagery and themes that have long
been central to marketing cigarettes. Magazine adverts for e-cigarettes in the USA
have, for example, been seen as depicting equivalents to the rugged masculinity
of the Marlboro Man or the glamorous independence of the Virginia Slims
woman, sponsorship of sports and music events, and the development of sweet
flavours are seen as enhancing appeal among youth, and blu™ e-cigarettes’ use of
a cartoon ‘Mr Cool’ evoked the notorious Joe Camel cartoons.35,36 In the UK,
rules on advertising limit such opportunities and the Advertising Standards
Authority recently upheld complaints about an advert for VIP e-cigarettes that
showed a woman vaping ‘in a sultry and glamorous way’, creating a strong
association with traditional smoking and thereby ‘indirectly promoting the use of
tobacco products’.37 Complaints about a UK advert for Vape Nation were upheld
as encouraging use of e-cigarettes among ex-smokers.37
Maintenance of extensive marketing freedom and potentially controversial
promotional strategies for e-cigarettes has been defended as likely to appeal to
smokers,38 and it has been argued that excessive regulation is likely to protect the
market monopoly of tobacco cigarettes by inhibiting competition from 
e-cigarettes.39 Analyses from a social marketing perspective, however, have
emphasised risks associated with e-cigarette marketing in general, and the role of
tobacco companies within such activities in particular.15,28 In presenting the
promotion of e-cigarettes as a reinvention of tobacco marketing, de Andrade et
al28 highlight the active promotion of dual use, in which marketing activities are
identified to have been ‘promoting long term use as a permanent alternative to
tobacco, and a temporary one in public places where smoking is banned’. An
analysis of the marketing strategy of tobacco company-owned e-cigarettes for
Cancer Research UK was organised around a distinction between marketing
targeted at potential consumers and those activities oriented towards
‘stakeholders’, such as policymakers and public health agencies28 (Table 9.1).
Although debate about the potential for such campaigns to renormalise or
inadvertently promote smoking continues, attention is increasingly focused on
the tobacco industry’s use of e-cigarettes and the wider harm-reduction agenda
to rebuild its links with policymakers, and public health and other key
stakeholders. 28
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9.4 Undermining tobacco control
The recognition of a fundamental conflict between public health objectives and
tobacco industry interests has become a central tenet of tobacco control,
epitomised by Article 5.3 of the World Health Organization (WHO) Framework
Convention on Tobacco Control (FCTC), which requires countries to protect the
setting and implementation of tobacco control policies from the industry’s
commercial and other vested interests.40 The emergence of a distinctive model of
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Table 9.1 Tobacco-owned e-cigarettes – the marketing strategy15
Marketing Marketing strategy
challenge
Who Consumers Stakeholders
Objective Long-term sales of tobacco Responsibility, legitimacy, credibility,
through ‘next-generation’ access to policymakers/regulatory
product (especially in processes, public–private partnership, 
developed countries), profit scientific proof
maximisation
What Reduced-harm product, safer Harm reduction
alternative to cigarettes, 
used for pleasure, lifestyle 
products
How Product: safe nicotine, used Product: harm reduction
anywhere, flavoured lifestyle 
products
Price: financial – affordable; Price: financial – priceless, saving lives;
psychological – safer and psychological – it would be negligent
glamorous to ignore this offering
Promotion: where tobacco Promotion: health bodies/experts, 
products cannot be charities, politicians, regulators
advertised, lifestyle and 
celebrity
Place: everywhere tobacco is Place: regulated space
available, company websites, 
point-of-sale displays
Positioning: safer smoking Positioning: differentiation from NRT
alternative, necessity, products, reframe perceptions of 
capitalise on consumer’s nicotine use, alternative for those who
preference cannot or will not quit
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health governance, centred on minimising engagement with the industry,41 has
led to tobacco companies experiencing increasing political marginalisation and
difficulty obtaining access to policy elites.42,43 In this context, investments in
harm reduction and e-cigarettes offer potential opportunities to claim legitimacy
in re-engaging with policymakers, and even to rehabilitate what has become a
pariah industry. If realised, these opportunities may therefore undermine tobacco
control.
Tobacco companies have long sought to redress the challenge of a toxic
reputation by seeking to establish partnerships or common ground with public
health researchers and advocates. A key element of PMI’s ‘Project Sunrise’ in the
mid-1990s, for example, was to ‘enhance our credibility’ by linking with
‘moderate’ tobacco control organisations on issues such as youth access
legislation.44 Tobacco companies’ interest in the concept of harm reduction
increased markedly following a 2001 Institute of Medicine report,45 driven by
recognition of a dual opportunity to both ‘(re-)establish dialogue with and access
to policymakers, scientists and public health groups and to secure reputational
benefits via an emerging corporate social responsibility agenda’.46 The emergence
of pure nicotine alternatives to traditional forms of tobacco consumption has
thus created increased opportunities for both interaction with policymakers and
the depiction of common ground with public health. In the context of a public
consultation on the future of the NHS, for example, Imperial Tobacco met with
the then minister for public health,47 and subsequently made a submission in
which the company invoked its interests in harm reduction to argue against
exclusion from policymaking and to position itself as a potential partner for the
government.48 Several tobacco industry submissions to a Department of Health
consultation on the future of tobacco control similarly used interests in harm
reduction as a basis for suggesting that it could positively contribute to the
challenge of reducing health inequalities.49
Exploiting such opportunities was a key part of the remit of Nicoventures
following its establishment by BAT. In 2012, Nicoventures initiated a medical
education plan named the Smoking Harm Reduction Education Programme
(SHARE), holding a series of meetings with healthcare professionals, including a
round table at the Royal Society of Medicine, and publishing proceedings in GP
and Pharmacy Magazine. In June 2013, Nicoventures approached public health
officials across various regions in the UK to discuss harm reduction and
regulation, with a sales representative describing the company as complying with
the regulatory standards required of a pharmaceutical company.50 BAT also
appointed Dr Richard Tubb to their board of directors in January 2013,
describing this former physician to the president of the USA and ex-director of
the White House Medical Unit as ‘a prominent and well respected expert in the
field of tobacco harm reduction’ whose appointment ‘further demonstrates our
commitment to putting science at the heart of our business’.51 The company
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devoted its 2013 sustainability focus report to the issue of harm reduction,
depicting BAT as a potential partner in a public health revolution; this included
an endorsement of the group’s strategy by Dr Delon Human, a global health
consultant and former head of the International Food and Beverage Alliance, as
having the expertise and public commitment to harm reduction to suggest that
‘BAT could become part of the solution to addressing the epidemic of tobacco-
related disease’.50,52 The report claims that ‘(m)ore collaboration between the
tobacco industry, academia and tobacco research centres is … key to establishing
an evidence-based regulatory framework to assess new products’.52
Alongside such examples of formal endorsements, tobacco companies have also
opportunistically cherry-picked statements from leading public health
organisations and researchers so as to imply common ground and a shared
perspective. The harm-reduction section of the PMI website53 cites a 2014 report
from Public Health England (PHE) as recognising a need for ‘appropriate
regulation, careful monitoring, and risk management’ for harm-reduction
products;54 the citation is presented under a headline claim that the ‘public and
private sectors are starting to embrace the public health opportunity new
products provide’,53 but does so without noting that the PHE report highlights
the involvement of the tobacco industry among ‘potential hazards, unintended
consequences, (and) harms to public health’.54
A key element of the strategic value of harm-reduction discourse to tobacco
companies is its ability to polarise opinions held by those involved in tobacco
control policy, fracturing the remarkable degree of political consensus that has
characterised the tobacco control movement and been central to its success.55
PMI’s ‘Project Sunrise’ centred on the recognition of unity as a key strength of
tobacco control, and promoting division was seen as critical to combating the
movement’s success. The company’s strategy sought to exploit latent tensions
between groups that it labelled ‘moderates’ and ‘prohibitionists’,44 and this finds
strong contemporary echoes in the depiction of competing wings of tobacco
control comprising ‘pragmatists’ who favour harm-reduction approaches being
opposed by ‘idealists’56 or ‘zealots’.57
In this context, the very public dispute in 2014 between competing perspectives
on harm reduction via ‘duelling letters’ from public health researchers and
practitioners to the director-general of WHO, Dr Margaret Chan, appears very
welcome from a tobacco industry perspective.58 The initial open letter of 24 May
2014 with 53 prominent signatories was prompted by a concern that harm
reduction was being ‘overlooked or even purposefully marginalised’59 in
preparing for the forthcoming sixth Conference of Parties of the WHO FCTC.
The letter began to receive significant media coverage on 29 May 2014,60,61 and
on the same day BAT issued a press release calling ‘for tobacco harm reduction to
be adopted as a progressive public health policy’.62 A quotation from a
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subsequent letter remains prominent on the harm-reduction pages of BAT’s
website,63 emphasising ‘the importance of dispassionate presentation and
interpretation of evidence’ and the challenge to find ‘an appropriate framework’
of regulation balancing opportunities and risks.64 These twin themes are also
repeatedly invoked in the company’s subsequent 2014 harm-reduction report. Its
introduction by chief executive Nicandro Durante suggests that ‘the challenge is
that these are new products which many governments are still unsure how to
regulate’ and cites ‘the growing weight of evidence and arguments in support of
harm reduction’.65 The report highlights a call from a paper by three of the
letter’s signatories for regulatory decisions to be ‘proportional, based on
evidence, and incorporate a rational appraisal of likely risks and benefits’,66
presenting a variation on BAT’s long-standing claim to ‘support sensible
regulation’.67
Although neither the reputational management nor policy engagement
opportunities afforded by harm reduction have yet been exploited with success
that can be considered transformational, a number of strategically valuable ‘wins’
for the tobacco industry can be identified. Notable here is the success of BAT’s
Nicoventures in securing marketing authority from the UK Medicines and
Healthcare products Regulatory Agency (MHRA) for its nicotine inhaler Voke, a
success has been described as ‘an important waypoint on the industry’s journey
to self-rehabilitation’.56 Vype, also owned by BAT’s Nicoventures, is marketed as a
‘pharmaceutical-grade product’ and sold via Lloyds Pharmacy, whereas Puritane
e-cigarettes, owned by the Imperial Tobacco subsidiary Fontem, are exclusively
available in Boots. Such distribution deals are inconsistent with advice from the
Royal Pharmaceutical Society,27 and both bring reputational benefits of
association with prominent high-street chemists and create strategic
opportunities. Puritane’s deal with Boots is seen as leaving it well placed to
benefit from any reclassification of e-cigarettes to ‘directly rival smoking
cessation aids’.11
9.5 E-cigarettes and the future of the tobacco industry
Tobacco companies’ investments in e-cigarettes, as with earlier incarnations of
the harm-reduction debate, have been characterised by considerable uncertainty,
false starts and fluctuations, and there is nothing to suggest that the recent
developments outlined above constitute a fixed and settled strategic direction,
whether for specific companies or for the industry as a whole. There is, however,
now a sufficient basis to draw some preliminary conclusions informed by
marketing campaigns, investor presentations and stated strategic priorities. Such
conclusions need to be informed by the historical experience of how and why
tobacco companies viewed earlier reduced-risk products, with which striking
similarities are becoming evident. One potential parallel has recently been drawn
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in light of the history of NRT,68 via tension between two competing conceptions
of NRT as a therapeutic device to aid cessation and as a cigarette alternative
capable of delivering nicotine in the ‘right way’. This analysis highlights the
dangers of the potential of e-cigarettes being ‘easily compromised in the hands of
tobacco companies, reflected by their tendency for imagining nicotine
replacements … as creatively complementing rather than creatively destroying
the market for combustible tobacco products’.68
More broadly, the tobacco industry’s recent involvement with e-cigarettes carries
echoes of its earlier rise to dominance of the Swedish snus market via
acquisitions and joint ventures between 2001 and 2009,69 eg an analysis of BAT
corporate documents from this period yielded no substantive evidence of the
company encouraging smokers to switch permanently to smokeless tobacco, but
indicated instead that these were essentially defensive investments that protected
the status quo and the dominance of the cigarette by shifting ‘snus from a threat
(a product that may have competed with cigarettes) to a major opportunity’ that
presented common interests with public health and an alternative future amid
long-term decline in cigarette sales.70
One significant difference that emerges from comparison with the snus
experience is the prominence afforded e-cigarettes and reduced-risk products in
contemporary investor presentations. This contrasts with a near absence of snus
from earlier BAT and PMI presentations, which suggest that snus was not central
to business strategy.70 The reformulation of BAT’s vision statement to become
‘the world’s best at satisfying consumer moments in tobacco and beyond’71
indicates newfound strategic centrality for nicotine projects, mirrored in PMI’s
designation of reduced-risk products as ‘our greatest growth opportunity’.72
Although the reputational and stakeholder engagement advantages of e-cigarettes
for tobacco companies are clearly considerable, this does seem also to represent a
consumer market in which growth prospects are being taken seriously.
The extent to which this constitutes a transformation of the strategic landscape
for tobacco companies should not, however, be overstated. To return to the image
of creative destruction, the emphasis seems to be very much on e-cigarettes
creatively complementing conventional products within an expanded portfolio,
not on displacing the industry’s ongoing reliance on the conventional cigarette.
Hence BAT has been unequivocal that their ‘ambition remains to lead the global
tobacco industry’,71 retaining confidence in the growth of the global tobacco
business and developing their portfolio of ‘beyond tobacco products’ within a
single integrated view of the consumer. New products are therefore positioned
alongside traditional cigarettes, combustible innovations and non-combustible
offers in creating multiple satisfying ‘consumer moments’.73 Similarly, PMI
chairman Louis Camilleri’s speech to the company’s 2015 annual meeting
emphasised that ‘we expect our combustible products to be the core of our
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profitability growth for many years to come’, notwithstanding the significance
attached to investing in and developing reduced-risk products.74 The decision to
launch the company’s heat-not-burn iQOS system under the Marlboro brand is
also consistent with ongoing concerns that tobacco companies are using 
e-cigarette marketing to promote dual use,28 thereby complementing and
sustaining rather than challenging the future dominance of the cigarette.
Any suggestion that tobacco companies are using investments in e-cigarettes as a
vehicle to secure their long-term exit from the cigarette market therefore looks
like misplaced optimism. Their engagement in harm reduction is likely to be
better understood in terms of exploring an emerging opportunity that can
buttress their core business, and promise the maintenance of both their licence to
operate and the prospect of rehabilitation. Appraising the implications of this
perspective for the broader role of harm reduction within the future of tobacco
control remains contentious, but it does serve to highlight the ongoing
importance of protecting health policy from tobacco industry interference and of
maximising compliance with guidelines for the effective implementation of WHO
FCTC Article 5.3.75 Although the most optimistic interpretations8,76 of increased
tobacco industry interests in reduced-risk products might suggest the prospect of
some degree of shared interest with public health, the economic and political
contexts within which such products are being promoted suggests that any such
appraisal is dangerously naive and holds the potential significantly to undermine
tobacco control policy and practice internationally. Interests in e-cigarettes and
other reduced-risk products create important strategic opportunities for the
tobacco industry, and therefore compound the complexities confronting public
health in dealing with the harm-reduction agenda. The appropriate response is
therefore to strengthen and broaden protections against conflicts of interest,
protecting ‘tobacco control activities from all commercial and other vested
interests related to [e-cigarettes], including interests of the tobacco industry’.77
9.6 Summary
> The e-cigarette market has demonstrated massive growth in value and, until
relatively recently, has been driven by independent e-cigarette companies.
> This success represents a potential challenge to the traditional business
model of the tobacco industry, but also creates important commercial and
political opportunities.
> After some delay the tobacco industry is now engaging in the e-cigarette
market, and the possible reasons for doing so include:
• promotion of low-efficacy products that are likely to fail and hence
minimise the threat to tobacco sales
• use of intellectual property rights to bring legal challenges against
competitors
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• ensuring a share in the emerging e-cigarette market to harness a new,
disruptive technology
• using these products to sustain tobacco smoking by promoting them as a
complement rather than an alternative to tobacco
• using the products also to promote smoking through advertising and
promotion to adults and children
• attracting customers who currently use competitors’ tobacco products
• creating justification to re-engage with policymakers, hence undermining
the WHO FCTC (Article 5.3)
• exploiting harm reduction to build credibility in corporate social
responsibility initiatives
• using harm reduction as a pretext to engage with and disrupt the activities
of scientists and advocates in tobacco control.
> The engagement of the tobacco industry in the e-cigarette market thus
represents a significant potential threat to UK national and global tobacco
control.
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10.1 What does nicotine product regulation need to achieve?
Products are regulated to ensure that they are safe and fit for purpose; the general
product regulations that apply to all consumer products sold in the UK, and
their equivalents in other countries, are intended to achieve this for general
consumer goods. In the case of products for which safety is particularly
important, these general product regulations are often supplemented or
superseded by higher levels of specific safety regulation, with medicines, for
example, being required to meet especially high standards of manufacturing,
safety, product information and efficacy. The overall purpose of all of this
regulation is, however, to ensure that consumers can access products that serve
their purpose within reasonable bounds of safety, quality and efficacy.
The rationale for regulating nicotine products is the same as for any other, but is
complicated by the fact that the market leader in nicotine products in the 20th
and 21st centuries, the cigarette, is so intrinsically hazardous that it is beyond the
scope of conventional general product regulations, and as an addictive product is
too entrenched in society to be amenable to prohibition. It is therefore important
that the approach to regulating non-tobacco nicotine products recognises the
need not only to meet the general requirements of safety and fitness for purpose,
but also to encourage the development and uptake of competitive alternatives to
the fatally toxic product currently chosen by most habitual nicotine users.
Therefore, although regulation of all products should be proportionate to their
potential hazard, proportionality in nicotine regulation must also incorporate the
consideration that regulation that discourages or delays the development and use
of non-tobacco nicotine is likely, in effect, to sustain tobacco smoking and hence
perpetuate harm to smokers and wider society.
This report has argued that nicotine use, of itself, presents relatively little risk to
users or wider society, and that most of the harm that arises from nicotine use is
attributable to the vehicle of delivery, with tobacco smoke being by far the most
hazardous. It therefore follows that, although the ideal course of action for any
smoker is to quit smoking and all nicotine use, quitting smoking by long-term
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substitution with a less hazardous nicotine source is the next best option.
Nicotine regulation should therefore be designed to make non-tobacco nicotine a
more attractive, available and affordable option for smokers than cigarettes, to
prevent, as far as possible, uptake of nicotine use by never-smokers, particularly
children, and to make smoked tobacco products as unappealing as possible.
When the RCP last reported on nicotine regulation in 2007,1 the range of
available nicotine products fell into three classes: smoked tobacco, smokeless
tobacco and nicotine replacement therapy (NRT). We argued then that the
prevailing regulatory structure intrinsically favoured smoked tobacco over both
NRT, which was regulated as a medicine, and smokeless tobacco, of which the
lowest-hazard product, Swedish snus, is prohibited in the UK. The emergence of
e-cigarettes has added a whole new product class to this range, and this spectrum
of choice is likely to be increased still further by new technologies in
development (see Chapter 5). The nicotine regulatory framework has also
undergone substantial change since 2007.
This chapter describes recent developments and impending changes in UK
nicotine regulation, identifies key areas of concern, and discusses alternative
approaches that might increase the public health benefit accrued from the
emergence of e-cigarettes and other non-tobacco nicotine. The discussion is
based in the UK setting and pertains to the three broad types of nicotine product
available on the UK market: tobacco, unlicensed nicotine products
(predominantly e-cigarettes) and nicotine products that are licensed as
medicines.
10.2 Current regulation of tobacco, and licensed and unlicensed
nicotine products
10.2.1 Tobacco products
Since 1998, a comprehensive tobacco control strategy has been introduced in the
UK, the component measures of which are discussed in more detail in Chapter 3.
Regulatory approaches have included: reducing affordability by increasing
taxation and reducing the size of the cheap and illicit market; imposing
packaging and labelling requirements (including the implementation of
standardised packaging legislation from May 2016); prohibiting all advertising,
promotion and sponsorship; restrictions on where, how and to whom tobacco
products can be sold; and smoke-free policies determining where tobacco can be
used. After unsuccessful attempts to regulate the cigarette itself by restricting tar
levels, regulation of product contents and emissions has not been extensively
pursued, other than to prevent fires by reducing ignition propensity. The overall
package of tobacco control policies in place in the UK is one of the most
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advanced in the world, with the UK currently highest in the European tobacco
control league table.2 The new EU Tobacco Products Directive (TPD)3 will, from
May 2016, impose a range of new restrictions on tobacco products, which
include a minimum pack size of 20 cigarettes (and 50 g hand-rolling tobacco),
restrictions on the shape of packs, combined pictorial and text health warnings
that cover 65% of the front and back of the pack, and prohibition of flavourings
including, after a delay, menthol.
10.2.2 Unlicensed nicotine products
E-cigarettes (most of which contain nicotine) and other unlicensed nicotine
products are currently regulated in the UK by the EU General Product Safety
Directive. This has recently been supplemented by legislation in England
imposing a minimum purchase age of 18 years, which is currently in the process
of being introduced elsewhere in the UK.4 General product regulations do not
require products to be tested before being put on the market, but do allow
retrospective action to remove products found to be faulty or harmful. In July
2015, the British Standards Institute (BSI) published a fast-track voluntary
standard for e-cigarettes (PAS 54115), which was sponsored by the Electronic
Cigarette Industry Trade Association (ECITA (EU) Ltd) and facilitated by the
BSI.5,6 This standard gives guidance on the manufacture, import, labelling,
marketing and sale of vaping products, including e-cigarettes, e-shishas and 
e-liquid mixing kits. However, at the time of writing it is not clear how widely
this standard is being adopted by manufacturers and importers.
E-cigarette marketing in the UK has to comply with compulsory advertising
codes administered by the Advertising Standards Authority (ASA). Although
those codes contain general rules that apply to all advertising, concerns about the
promotion of e-cigarettes led the ASA to introduce sector-specific rules in
November 2014.7 These require the following of e-cigarette advertising: to be
socially responsible; not to promote any design, imagery or logo that might be
associated with a tobacco brand or show the use of a tobacco product in a
positive light; to make clear that the advertised product is an e-cigarette and not
a tobacco product; not to undermine quit smoking messages; and not to contain
health or medicinal claims unless the product holds a medicines licence. There is
a commitment to review progress with these rules after 12 months.
Although not subject to the smoke-free legislation that prohibits tobacco
smoking in enclosed public places and workplaces, some businesses and
organisations prohibit e-cigarette use in places where this legislation already
prohibits smoking. Given the lack of evidence on the harmfulness of e-cigarette
vapour to others (see Chapter 5), it would be inappropriate for national
legislation to prohibit their use in public places and workplaces. At the time of
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going to press, an attempt by the Welsh government to legislate to ban the use of e-
cigarettes in some enclosed places and workplaces had failed and was considered
unlikely to be reintroduced in the next parliament after the elections in May.8
There are some circumstances, such as prisons and mental health settings, where
tobacco smoking is particularly prevalent. The option to use e-cigarettes where
tobacco smoking is banned could help to introduce and sustain fully smoke-free
policies, eg the South London and Maudsley NHS Foundation Trust implemented
a policy that allows some types of e-cigarette to be used, as part of a care
treatment pathway, in private spaces or grounds where smoking is prohibited.9
Prisons in England and Wales have made single-use e-cigarettes available for sale
to prisoners as a smoking substitute, in preparation for implementing fully
smoke-free policies across the prison estate which started in late 2015.10
10.2.3 Licensed nicotine products
Nicotine products licensed as medicines, generally known as nicotine
replacement therapy (NRT), have been available in the UK since 1980. They were
initially licensed by the Medicines Control Agency (MCA) for use to relieve
nicotine withdrawal symptoms during attempts to quit smoking, and were
subject to an extensive range of cautions and contraindications that arose from
the use of comparison of adverse effects with those of placebo, rather than
continued smoking.
The MCA was replaced in 2003 by the UK Medicines and Healthcare products
Regulatory Agency (MHRA), which was established with a wider remit, including a
new objective to make ‘an effective contribution to public health’. In 2005 the
MHRA made some substantial changes to their regulation of NRT products in
response to a review and recommendations by the Committee on Safety of
Medicines, an advisory committee to the MHRA.11 These included the adoption of
smoking rather than placebo as the comparator for NRT, which allowed some
contraindications (eg stable cardiovascular disease) that inhibited use of NRT by
smokers to be removed, extending the licence for NRT to include pregnant
smokers, and smokers aged 12 and over, and allowing some NRT products to be
used for cutting down in order to quit, as well as for abrupt quitting. There has also
been a progressive relaxation of restrictions on the availability of NRT over recent
years, starting in 2001 when prescriptions of NRT products became reimbursable
through the NHS, and subsequently through extensions to retail availability by
allowing NRT products to be sold by general retailers as well as pharmacies. Direct
advertising of NRT to the public is permitted subject to regulations12 requiring the
following from promotions: they are not misleading and do not imply that
products are ‘safe’; they are compliant with the details listed in the summary of
product characteristics; they are presented objectively to encourage rational use of
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the product; and they are not directed exclusively or principally at people aged
under 16. Provision of free samples of NRT for promotional purposes remains
prohibited. Since 2007, NRT sold over the counter has been subject to VAT at a
reduced rate of 5% to help make products more affordable.13
In 2010, the MHRA expanded the indication for NRT to allow long-term use as a
harm-reduction alternative to smoking for those who were unwilling or unable
to quit.14 The question of whether e-cigarettes should be regulated as medicines
was considered by the MHRA at this time, which proposed that nicotine be
deemed a medicine by function, thereby requiring that e-cigarettes should either
be licensed as medicines or removed from the market. However, as immediate
classification as medicines would have caused all e-cigarettes on the market at the
time to be withdrawn, and hence potentially cause the many smokers who had
already switched from using tobacco cigarettes to e-cigarettes to go back to
tobacco smoking, the MHRA consulted on options15 that included implementing
medicines regulation immediately, or after a delay allowing e-cigarette
manufacturers and importers to comply, or else imposing no additional
regulation. The proposed licensing option was described by the MHRA as ‘light
touch’ and presented as a simplified, and hence quicker and less costly, route to
medicines licensing. In particular, the proposed ‘light touch’ approach assumed
that any product that delivered nicotine to a degree comparable with existing
licensed nicotine products was clinically effective, thus removing the requirement
for manufacturers or importers of e-cigarettes or other nicotine-containing
products to carry out clinical trials to demonstrate efficacy.
The consultation received over 1,000 responses, most of which came from 
e-cigarette users opposed to any regulation, or else supporting regulation
introduced in a way that allowed e-cigarettes to remain available to them.
Responses from public health organisations, including the RCP, were generally
supportive of ‘light touch’ regulation, but most recommended a delay to allow
time for manufacturers to comply. Support for immediate regulation, with
removal of unlicensed products from the market within 21 days, came from
organisations including pharmaceutical companies, pharmacist and trading
standards groups, and Imperial Tobacco.15 The MHRA responded by allowing 
e-cigarettes to remain on the market pending further consideration, and in 2013
announced that it would require all nicotine products to be licensed as medicines
from the date of implementation of a revision of the TPD (see Section 10.3
below). The TPD version under consideration at that time required medicines
regulation for all but very-low-dose products. The MHRA later rebadged the
medicines licensing process for nicotine products as ‘right touch’ regulation.
In 2014, a revised version of the TPD, which superseded the MHRA proposal by
providing an alternative route to market for e-cigarettes without a medicines
licence, was negotiated and agreed.3,16 Medicines regulation remained an option
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for manufacturers and importers of e-cigarettes, and the MHRA continues to
encourage companies to apply voluntarily for licences.17 However, licensing is no
longer mandatory and, at the time of going to press in early 2016, only one 
e-cigarette, owned by British American Tobacco (BAT), had been awarded a
medicines licence by the MHRA and was not yet commercially available.18 It is not
known whether medicines licence applications have been made for other 
e-cigarette products. A medicines licence has, however, been awarded to a nicotine
inhaler (not an e-cigarette) called Voke, developed by Kind Consumer and licensed
to BAT, but at the time of going to press this product had not been marketed.19
10.3 The 2014 EU TPD
The 2014 revision of the EU TPD,3 which comes into effect from May 2016,
imposes significant new regulations on nicotine products, including e-cigarettes
and refill containers that do not have a medicines licence. Although limited areas
of flexibility in implementation for member states remain, the main provisions
of the TPD in relation to e-cigarettes are as follows:
1 Manufacturers and importers of e-cigarettes must provide a detailed notification
to the government-appointed ‘competent authority’ of a range of details relating
to each product, and make this information publicly available. Non-compliant
products can be manufactured until 20 November 2016 and sold until 20 May
2017. Products already on the market by 20 May 2016 must be notified by 20
November 2016. New products or substantial modifications introduced into the
market between 20 May and 19 November 2016 must be notified at least 1 day
in advance of going on sale. From 20 November 2016 all new products or
substantial modifications must be notified 6 months in advance of going on sale.
2 Required details include: quantification and toxicological data for all
ingredients and emissions, including when heated, and their potential health
and addictive effects; nicotine delivery and uptake; a description of the
product components and production process; and a declaration of
responsibility for the quality and safety of the product when used under
normal or reasonable foreseeable conditions.
3 There will be a limit on total nicotine content in e-cigarettes, which will be
allowed to contain a maximum of 2 mL nicotine solution at a maximum
nicotine concentration of 20 mg/mL. Refill containers will be subject to a
maximum volume of 10 mL. Nicotine and all other ingredients used in
manufacture must be of high purity and not pose a risk before or after
heating, and substances other than those declared should be present only in
trace quantities, which are unavoidable during manufacture. Products 
must be child and tamper proof, and protected against breakage and leakage.
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4 Nicotine doses are required to be delivered at consistent levels under normal
conditions of use.
5 Products should include a leaflet, which, among other things, contains
instructions, warnings, and information on contraindications, possible
adverse effects, addictiveness and toxicity. Outside packaging must list
ingredients, nicotine content and delivery per dose, carry a batch number,
and a health warning stating ‘This product contains nicotine which is a
highly addictive substance’. Outside packaging must not include any
promotional element or feature to suggest that the product is less harmful or
has other health or lifestyle benefits.
6 Cross-border advertising, sponsorship and promotion in the press and
broadcast and internet media are prohibited, as are cross-border sales unless
subject to a registration scheme. Domestic advertising through billboards, at
point of sale, on public transport or other local media is permitted unless
prohibited by domestic legislation, as is under consideration in Scotland.
Provision of information about products online is still legal.
7 Manufacturers and importers must deliver an annual submission on their
products to governments, which should include comprehensive data on sales
volumes, consumer preferences, mode of sale and market developments.
These submissions should be made publicly available unless classified as
trade secrets.
8 Manufacturers, importers and distributors of products are required to
establish and maintain a system for collecting information about all the
suspected adverse effects on human health. Corrective action is required if
there are reasons to believe that products are not safe or of good quality, or
not conforming to the directive.
9 Regulation of flavours, and age of sale, remains the responsibility of 
member states.
At the time of going to press, the UK government’s intention to transpose the
TPD into UK law was still the subject of a legal challenge by an e-cigarette
company, Totally Wicked. However, in December 2015 the advocate general
dismissed this and other challenges to the TPD20 and, although a final court
ruling is not due until 4 May, it now seems likely that the TPD will be
implemented as originally proposed on 20 May 2016. The UK competent
authority for e-cigarettes under the EU TPD will be the MHRA.21 From 20 May
2016, therefore, all e-cigarettes sold in the UK will be regulated by the MHRA
either under the provisions of the TPD or as medicines, or both.
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10.4 Advantages and disadvantages of medicines and TPD
regulation of non-tobacco nicotine
The impending need for e-cigarettes and other non-tobacco nicotine products,
either currently on the market or in development, to comply with one of the
above regulatory options has significant implications for suppliers of these
devices, and for wider public health. Both approaches have significant advantages
and disadvantages, which suppliers will have to balance in their decision on
which route or routes to pursue. These are as follows.
10.4.1 Medicines licensing
Key advantages to manufacturers who pursue medicines licensing include:
> higher consumer confidence in product quality and safety
> relief from TPD limits on nicotine solution concentration and volume
> freedom to advertise on TV, radio and in printed media, in line with MHRA
rules12
> freedom to make justified health claims in relation to quitting and harm
reduction
> no obligation to carry health warnings informing consumers that nicotine is
addictive
> eligibility for use in, and for subsidised prescription through, the NHS
> potentially subject to 5% rather than 20% VAT in the UK.
The main disadvantage of medicines licensing is the cost in time and money of
the application process itself, and of the much higher manufacturing standards
required of medicines. It is understood that the MHRA estimates first application
costs at between £252,000 and £390,000, and annual recurring costs at between
£65,000 and £249,000 for each product.22 In practice, however, it is likely that
application costs incurred by companies inexperienced in negotiating this
regulatory system may be significantly higher, whereas the additional cost of
manufacturing to the medicines standard is estimated at several million
pounds.22 These financial and related opportunity costs inevitably represent a
significant barrier to innovation and market entry for new licensed nicotine
products, and favour larger, better resourced entities such as pharmaceutical and
transnational tobacco companies. Licensing and presentation of products as
medicines may also undermine the perception of e-cigarettes as a consumer
rather than a medical product, and hence inhibit experimentation and use.
That only one licence has been awarded to an e-cigarette product in the 5 years
since the MHRA announced its ‘light touch’ licensing option, despite the rapid
growth and hence evident value of the e-cigarette market and verbal reports from
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the MHRA that ‘several’ e-cigarette companies had enquired about licensing,
indicates that mandatory medicines regulation, had it been imposed as originally
intended by the MHRA, would indeed have resulted in a period of several years
in which no e-cigarettes were available for sale in the UK. Mandatory medicines
licensing, as originally proposed, would therefore have been counterproductive to
public health. Given the high product quality and safety standards that medicines
licensing guarantees, as well as the option of providing products on prescription
to those on low incomes, it is clearly desirable that the range of e-cigarette
products available to consumers and health professionals includes some that are
licensed as medicines. As recommended elsewhere,22 a review of the MHRA
licensing process for e-cigarettes, to minimise the extent to which licensing
procedures and demands unnecessarily obstruct the progress of new medicinal
products to market, is clearly needed.
10.4.2 TPD regulation
At the time of writing, the exact detail of how the proposed TPD regulation will
operate has not been published. It appears likely, however, that regulation under
the TPD will offer e-cigarettes and other non-tobacco nicotine products a route
to market that is less onerous, and hence quicker and less expensive, than
medicines regulation.
The principal benefits of TPD regulation to consumers are that they will ensure
that products that claim to deliver nicotine actually do so, and therefore that
consumers are likely to find them effective, and provide reassurance that toxins
and other by-products in vapour are at known and pragmatically low levels, thus
protecting consumers from easily avoidable harm. Although it is inevitable that
these reporting and performance requirements will impose costs on
manufacturers and importers, these TPD measures appear to be congruent with
the basic regulatory objective of ensuring that products are fit for purpose, and
reasonably safe.
Other measures imposed by the TPD on e-cigarettes are less overtly constructive,
however. The cap on nicotine concentrations may limit the effectiveness of 
e-cigarettes as a smoking substitute, particularly for heavier smokers. The
derogation to member states of limits on the use of flavours, which may be a
significant source of oxidant activity in e-cigarette vapour23 (see Chapter 5), may
result in marked differences in relative potential harm of e-cigarettes available in
different member states. Restrictions may also result in non-compliance. The
restrictions on e-cigarette marketing, in effect limiting these to the point of sale,
billboards, bus stops and other advertising that does not cross borders, limits
opportunities for inappropriate promotion of e-cigarettes to non-smokers,
including children, but also inevitably inhibits promotion to smokers. However,
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as most smokers are aware of e-cigarettes, and word of mouth and social media
appear to have been the main drivers of use to date, it remains to be seen
whether these advertising restrictions will reduce uptake by smokers. The
Scottish Parliament is currently considering going further than the TPD to
prohibit all advertising of e-cigarettes in Scotland other than at the point of
sale.24
The requirement for nicotine products covered by the TPD to carry a health
warning emphasising the risks of nicotine, when licensed nicotine products do
not, appears illogical, as does the restriction on statements comparing the relative
risks of e-cigarettes and tobacco cigarettes. The health warning required under
the TPD provisions may also reinforce misperceptions about nicotine (see
Section 10.7 below).
A further concern about TPD regulation is that, although a facility to recall
products from the market is written into the legislation, there are no powers to
relax regulations if usage and innovation are unnecessarily or inappropriately
constrained by them. Despite requiring a review 3.5 years after implementation
and at 2-yearly intervals thereafter, the previous EU TPD was not revised for 
13 years, which is of great concern because much quicker mechanisms of
feedback and revision will be required to maximise the benefits as well as
minimise the risks of e-cigarettes. For these reasons, it is clearly important that
TPD implementation be closely monitored to assess the extent of unintended, as
well as intended, effects on the availability and use of non-tobacco nicotine
products and, in particular, the consequences of these effects on tobacco smoking
rates; it should also ensure that prompt action be taken if TPD regulation proves
to work against, rather than for, the benefit of public health. We therefore
recommend annual review in the UK.
10.5 The future of nicotine regulation
The UK is currently ahead of most countries in having an agreed set of principles
on what nicotine regulation should be designed to achieve, which, as stated in
our last report, is that ‘The current nicotine regulatory framework needs to be
changed so that it encourages as many smokers as possible to quit smoking and
all nicotine use completely, and encourages those who cannot quit to switch to a
safer source of nicotine, while minimising use by people who would not
otherwise have used nicotine products’. The UK government has reinforced the
need for harm reduction alongside abrupt cessation and preventive approaches
to tobacco control by introducing ‘new routes to quitting’,25,26 which involve
encouraging smokers to reduce their cigarette consumption as a precursor to
complete quitting, manage their nicotine addiction by using a safer alternative
product when unable to smoke, and dramatically reduce harm to themselves and
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others by using a safer alternative to smoking whenever possible at other times.
The UK government also encouraged innovation in the design and marketing of
nicotine delivery medicines.25,27 The MHRA, by relaxing its regulation of
nicotine-containing products, is following the same path. In 2013, the National
Institute for Health and Care Excellence (NICE) produced public health
guidance on harm-reduction approaches to smoking,28 recommending the
integration of harm reduction into NHS and other care pathways. Public Health
England29 has also recently endorsed the principles of the approach set out in the
RCP’s 2007 report,1 as has civil society, through the more than 120 health-related
organisations that endorsed the recent Smoking still kills policy document
published by Action on Smoking and Health in 2015.30
However, there is still some disagreement about the appropriate level of
regulation to meet these principles. Some argue that medicines regulation is the
best guarantee of safety, although experience to date suggests that it is too
restrictive; some argue that the TPD regulatory framework about to be
introduced is too stringent and will undermine the growing market for less
harmful alternative nicotine products and restrict innovation; some believe that
proposed TPD regulation does not sufficiently address the potential short- and
long-term hazards of e-cigarette use which, although likely to be far less than
those of smoking (see Chapter 5), could be minimised by medicinal quality and
safety standards.
In 2007, the RCP argued for the creation of a regulatory authority specifically
designed to cover all nicotine products, and to rationalise regulatory controls by
making them proportionate to product hazards.1 However, experience elsewhere
of giving powers to regulatory bodies to cover all nicotine products, eg in the
USA and Canada, has not been encouraging (see Chapter 11), although in any
case the current aversion to new regulation in the UK does not make a new
regulatory body a feasible option at present.31 Some countries have regulated 
e-cigarettes in the same way as tobacco products, which we believe to be entirely
inappropriate because e-cigarettes do not contain tobacco, and have a very
different profile of risk. The political reality is therefore that, for the coming
years, unless the legal challenge to the TPD is successful (see below), non-tobacco
nicotine products in the UK will be regulated either by the TPD or as a medicine,
whereas tobacco products will continue to be limited by the TPD and other
national restrictions on use and presentation. It remains to be seen whether this
approach will benefit public health by encouraging widespread substitution of
smoked tobacco by non-tobacco nicotine in current and future smokers, or will
in effect sustain smoked tobacco as the most widely used nicotine product. Much
will depend on the approach taken by the MHRA in its role as the competent
authority for TPD implementation. It is, however, crucial that the UK takes care
to implement the revised TPD in such a way as to minimise, as far as is
consistent with the regulations, the burden to manufacturers and importers in
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meeting the TPD requirements. It is also important to look again at the
medicinal licensing route to market, to try to make compliance more attractive to
producers.
10.6 If e-cigarettes are removed from the TPD, what are the
alternatives?
Following the December advocate general’s legal opinion, it seems likely that
regulation under the TPD will go ahead. However, starting from the
counterfactual32 allows options for a more appropriate regulatory structure to
be set out within a European context. If the legal challenge to e-cigarette
regulation under the revised TPD succeeds, then the previous status will
prevail, unless and until the EU develops a new regulatory framework. This
could be in the form of a new revision to the TPD, but past experience
indicates that this would be likely to take years to materialise. An alternative is
the earlier MHRA proposal to regulate all nicotine products as medicines,
which to date has proved to operate against public health interest and has, in
any case, been subject to successful legal challenges in other EU member
states.32 Another option is to develop harmonised EU-wide standards under
the General Products Safety Directive process, which could be less costly for
manufacturers and importers to comply with than if each member state
developed its own.33 Such standards could build on those being developed
under the European CEN/TC 437 process,34 which is one of the three European
standardisation organisations officially recognised by the EU and the European
Free Trade Association (EFTA) as responsible for developing and defining
voluntary standards at the European level.
A balance is needed to make products attractive, palatable, satisfying and effective
substitutes for tobacco smoking, but also as safe as is reasonably possible, and
avoiding use by adolescents and never-smokers. A pragmatic approach would
retain the reporting requirements on nicotine delivery and toxins in e-cigarette
vapour proposed under the TPD (see Section 10.3 above), adhere to industry and
product standards, incorporate obvious safety measures such as childproof and
tamper-proof seals and design, and simple advice on how to charge e-cigarettes
safely. Advertising should be permitted as per current codes of practice
administered by the ASA (with regular reviews to ensure that they remain fit for
purpose), with the facility to promote claims of reduced risk in relation to
tobacco smoking. Limits on nicotine dose and the requirement for health
warnings are probably not appropriate. Any voluntary approach would have to
build on the current BSI PAS 54115 standard for product regulation and the
compulsory advertising codes, which are currently under review. Alternatives to
the above approaches have been suggested, such as regulation as food or
cosmetics, but neither regulatory structure seems appropriate to a product that is
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inhaled. Whatever approach is taken, it will remain essential to monitor sales and
uptake of non-tobacco nicotine products, so that early action can be taken to
deal with any trends or patterns of use likely to be detrimental to public health
interest.
10.7 Providing consistency in messages to smokers
Recent evidence indicates that smokers are confused about the relative risks of
tobacco and e-cigarettes,35 with many coming to believe that the health hazards
of e-cigarettes and tobacco cigarettes are similar. Health professionals are also
uncertain about the role of unlicensed nicotine products in healthcare provision,
with many feeling reluctant to recommend or endorse a product or product class
that is relatively unregulated and has unknown long-term health effects. The
introduction of a regulatory structure for unlicensed products, as, for example,
proposed under the TPD, may help to overcome these reservations, but there is a
need for clear guidance on the role of unlicensed nicotine products in clinical
services. The National Centre for Smoking Cessation and Training has produced
new guidance on integrating e-cigarette use into the provision of smoking
cessation services*, but to date NICE, which has issued extensive guidance on
smoking cessation and harm reduction to organisations responsible for public
health and tackling tobacco use, health professionals and the general
public,28,36–39 has not addressed this issue. Some stop smoking services are
providing advice and behavioural support to smokers interested in using 
e-cigarettes with encouraging results (see Chapter 6), but health professionals
have a wider role to play in providing support and reassurance to e-cigarette
users in routine contacts. NICE guidance should, therefore, be updated to
include pragmatic recommendations on the role of e-cigarettes in tobacco harm
reduction.
10.8 Taxation and price
Price is a key driver of consumer behaviour and, if the potential for e-cigarettes
and other non-tobacco nicotine products to act as a widespread substitute for
smoked tobacco is to be fully realised, it is crucial that they are priced as
advantageously as possible in relation to tobacco. It is for this reason that the
VAT applied to NRT products in the UK was reduced from 20% to 5% in 2007.
Adding to the tax burden of e-cigarettes by including them in the remit of the
EU Tobacco Tax Directive, and hence requiring them to be taxed as tobacco
products in addition to the current taxation through VAT,40 would therefore be
counterproductive. A rational approach to nicotine taxation would be to apply
© Royal College of Physicians 2016 163
*www.ncsct.co.uk/usr/pub/Electronic_cigarettes._A_briefing_for_stop_smoking_services.pdf
HRR Chapter 10:Layout 1  07/04/2016  15:27  Page 163
Tobacco harm reduction
tax in proportion to their hazard, in which case the tax on e-cigarettes and
other non-tobacco nicotine products should be held stable or even reduced.
The availability of these products as a viable alternative for people addicted to
nicotine does, however, provide justification for further tax increases on
tobacco.
10.9 Summary
> The ideal regulatory framework for nicotine products is one that minimises
harm to society arising from nicotine use.
> At present, nicotine is in widespread use in UK society and the most popular
source of nicotine, the cigarette, is by far the most hazardous of those available.
> Nicotine regulatory approaches should therefore be designed to encourage as
many smokers as possible to either quit all nicotine use, or switch completely
from smoking to an alternative source of nicotine.
> Products are regulated to ensure that they are safe and fit for purpose.
Regulation of e-cigarettes and other similar products should therefore aim to
minimise potential exposure to harmful vapour constituents, ensure that
those that deliver nicotine do so in doses that smokers find satisfying, and
encourage substitution for smoked tobacco.
> Regulatory restrictions should therefore be designed to safeguard against
unnecessary hazard but should also be proportionate, so as not unnecessarily
to inhibit the development, availability and use of viable alternatives to
smoking.
> Attempts by the MHRA over the past 5 years to adapt medicines licensing to
the rapidly developing e-cigarette market has resulted in the award of only
two medicines licences for alternative nicotine products, and no licensed 
e-cigarette has come to market.
> Regulations for e-cigarettes proposed in the new revision of the EU TPD
include quality controls that are more permissive and, in our view, more
proportionate than medicines regulation, but include some measures that
may inappropriately constrain the e-cigarette market and hence inhibit 
e-cigarette use.
> At the time of going to press, the TPD regulations for e-cigarettes are still 
the subject of a legal challenge, but are expected to come into effect from 
20 May 2016.
> In the event that the legal challenge succeeds, then a replacement regulatory
approach should retain the requirements on reporting of nicotine delivery
and toxins in e-cigarette vapour proposed under the TPD, and adhere to
industry and product standards.
> To encourage smokers to switch from tobacco to less hazardous sources of
nicotine, it is vital that non-tobacco nicotine products be excluded from
tobacco taxes.
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> It is essential that NICE and other health organisations give clear guidance
on the role of e-cigarettes, licensed or unlicensed, in smoking cessation and
tobacco harm reduction.
> Effective regular surveillance, which we recommend should be annual, will
will be required to monitor intended and unintended impacts of regulation,
and a rapid feedback mechanism to allow changes to be made to ensure that
the potential benefits of e-cigarettes are maximised, while minimising the
risks.
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Harm reduction and e-cigarettes: an
international perspective11
11.1 Harm reduction and tobacco control policy
implementation in the UK
Since the publication of the white paper Smoking kills in 1998,1 the UK has
introduced an extensive and comprehensive range of tobacco control measures (see
Chapter 3) and, having been at the forefront of the global smoking epidemic of the
20th century, is now a world leader in smoking prevention.2 As a result, UK smoking
prevalence has declined substantially and at a rate similar to that observed in other
countries that have also implemented comprehensive tobacco control programmes
such as Australia, Canada, the USA (in California) and Uruguay.3,4 As discussed in
Chapter 10, in addition to this comprehensive package of conventional tobacco
control policies, England has also adopted a complementary harm-reduction policy
strand that is embedded in national policy through government health and tobacco
control strategies,5–8 guidance by the National Institute for Health and Care
Excellence (NICE)9 and medicines regulation.10–12 To our knowledge the UK is the
only country in the world to have developed, and to be in the process of imple-
menting, a proactive tobacco harm-reduction approach to smoking prevention. This
chapter describes the regulation of e-cigarettes and their use in other countries.
11.2 Approaches to regulation of e-cigarettes in other countries
There is a wide variation in approaches taken in different countries to the
regulation of e-cigarettes and other unlicensed, non-tobacco nicotine products.
The Institute for Global Tobacco Control (IGTC)13 summarises policy
approaches in a total of 123 countries, including 90 from a World Health
Organization (WHO) report on e-cigarette policies.14 Regulations are evolving
rapidly, so the discussion here and in the following sections is based on data
reported on the IGTC website* unless otherwise stated, and was accurate at the
time of going to press. A discussion of whether published regulations have
actually been enforced is beyond the scope of this chapter.
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Also at the time of going to press, the use of e-cigarettes had been completely
prohibited in three countries (Cambodia, Jordan and the United Arab Emirates),
prohibited in enclosed public places in 15 countries and restricted in a further
eight, prohibited on public transportation in 19 countries and restricted (or
limited to non-nicotine-containing products) on certain public transportation
vehicles in three. Restrictions on purchase or sale comprise: a minimum age for
e-cigarette purchase which is usually the same as that for traditional cigarettes,
and ranges from 18 to 21 years in 16 countries; prohibition (26 countries) or
restrictions (21 countries) on the sale of all types of e-cigarette, including
restriction or prohibition of sale or requirement for marketing authorisation for
products that have nicotine. Of the 47 countries banning or restricting sale, 
33 also prohibited or restricted advertising, promotion or sponsorship of 
e-cigarettes in their policies. Twelve other countries had explicit promotion
bans/restrictions. Two countries (Togo and the Republic of Korea) impose taxes
on e-cigarettes in addition to general sales taxes. Similar to the UK, some
countries, including the USA, allow e-cigarettes to be sold under general
consumer product regulations.
The experience of regulating e-cigarettes along with other nicotine products in a
single regulatory structure, as proposed by the RCP in 2007,15 has since proved
less encouraging than hoped. The US Food and Drug Administration (FDA),
already responsible for regulating medicinal nicotine, was given responsibility for
regulating tobacco products in 2009 and, after a legal decision, announced in 2011
that e-cigarettes would be brought within the remit of tobacco product
regulation.16 At the time of writing the FDA still has more stringent regulations
on the sale of medicinal nicotine than the UK, and has not yet put a regulatory
process for e-cigarettes in place. Similar to the US experience with FDA
regulation, Health Canada’s jurisdiction over all tobacco and nicotine products,
which regulates nicotine under the Food and Drug Act, requires a marketing
authorisation for e-cigarettes containing nicotine, and none has yet been awarded.
The effect of this is therefore an actual prohibition of sale. In practice, however,
this is not being observed, because a recent Canadian House of Commons’ report
concluded that e-cigarettes with nicotine were still available in Canada.17 The
report put forward recommendations to develop a new legislative framework for
e-cigarettes that would probably allow their sale with nicotine, but with strict
controls on marketing in line with those for tobacco.17 In the absence of a clear
regulatory approach by Health Canada at the federal level, a number of provinces
have already moved to impose strict regulations on e-cigarettes, including
prohibition of use in public places, and of advertising and display.*
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Thus, the experience of a single regulatory authority in both the USA and
Canada is that, in both cases, the authority has been unable to use its powers
effectively to regulate nicotine products in relation to their hazard. Indeed, in
both cases, single-body regulation of all nicotine products has probably hindered,
rather than enabled, access to reduced-hazard nicotine products.
11.3 Awareness and use of e-cigarettes in different countries
Although there is a rapidly growing body of research on the prevalence of 
e-cigarette use in adults and adolescents internationally, methodological
differences in the definition and measurement of ever, past or current use,
particularly in adolescent research, make direct comparisons between studies
difficult. This section therefore describes trends internationally drawing
predominantly on between-country surveys; Section 11.4 analyses the
relationship between regulatory frameworks and use where the evidence enables
such comparisons to be made.
11.3.1 Awareness and use of e-cigarettes in adults
Significant variability in the prevalence of use of e-cigarettes has been observed
between countries over time, but international surveys demonstrate rapid global
increases in e-cigarette use across high-, middle- and low-income countries. The
earliest between-country study18 assessed e-cigarette awareness and use among
nationally representative samples of smokers and recent ex-smokers based on
2010–11 data from the International Tobacco Control policy evaluation project
(ITC) in the UK, the USA, Australia and Canada. In the UK and the USA, 
e-cigarettes are regulated as consumer products; in Canada, e-cigarettes
containing nicotine require authorisation, but none has been authorised; in
Australia there is a ban on the sale and importation of e-cigarettes with nicotine,
although there is a mechanism for legal import as an unapproved medicine with
a doctor’s prescription. Awareness and current use were higher in the two
countries where there were fewer restrictions (the USA and the UK).
The Canadian Tobacco, Alcohol and Drugs Survey (CTADS) also found, in 2013,
much lower levels of e-cigarette use among adults in Canada than in the UK.19
Another ITC study compared trends in awareness, trial and use of e-cigarettes
among nationally representative samples of smokers and ex-smokers in the UK
and Australia.20 Use (defined as less than monthly or more often) of e-cigarettes
was 18.8% in the UK and 6.6% in Australia in 2013; however, use increased at
the same rate in both countries between 2010 and 2013.20 It therefore appears
that prohibition may have delayed the uptake of e-cigarettes in Australia, but has
not prevented a subsequent rapid increase in use.
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A further ITC study21 presented data from 10 countries (the USA, the UK,
Australia, Canada, the Netherlands, South Korea, Malaysia, Brazil, Mexico and
China) surveyed at different time points between 2009 and 2013. Again, there
was considerable variation in e-cigarette awareness and use among them:
awareness varied from 88% in the Netherlands (where e-cigarettes are regulated
as a consumer product with some restrictions13) to 31% in China (where sale
and purchase are legal at the national level, although may be restricted in some
regions22); self-reported trials varied from 20% in Australia to 2% in China; and
current use from 14% in Malaysia (where sale, distribution or importation of
unlicensed nicotine-containing e-cigarettes is prohibited; nicotine-containing 
e-cigarettes can be sold only by licensed pharmacies or registered medical
practitioners13) to 0.05% in China. These differences are likely to be due in part
to differences in survey dates, but also to differences in regulations, market forces
and enforcement. However, Malaysia had the highest prevalence of e-cigarette
use despite tight restrictions on their sale.
The Global Adult Tobacco Survey23 has also published data on e-cigarette use
among smokers and non-smokers from four middle- and low-income countries:
Indonesia (in 2011), Malaysia (2011), Qatar (2013) and Greece (2013). At the
time of the surveys, all these countries prohibited the sale of e-cigarettes apart
from Malaysia, where only nicotine-containing e-cigarettes were restricted.13
E-cigarette awareness was highest in Greece (88.5%), followed by Qatar (49%),
Malaysia (21%) and Indonesia (10.9%). Current use (daily and non-daily) of 
e-cigarettes among smokers was again highest in Malaysia (in this survey
prevalence of use was 10.4%), followed by Qatar (7.6%), Indonesia (4.2%) and
Greece (3.4%). Use of e-cigarettes among non-smokers was highest in Greece
(1.3%), followed by 0.4% in each of the other three countries. Again, these data
demonstrate little evidence that more restrictive national policies on e-cigarettes
result in lower levels of use.
The most recent Eurobarometer 429 survey,24 carried out in November and
December 2014, enabled an assessment of use of both tobacco cigarettes and 
e-cigarettes (defined as e-cigarettes or other similar electronic device) among
people aged 15 years and over in the 28 European Union (EU) member states.
France, Cyprus and Estonia (where e-cigarettes are regulated as either consumer
or medicinal products according to nicotine content)13,25 had the highest
proportions of respondents stating that they had ever tried e-cigarettes (17% or
higher); France and the UK had the highest prevalence of current e-cigarette use
(both 4%) and the UK had the highest proportion of current smokers who also
used e-cigarettes (11%). Fewer than 1% of never-smokers currently used 
e-cigarettes in every country surveyed. The most common reason given for using
e-cigarettes was to stop or reduce smoking. Across the EU, 14% of smokers or ex-
smokers who had tried e-cigarettes reported that they had helped them to stop
smoking completely, 13% that they had helped them to stop for a while before
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relapsing, 45% that they had not reduced their tobacco smoking and 21% that
they helped them to reduce, but not stop, tobacco use. Ireland (24%) and the
UK (21%) had the highest proportions of respondents who reported
successfully stopping smoking with the help of e-cigarettes. The proportion of
smokers using e-cigarettes in their quit attempts was highest in countries
regulating them as consumer products: the UK and Ireland (19%), France
(18%) and Cyprus (16%). The Eurobarometer noted that there were
continuing declines in smoking across the EU at a time when e-cigarette use
was increasing, as has been observed in UK surveys (see Chapters 2 and 7) and
in the USA.26
11.3.2 Awareness and use of e-cigarettes by adolescents
We have been unable to find any survey using a consistent methodology to
compare awareness and use of e-cigarettes among adolescents in different
countries. Data on people aged 15 and over are included in the 2014
Eurobarometer study referred to above,24 which reported the prevalence of
current use of e-cigarettes among people who had never smoked at 0%,
suggesting that there were few such users among young or older people.
Survey data on the prevalence of e-cigarette use in young people at the country
level are more extensive, but methodological differences, including the use of
different definitions or terms to describe the different stages of e-cigarette use
(ever, trial, current use), and differences in age ranges studied, limit the
comparability of these findings. A recent review concluded that the common
pattern emerging in countries where data were available was of very high
awareness and increasing trial of e-cigarettes among young people, but very low
levels (3% or less) of regular use.27 However, there were two countries where
current use was substantially higher: Poland (where e-cigarettes are classified as
consumer products, but with cartridges subject to regulations on chemical
mixtures) at around 30%28 and Hawaii (where e-cigarettes are classified as
consumer products), where 29% of the sample of young people had tried 
e-cigarettes and 18% had used them in the past month.29
Serial surveys of young people in the USA have documented a rising
prevalence of ever use of e-cigarettes30–32 and demonstrated that, as in the UK
(see Chapter 7), those who use e-cigarettes are more likely also to smoke
tobacco.31 A cohort study from California33 found that secondary school
pupils who had not smoked, but reported having ever tried an e-cigarette,
were more likely at 6- or 12-month follow-up to have ever tried a tobacco
cigarette. A cohort study of a national US sample of 694 never-smokers who
were classified as non-susceptible to tobacco smoking at baseline in 2013–14,
and restudied in 2015,34 found that the 16 participants who reported ever
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having used an e-cigarette at baseline were significantly more likely, after
controlling for other covariates, to have become susceptible to cigarette smoking
or have smoked at least one puff of a cigarette at follow-up. However, claims that
these findings indicate that e-cigarette use may cause uptake of tobacco smoking
have been challenged on the grounds of common liability (see Chapter 8), lack of
measures of more regular use of either e-cigarettes or tobacco cigarettes, and
that, during the time that these studies have been carried out, the prevalence of
tobacco smoking among young people in the USA fell to a 22-year low.35–37
There is evidence from the USA that adolescent smokers using e-cigarettes are
also more likely to use products such as tobacco hookahs or shisha and blunts
(marijuana and tobacco).38
11.4 Patterns of use across countries with different regulatory
regimens
Although standardised between-country data on e-cigarette use over time are
generally lacking, it is clear from the evidence presented above that, whereas
countries with more liberal policies (which typically involve regulating 
e-cigarettes as consumer products) have higher levels of adult e-cigarette use,
prohibition and tight restrictions have not prevented increasing uptake of 
e-cigarette use among adults in other countries. For adolescents the data are less
clear but, as an example, the 2013 CTADS of Canadians aged 15 years and older
found that 9% had ever tried an e-cigarette, with trials being higher among
young people aged 15–19 years at 20%.19 This latter percentage is not dissimilar
from the percentage who had tried e-cigarettes in the UK in 2015 (12.7% of 11-
to 18-year-olds). Again, therefore, it appears that prohibition of sale has had little
effect on experimentation with e-cigarettes in Canada, at least not in the younger
age groups in these studies. A recent US study assessed the impact of state bans
on sales of e-cigarettes on smoking rates among 12- to 17-year-olds across the
USA,39 and found that reducing access through age-of-sale laws increased
smoking among 12- to 17-year-olds, suggesting that restrictive regulations on e-
cigarettes may be counterproductive.
In the EU, as set out in Chapter 10, the introduction of the Tobacco Products
Directive40 will lead to a common regulatory platform from May 2016,
although individual member states will be able to go further in prohibiting all
advertising (as is under consideration in Scotland), restricting or prohibiting
their use in public places (recently under consideration in Wales), legislating
for an age of sale (set at 18 in England), restricting or prohibiting flavours,
and implementing additional taxation. Monitoring the impact of these
regulatory changes, and of their variations across the EU, will provide a useful
indicator of the impact of different regulatory approaches.
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11.5 Harm reduction and the WHO Framework Convention on
Tobacco Control
E-cigarettes were not available when the World Health Organization (WHO)
Framework Convention on Tobacco Control (FCTC) was first negotiated.
However, the FCTC41 alludes to harm reduction in Article 1, where tobacco
control is defined as including ‘harm reduction strategies that aim to improve
the health of a population by eliminating or reducing their consumption of
tobacco products and exposure to tobacco smoke’. This is further considered in
Article 5.2(b), which states that ‘each Party shall, in accordance with its
capabilities … adopt and implement effective legislative, executive,
administrative and/or other measures and cooperate, as appropriate, with other
Parties in developing appropriate policies for preventing and reducing tobacco
consumption, nicotine addiction and exposure to tobacco smoke’. The FCTC
does not have a remit for the regulation of medicinal nicotine, although it has
produced guidelines on tobacco dependence and cessation (Article 14 of the
FCTC).42
The growing popularity of e-cigarettes led to discussions on their role at the
biennial FCTC Conference of the Parties (COP), the governing body of the
treaty, in 2010 and 2012. At the 2012 COP5, the WHO was asked to produce a
report on ‘options for prevention and control’ of e-cigarettes (referred to as
electronic nicotine delivery systems or ENDSs) for consideration at the next
COP.43 The WHO report to COP614 focused on three areas of concern: health
risks to users and non-users; efficacy in helping smokers to quit smoking and
(ultimately) nicotine use; and interference with existing tobacco control efforts
and implementation of the FCTC. The main focus of the report was on the
latter issues, but, in terms of health risks, the report concluded that ‘well-
regulated ENDS’ would be likely to be less toxic than tobacco cigarette smoking
for established adult smokers. In relation to smoking and nicotine cessation,
the report concluded that e-cigarettes might have a role in supporting attempts
to quit for individuals who had failed treatment, or who were intolerant of or
refused conventional treatments. The report discussed and recommended
parties to regulate e-cigarettes as either medicines or tobacco products, in
accordance with the FCTC.
In response, the Framework Convention Alliance (FCA, a coalition of over 350
non-governmental organisations from over 100 countries) developed a
consensus position.44 The FCA concluded that, because of differences in
regulatory systems and national circumstances, it would be difficult to reach
consensus at COP6 on specific regulatory approaches to ENDSs. Instead, the
FCA position paper set out the following principles as a starting point for
reaching agreement on the role and regulation of e-cigarettes, for consideration
by the COP:
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1 The global burden of death and disease from tobacco is primarily caused by
smoking.
2 Although quitting tobacco use is paramount, quitting nicotine use altogether is
the best option.
3 For those unable to quit, switching to alternative sources of nicotine that are
less harmful than tobacco can reduce, often very substantially, the harm that
smoking causes to the individual.
4 The benefits of such an approach would be maximised if uptake were limited
to existing smokers who are unable to quit.
5 The risks of such an approach would be minimised by limiting uptake by
never-smokers, in particular among young people, and by taking measures to
protect non-users and discourage long-term dual use.
6 There could be negative unintended consequences from over-regulation, just
as there could be from under-regulation.
7 The involvement of tobacco companies in the production and marketing of 
e-cigarettes is a matter of particular concern, because there is an irreconcilable
conflict of interest between those profiting from the sale of tobacco and public
health.
After discussion by the COP, a decision was taken to ask parties to the FCTC to
take note of the WHO report, and the WHO was asked to produce a further
report with updated intelligence for consideration in time for COP7, which will
be held in the last quarter of 2016. The decision also asked parties to the FCTC
to consider ‘prohibiting or regulating’ e-cigarettes, suggesting that this could be
as tobacco, or medicinal or consumer products, and to comprehensively monitor
their use.45 E-cigarettes will therefore be discussed again at the next WHO FCTC
COP in November 2016 in India.
In the case of tobacco, a range of comprehensive tobacco control measures has
been found to be effective and been codified in the FCTC. E-cigarette
regulation does not sit appropriately within the context of the FCTC, the
explicit objective of which is control of the supply of and demand for a lethal
product, tobacco, through the introduction of increasingly restrictive and
prohibitive regulatory measures. Furthermore, there is as yet an insufficient
evidence base or range of national experience that would enable the
development of a detailed set of recommendations for the specific approaches
to many of the complicated regulatory issues that these products raise at the
global level.
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11.6 Summary
> A variety of different approaches to tobacco harm reduction and regulation
of e-cigarettes, including extension of regulations for alternative products to
e-cigarettes and including complete prohibition, have been adopted in
different countries around the world.
> The prevalence of use of e-cigarettes is rising or already significant in some
countries that have attempted to prohibit use, suggesting that prohibition is
not an effective approach to regulation.
> Surveillance data are limited in most countries, as are the use of consistent
terminology and standardised measures of e-cigarette use, so between-
country differences are difficult to assess.
> There is general recognition that comprehensive monitoring and
surveillance of the evidence and national regulatory experience of 
e-cigarettes are essential.
> The WHO recognises a role for e-cigarettes as part of a harm-reduction
strategy for smokers, but in the context of a recommendation by the FCTC
COP that they be regulated to minimise any potential risks.
> However, currently there is no consensus about what this regulatory
framework should be, and as yet an insufficient evidence base, or range of
national experience, that would justify the development of a regulatory
structure at a global level.
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12.1 Moral and ethical considerations of harm-reduction
strategies
This report has made the case for applying harm-reduction principles to tobacco
smoking, principally to prevent avoidable harm to smokers. There is, however, a
strong ethical dimension to the use of harm-reduction strategies in tobacco
control that were discussed in some detail in our earlier report;1 these strategies
include a duty to ensure that options to reduce harm are made available to
smokers, and provision of a substitute for tobacco to smokers, particularly those
on low incomes, to protect them from the hardship that might otherwise arise
from applying tax increases to provide a stronger fiscal disincentive to smoke.
There are, however, wider considerations arising from concerns over the broader
effects of applying harm-reduction strategies in society.
The central ethical concern is with harm, and whether the harm-reduction
strategies identified and adopted will, in practice, reduce it. However, there are
also wider questions relating to the ethos of harm reduction itself, over and
above any examination of the effectiveness of particular strategies. In some areas
of public health (particularly in drug control, alcohol control and sex work
control, for example), there is a societal concern that the behaviour being
targeted is inherently wrong. Drug addiction, prostitution and drunkenness, it is
sometimes thought, are inherently bad, and the proper focus of public health
should not be on making the use of drugs, or sex work, or excess alcohol
consumption safer; it should be on eradicating these behaviours. In tobacco
control, however, this argument is rarely made: few people acknowledge smoking
as a behaviour that is immoral. Its harms are real and serious, and inflicting these
on unwilling third parties is wrong, but these concerns fit quite naturally within
the harm-reduction model.
A second concern is with the distribution of harm. A harm-reduction strategy
could be considered to have failed if the net harm were reduced, but the
distribution of harm changed in a way that was unjust, eg if, as a result of the
harm-reduction strategy, some socially or economically vulnerable group
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became more at risk of harm, or systematically less able to benefit from
smoking cessation and prevention strategies. The benefit to existing smokers of
switching to e-cigarettes is clear, but, if large numbers of never-smokers were to
take up e-cigarette use, they would be exposing themselves to health risks that
would otherwise be avoided, and financial costs, which are of particular
detriment to poorer smokers, that they would not otherwise incur. At present
this does not appear to be happening, but it could occur, for example, if the
addictive potential of e-cigarettes and other non-tobacco nicotine products
increases over time.
A third concern relates to social responsibility: if engaging in harm reduction
involves working with corporate actors with a track record of deceit or other
socially irresponsible business practices, and particularly of undermining public
health, then there is a concern that doing so may have wider ramifications than
the harm-reduction strategy itself. Such engagement might, for example,
discredit other public health interventions or institutions that are focused on
ending these bad practices. We can think of this as ‘reputational harm’.
Conversely, it may be that such corporate actors acquire some perverse benefit
from such engagement: by appearing to be responsible in one area (the provision
of reduced-harm products) they might be able to reclaim a good reputation in
other areas, however undeservedly. From a ‘harm-reduction’ point of view, these
factors must be considered, but these harms may be inchoate and hard to
measure, certainly compared with the real benefits accruing to harm-reduction
products in terms of reductions in mortality and morbidity.
Setting aside these objections to harm reduction in principle, we turn instead to
the objections that might be raised against particular harm-reduction strategies
from within a focus on harm. Obviously, the most important consideration is
whether the harm-reduction intervention actually does reduce harm, in terms of
reduction of lives (and life years) lost, increase in numbers of smokers who
successfully quit smoking tobacco, reductions in the numbers of new smokers,
etc. However, as for any other medical or public health intervention, we need to
consider any particular strategy in the light of available alternatives: in particular,
if we focus on regulation of a tobacco harm-reduction product, we need to ask
whether the regulatory mechanism is the most effective in reducing harm, or
whether some other approach would be more effective. We need to ask whether
adoption of a particular regulatory approach makes the production of some
products more likely than others, and whether the products favoured by this
approach are, in fact, better from a harm-reduction and public health point of
view than those disfavoured. As within the harm-reduction model, the least
harmful intervention is the most ethical intervention, we need always to keep in
mind that choice of regulatory approach must be seen in ethical terms. The
evidence summarised in this report goes some way towards addressing these
questions.
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12.2 Smoking and public health
Tobacco smoking is the biggest avoidable cause of death and disability in the UK.
In 2014, 21% of men and 16% of women were smokers,2 which in absolute terms
represents almost 9 million people. Half these smokers, or 4.5 million people,
alive in the UK today will have their lives cut short by smoking and, if their
smoking continues unabated, their total loss of life will amount to nearly 
90 million years.3,4 Their smoking will also cause thousands of fetal deaths and
cases of childhood illness, and deaths in non-smoking adults, and cost our health
services and wider society billions of pounds. This massive burden of death,
disability and lost opportunity has been entirely avoidable, and much of it can
still be prevented by measures that encourage as many smokers as possible, as
soon as possible, to stop smoking. As the biggest beneficiaries of preventing
smoking are individuals who are disadvantaged, marginalised or have mental
health problems, prevention of smoking will make society both healthier and
more equal. Smoking may be less prevalent today than when the RCP published
its first report on smoking and health in 1962,5 but it is still our biggest health
problem. All measures that can be deployed to prevent smoking should therefore
be applied, as quickly as possible, and to their maximum effect.
12.3 The effect of conventional tobacco control approaches
The UK is a world leader in tobacco control policy. Since the late 1990s, a
comprehensive package of policies, including an advertising ban, smoke-free
legislation, high taxes, minimum purchase age, mass media campaigns, a point-
of-sale display ban and clinical services to help smokers to quit, has been
introduced, and will be enhanced in 2016 by standardised packaging
legislation. The result in the UK has been the same as in other countries that
have followed this approach: smoking prevalence has fallen steadily, but slowly.
However, the decline in smoking prevalence that has occurred over recent
decades appears to owe more to success in preventing the uptake of smoking:
quit rates among established smokers have changed relatively little. However, it
is the adults smoking today, particularly those in middle and older age, who
will generate most of the burden of death and disability caused by smoking in
the short- and near-term future, and it is these adults whom tobacco control
policies need to target in particular if this burden of harm is to be reduced. All
existing and new policies with the potential to promote smoking cessation,
particularly among disadvantaged groups, should therefore be applied to their
fullest extent.
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12.4 Priorities for conventional tobacco control policy
implementation
Of the range of policies available, the UK has already achieved a relatively high
level of prohibition of tobacco advertising and smoke-free policy. Opportunities
to promote tobacco brands will be further reduced by the introduction of
mandatory standardised packaging in May 2016, although a great deal more
could be done to reduce exposure of children and young people to the
normalising effect of smoking imagery in the media, including films, television
programmes, music videos and computer games. Children may also be less
likely to grow up thinking that smoking is a normal or aspirational adult
behaviour if they were exposed less to smoking behaviour among adults in their
everyday lives, which could be achieved by extending smoke-free policies to
outdoor areas, eg at school gates, play areas, town centres and other areas where
smokers congregate in view of children. Making hospital premises completely
smoke free generates an opportunity to initiate and support cessation among
the many smokers, and their visitors, who use hospital services. Similarly,
making prisons smoke free will provide an opportunity to reduce the very high
prevalence of smoking among prisoners. More could also be done to reduce
retail availability of tobacco to children, particularly in areas close to schools,
and the requirement that tobacco retailers be licensed would be a useful step
towards making enforcement of regulations easier. Mass media campaigns are
effective in motivating smokers to try to quit, but require funding to achieve
and sustain the necessary intensity and salience for success. Cessation services
also need to be adequately funded, and in clinical settings integrated much more
systematically into routine health service delivery. Large increases in tobacco
prices, particularly in the lower cost range of products preferred by low-income
smokers, have a particular potential to reduce smoking among disadvantaged
groups. Proper funding of enforcement measures against illicit tobacco and
measures to curtail the tobacco industries’ own involvement in this trade are
crucial. All these measures would be likely to help to achieve further reductions
in smoking prevalence. However, almost all would be complemented by
promoting harm-reduction approaches that encourage smokers, who otherwise
prove unwilling or unable to quit smoking, to switch to an alternative, low-
hazard source of nicotine.
12.5 Nicotine addiction and its effects
Nicotine is the main addictive component of tobacco smoke. Although other
tobacco smoke components probably contribute to the development of nicotine
addiction, it is the capacity to achieve rapid increases in systemic arterial levels
through pulmonary absorption that makes tobacco smoking particularly
addictive, as well as lethal, although factors such as the taste and smell of
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cigarette smoke, and the behavioural action of smoking, can reinforce nicotine
use and hence themselves become important drivers of continued smoking. At
low doses, nicotine is a stimulant, which in the short term increases heart rate
and may improve attention, memory and fine motor skills. Although potentially
lethal at very high doses, at the blood levels typically achieved by smoking
nicotine does not result in clinically significant short- or long-term harms.
Nicotine is not a carcinogen; there is no evidence that sustained human use of
nicotine alone increases the risk of cancer. It is possible that nicotine exposure
during the fetal and/or adolescent periods causes cognitive impairment, but in all
other respects, and certainly in relation to tobacco smoke, the real and potential
hazards of sustained nicotine use are negligible. The harm of smoking is
therefore caused not by nicotine, but by other constituents of tobacco smoke.
Non-tobacco nicotine products that reproduce the nicotine delivery and
behavioural characteristics of smoking, without the many other toxins in tobacco
smoke, therefore have the potential to allow smokers to continue to use nicotine
and avoid the significant harm to themselves and others that smoking causes.
12.6 Non-tobacco nicotine products
A wide range of nicotine replacement therapy (NRT) products, licensed as
medicines to reduce symptoms of nicotine withdrawal among people trying to
quit smoking, is available. In clinical trials, NRT has been shown consistently to
be effective in helping smokers to quit smoking. Although initially developed to
help people give up all smoking and nicotine use, NRT licences have been
extended to include short-term use to relieve withdrawal symptoms during
temporary abstinence from smoking, and long-term use as a partial or complete
substitute for smoking (harm reduction).6 These licensed applications of NRT,
which are endorsed by the National Institute for Health and Care Excellence
(NICE),7 promote dual use of NRT and tobacco on the grounds that smokers
who learn to use NRT in this way are more likely to quit smoking completely.7
NRT products have to date been produced by pharmaceutical companies and
offer high levels of purity and hence safety, such that a smoker who switches
from tobacco to NRT use, but continues to use NRT in the long term, probably
achieves much the same in health terms as a smoker who quits all tobacco and
nicotine use.
The choice of non-tobacco nicotine products in the UK has been substantially
extended by the emergence of e-cigarettes, which have to date been marketed as
consumer alternatives to smoking. E-cigarettes offer a behavioural experience
that is much closer to smoking than is the case with NRT products, and later-
generation e-cigarettes appear able to achieve venous nicotine levels similar to
those of tobacco smoking. The extent to which inhalation of e-cigarette vapour
results in rapid pulmonary absorption remains uncertain, but it seems likely that,
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as the technology improves, the degree of pulmonary absorption will increase,
making the products more effective as smoking substitutes, but also increasing
addictiveness, and hence posing the new ethical problems highlighted above. 
E-cigarettes generate vapour from a solution that typically contains nicotine,
propylene glycol and glycerine, but, in addition to these constituents, e-cigarette
vapour contains a variable range of compounds arising from impurities in the
solutions or generated by the heating process that produces vapour. There appear
to be few, if any, significant short-term adverse effects of e-cigarette use, but
adverse health effects from long-term exposure to constituents of vapour cannot
be ruled out. Although unknown, the hazard to health arising from long-term
vapour inhalation is unlikely to exceed 5% of the harm from tobacco smoke.
Switching from tobacco to e-cigarettes is therefore likely to be almost as effective
in preventing harm as switching to NRT. However, the recent award of a
medicines licence to an e-cigarette product raises the prospect of e-cigarettes
with safety profiles similar to NRT becoming available in the near future.
12.7 How smokers in the UK try to quit, and their chances of
success
Around one in three smokers in the UK tries to quit each year, but only around
one in every six of those who try to quit is successful. Those who try are slightly
more likely to be younger and female, and to be in non-manual occupations;
those in non-manual occupations are also more likely to succeed. Most of those
who try to quit do so without help, or until recently by using NRT bought over
the counter. Over the past 3 years, however, e-cigarettes have become the most
widely used aid to quitting.
The observational data on quitting used in this report suggest that those who use
prescribed medication and behavioural support from a qualified stop smoking
adviser (typically through NHS Stop Smoking Services (SSSs)) are two to three
times more likely to succeed than those using no help. However, the use of NHS
SSSs has declined significantly in recent years, such that they are now accessed by
only a small minority of smokers. For reasons that are not clear, those who use
over-the-counter NRT appear to be no more likely to succeed in quitting
smoking than those using no help, whereas those who use e-cigarettes, or NRT or
other pharmacotherapy provided by a healthcare professional, are around 50%
more likely to succeed than those using no help at all.
The popularity of e-cigarettes has thus resulted in a substantial increase in the
proportion of smokers using effective help to quit. It is probable that adding
behavioural support would increase the likelihood of quitting with e-cigarettes
still further, and this is an important area for new research. Possible explanations
for the popularity of e-cigarettes, and their effectiveness relative to NRT, include
© Royal College of Physicians 2016 185
HRR Chapter 12:Layout 1  07/04/2016  09:07  Page 185
Tobacco harm reduction
their ability to replace some of the behavioural components of smoking, their
relatively high nicotine delivery, the fact that smokers tend to try them for longer
and with more frequent dosing than NRT, and their cultural acceptability.
Smokers are motivated to make a quit attempt in particular by cost and health
concerns. Price rises, media campaigns and health professional advice are
therefore likely to increase the numbers of smokers trying to quit.
12.8 Use of e-cigarettes by smokers and non-smokers
E-cigarettes are used almost exclusively by smokers who are trying to cut down
or quit smoking, or who have quit smoking. Among adults, use by non-smokers
is extremely rare. A higher proportion of non-smoking children than adults have
experimented with e-cigarettes, but most of those who do have smoked in the
past, or are current smokers. More than experimental use among children who
are not also experimenting with tobacco is rare. Among regular users, whether
children or adults, second- and third-generation devices are now much more
widely used than first-generation ‘cigalike’ devices. Fruit flavours are popular
among e-cigarette users, whether adults or children.
12.9 Harm reduction and population health
The emergence and consumer success of e-cigarettes, as a partial or complete
substitute for smoking, reflects significant potential to reduce the harm caused by
smoking to society by encouraging as many smokers as possible to use 
e-cigarettes, or indeed other non-tobacco nicotine products, rather than tobacco
cigarettes. There are many, however, who retain significant concerns over the
potential risks and adverse effects of this approach, for both individuals and
wider society.
Concerns that e-cigarettes are not hazard free are justified, but this hazard could
be minimised by a combination of technological development and appropriate
regulation. Concerns that e-cigarettes will be used dually by smokers are
inconsistent with current guidance and licence indications for NRT, which
encourage dual use as a step towards quitting smoking and of protecting those
around the smoker from the harmful effects of second-hand smoke. All the UK
evidence, and almost all the international evidence, on the use of e-cigarettes by
children and young people to date indicates that concerns about e-cigarettes
helping to recruit a new generation of tobacco smokers through a gateway effect
are, at least to date, unfounded, although vigilant surveillance is required to
ensure that the emergence of any such effect is detected and reversed promptly.
Renormalisation concerns, based on the premise that e-cigarette use encourages
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tobacco smoking among others, also have no basis in experience to date.
Exploitation of e-cigarette advertising as a means of promoting tobacco smoking
by tobacco companies is perhaps a more real concern, but will largely be
prevented by impending controls on advertising in the EU Tobacco Products
Directive (TPD).8
12.10 Regulation and harm reduction
It is difficult to determine, and more difficult still to apply, the right level of
regulation for reduced-harm products. The wide range of different regulatory
approaches adopted in different countries in relation to e-cigarettes, which spans
a spectrum from freedom to market as a consumer product to complete
prohibition, reflects a desire, on the one hand, to encourage as many smokers as
possible to switch from tobacco to e-cigarettes and, on the other, to prevent harm
to users or others from e-cigarette use. A risk-averse, precautionary approach to
e-cigarette regulation can be proposed as a means of minimising the risk of
avoidable harm, eg exposure to toxins in e-cigarette vapour, renormalisation,
gateway progression to smoking, or other real or potential risks. However, if this
approach also makes e-cigarettes less easily accessible, less palatable or acceptable,
more expensive, less consumer friendly or pharmacologically less effective, or
inhibits innovation and development of new and improved products, then it
causes harm by perpetuating smoking. Getting this balance right is difficult.
In the UK, consumer product regulation supported by advertising codes of
practice has worked well to date, but does not guarantee that products actually
deliver nicotine to a degree that smokers will find satisfying or, more
importantly, that vapour is as toxin free as is reasonably possible. Medicines
regulation guarantees efficacy and safety, but imposes high manufacturing,
compliance and opportunity costs. That even the streamlined Medicines and
Healthcare products Regulatory Agency (MHRA) ‘right touch’ medicines
regulation has to date awarded a licence to only one e-cigarette, and none that
has come to market, indicates that mandatory medicines regulation of 
e-cigarettes, although valuable as a complement to other regulatory approaches,
is not ideal as a single regulatory approach. EU TPD regulation, if implemented
as planned, offers a compromise between these two approaches by requiring
emission reporting that will enable consumers to identify the best and cleanest
nicotine delivery systems, but includes much, such as health warnings and
nicotine content limits (see Chapter 10), that is potentially counterproductive.
None of these approaches is therefore ideal, and experience in other countries
does not offer better alternatives. The UK needs a nicotine regulatory system that
applies controls on products in proportion to their potential harm, to promote
innovation and diversity, ensure reasonable levels of protection for consumers
and, above all, discourage tobacco use.
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The use of reduced-harm products, and hence the health gains that they generate, is
also influenced by other regulatory policies. Applying low levels of tax to non-
tobacco nicotine products, as, for example, the 5% VAT rate levied on NRT, helps to
make reduced-harm products attractive to smokers and offset the potentially
regressive effect of tobacco tax increases. Allowing messages on harm relative to
smoking in commercial and government media campaigns could help to reverse the
growing misconception that e-cigarettes and tobacco cigarettes are similarly harmful
(see Chapter 10). Prohibition of use of e-cigarettes where smoking is also prohibited
may discourage smokers from trying e-cigarettes, and may also contribute to a false
impression that they are similarly harmful. The inclusion of recommendations on
use of unlicensed (and, in due course, licensed) e-cigarettes in NICE guidance is
another example of an area where policies can change to encourage more smokers
to switch from smoking to a non-tobacco nicotine product.
12.11 The tobacco industry and e-cigarettes
Tobacco companies make their money by selling tobacco, and the industry’s
recent programme of investment and acquisitions in e-cigarettes perhaps
indicates recognition that these products represent a disruptive technology that
should be harnessed to protect the core business of selling tobacco, exploited to
expand tobacco markets or developed as an opportunity to make nicotine
products attractive to non-smokers. There is little likelihood that the industry
sees e-cigarettes as a route out of the tobacco business, but it is highly likely that
e-cigarettes will be exploited to enhance claims of corporate social responsibility,
and to undermine implementation of Article 5.3 of the World Health
Organization Framework Convention on Tobacco Control.
9
There is no firewall
between a ‘good’ tobacco industry that is marketing harm-reduction products in
the UK and a ‘bad’ one that promotes smoking, or undermines tobacco control
activities, in low- and middle-income countries.
12.12 Conclusions
Harm reduction was proposed by the RCP in 20071 as a means of reducing still
further the vast burden of death and disability that tobacco smoking causes in
our society. The evidence summarised in this report demonstrates that the
emergence of e-cigarettes has generated a massive opportunity for a consumer-
as well as a healthcare-led revolution in the way that nicotine is used in society.
As the technology of these and other non-tobacco nicotine products improves, so
the vision of a society that is free from tobacco smoking, and the harm that
smoking causes, becomes more realistic. Experience to date suggests that, as
predicted in principle in the 2007 report,1 the availability of e-cigarettes has been
beneficial to UK public health. There is, however, no room for complacency and
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it is particularly important that patterns of use of tobacco and non-tobacco
nicotine continue to be monitored closely, and prompt remedial measures
applied to deal with changes that are counterproductive to health. The potential
for the tobacco industry to exploit and appropriate harm reduction, to
undermine public health and bolster sales of tobacco, is a real problem that is
likely to become more acute as tobacco companies move into the licensed, as well
as unlicensed, nicotine market, but that problem can be managed with vigilance
and care. Large-scale substitution of e-cigarettes, or other non-tobacco nicotine
products, for tobacco smoking has the potential to prevent almost all the harm
from smoking in society. Promoting e-cigarettes, NRT and other non-tobacco
nicotine products as widely as possible, as a substitute for smoking, is therefore
likely to generate significant health gains in the UK.
12.13 Summary
> Smoking is the biggest avoidable cause of death and disability, and social
inequality in health, in the UK.
> Most of the harm to society and to individuals caused by smoking in the
near-term future will occur in people who are smoking today.
> Vigorous pursuit of conventional tobacco control policies encourages more
smokers to quit smoking.
> Quitting smoking is very difficult and most adults who smoke today will
continue to smoke for many years.
> People smoke because they are addicted to nicotine, but are harmed by other
constituents of tobacco smoke.
> Provision of the nicotine that smokers are addicted to without the harmful
components of tobacco smoke can prevent most of the harm from smoking.
> Until recently, nicotine products have been marketed as medicines to help
people to quit.
> NRT is most effective in helping people to stop smoking when used together
with health professional input and support, but much less so when used on
its own.
> E-cigarettes are marketed as consumer products and are proving much more
popular than NRT as a substitute and competitor for tobacco cigarettes.
> E-cigarettes appear to be effective when used by smokers as an aid to
quitting smoking.
> E-cigarettes are not currently made to medicines standards and are probably
more hazardous than NRT.
> However, the hazard to health arising from long-term vapour inhalation
from the e-cigarettes available today is unlikely to exceed 5% of the harm
from smoking tobacco.
> Technological developments and improved production standards could
reduce the long-term hazard of e-cigarettes.
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> There are concerns that e-cigarettes will increase tobacco smoking by
renormalising the act of smoking, acting as a gateway to smoking in young
people, and being used for temporary, not permanent, abstinence from
smoking.
> To date, there is no evidence that any of these processes is occurring to any
significant degree in the UK.
> Rather, the available evidence to date indicates that e-cigarettes are being
used almost exclusively as safer alternatives to smoked tobacco, by confirmed
smokers who are trying to reduce harm to themselves or others from
smoking, or to quit smoking completely.
> There is a need for regulation to reduce direct and indirect adverse effects of
e-cigarette use, but this regulation should not be allowed significantly to
inhibit the development and use of harm-reduction products by smokers.
> A regulatory strategy should, therefore, take a balanced approach in seeking
to ensure product safety, enable and encourage smokers to use the product
instead of tobacco, and detect and prevent effects that counter the overall
goals of tobacco control policy.
> The tobacco industry has become involved in the e-cigarette market and can
be expected to try to exploit these products to market tobacco cigarettes, and
to undermine wider tobacco control work.
> However, in the interests of public health it is important to promote the use
of e-cigarettes, NRT and other non-tobacco nicotine products as widely as
possible as a substitute for smoking in the UK.
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